CRISPR effector system-based diagnostics for virus detection
Through the CRISPR system combining guide RNA and masking constructs, the problems of sensitivity and specific trade-offs of nucleic acid detection methods in the prior art are solved, and fast and low-cost high-sensitivity nucleic acid detection is achieved, which is suitable for the diagnosis of a variety of diseases and viruses.
Patent Information
- Application Number
- CN201880032672.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2017-12-08
- Filing Date
- 2018-03-15
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2038-03-15
AI Technical Summary
The existing nucleic acid detection methods have trade-offs in sensitivity, specificity, simplicity and speed, and it is difficult to provide rapid diagnosis with high specificity and high sensitivity at low cost, limiting their application in clinical and basic research.
The CRISPR system, including RNA-targeted effector proteins such as C2c2 and guide RNA designed to bind to target molecules, combines RNA-based masking constructs and nucleic acid amplification reagents, to achieve a method for rapid detection of target RNA or DNA.
It realizes high sensitivity and high specific nucleic acid detection in low-cost and fast time, and is suitable for the diagnosis of a variety of diseases and viruses, and is highly adaptable, and is suitable for the detection of portable platforms and clinical samples.
Smart Images

Figure CN111108220B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application Nos. 62 / 471,931, filed March 15, 2017, 62 / 484,857, filed April 12, 2017, 62 / 530,086, filed July 7, 2017, 62 / 568,315, filed October 5, 2017, 62 / 588,138, filed November 17, 2017, and 62 / 596,735, filed December 8, 2017. The entire contents of the above-identified applications are hereby incorporated by reference herein in their entirety.
[0003] Statement Regarding Federally Funded Research
[0004] This invention was made with government support under Grant Nos. MH100706, MH110049, and AI110818 awarded by the National Institutes of Health and Grant No. HDTRA1-14-1-0006 awarded by the Defense Threat Reduction Agency. The government has certain rights in this invention. Technical Field
[0005] The subject matter disclosed herein generally relates to rapid diagnostics associated with the use of CRISPR effector systems. Background Art
[0006] Nucleic acids are universal markers of biological information. The ability to rapidly detect nucleic acids with high sensitivity and single-base specificity on a portable platform has the potential to revolutionize the diagnosis and monitoring of many diseases, provide valuable epidemiological information, and serve as a generalizable scientific tool. Although many methods have been developed for detecting nucleic acids (Du et al., 2017; Green et al., 2014; Kumar et al., 2014; Pardee et al., 2014; Pardee et al., 2016; Urdea et al., 2006), they inevitably involve trade-offs between sensitivity, specificity, simplicity, and speed. For example, qPCR methods are sensitive but expensive and rely on complex instrumentation, which limits the availability of trained operators in laboratory settings. Other methods, such as novel methods that combine isothermal nucleic acid amplification with portable platforms (Du et al., 2017; Pardee et al., 2016), offer high detection specificity in point-of-care (POC) settings but have somewhat limited applications due to low sensitivity. As nucleic acid diagnostics become increasingly relevant for a variety of healthcare applications, detection technologies that provide high specificity and sensitivity at low cost will be of great utility in both clinical and basic research settings. Summary of the Invention
[0007] In one aspect, the present invention provides a nucleic acid detection system comprising: a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind to corresponding target molecules; an RNA-based masking construct; and optionally, a nucleic acid amplification reagent for amplifying target RNA molecules in a sample. In another aspect, an embodiment provides a polypeptide detection system comprising: a CRISPR system comprising an effector protein and one or more guide RNAs designed to bind to trigger RNAs; an RNA-based masking construct; and one or more detection aptamers comprising a masked RNA polymerase promoter binding site or a masked primer binding site.
[0008] In other embodiments, the system may also include a nucleic acid amplification reagent. The nucleic acid amplification reagent may include a primer comprising an RNA polymerase promoter. In certain embodiments, the sample nucleic acid is amplified to obtain a DNA template comprising an RNA polymerase promoter, whereby a target RNA molecule can be produced by transcription. The nucleic acid can be DNA and amplified by any method described herein. The nucleic acid can be RNA and amplified by a reverse transcription method as described herein. After demasking the primer binding site, the aptamer sequence can be amplified, whereby triggering RNA is transcribed from the amplified DNA product. The target molecule can be a target DNA, and the system may also include a primer that binds to the target DNA and comprises an RNA polymerase promoter.
[0009] In one exemplary embodiment, the CRISPR system effector protein is an RNA targeting effector protein. Exemplary RNA targeting effector proteins include C2c2 (now called Cas13a), Cas13b and Cas13a. It will be understood that the term "C2c2" is used interchangeably with "Cas13a" herein. In another exemplary embodiment, the RNA targeting effector protein is C2c2. In other embodiments, the C2c2 effector protein is from an organism of the genus selected from the group consisting of Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Filifactor, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Flaviivola, Flavobacterium, Sphaerochaeta, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibaculum, Staphylococcus, Nitratifractor, Mycoplasma, Campylobacter, and Lachnospira, or the C2c2 effector protein is an organism selected from the group consisting of Leptotrichia In another embodiment, the one or more guide RNAs are designed to detect single nucleotide polymorphisms, splice variants of transcripts, or frameshift mutations in the target RNA or DNA.
[0010] In other embodiments, one or more guide RNAs are designed to bind to one or more target molecules that are diagnostic for a disease condition. In other embodiments, the disease condition is an infection, an organ disease, a blood disease, an immune system disease, a cancer, a brain and nervous system disease, an endocrine disease, a pregnancy or childbirth-related disease, a genetic disease, or an environmentally acquired disease. In other embodiments, the disease condition is cancer or an autoimmune disease or infection.
[0011] In other embodiments, one or more guide RNAs are designed to bind to one or more target molecules comprising cancer-specific somatic mutations. Cancer-specific mutations can confer drug resistance. Drug-resistant mutations can be induced by treatment with ibrutinib, erlotinib, imatinib, gefitinib, crizotinib, trastuzumab, vemurafenib, RAF / MEK, checkpoint blockade therapy, or anti-estrogen therapy. Cancer-specific mutations may be present in one or more genes encoding proteins selected from the group consisting of programmed death ligand 1 (PD-L1), androgen receptor (AR), Bruton's Tyrosine Kinase (BTK), epidermal growth factor receptor (EGFR), BCR-Abl, c-kit, PIK3CA, HER2, EML4-ALK, KRAS, ALK, ROS1, AKT1, BRAF, MEK1, MEK2, NRAS, RAC1, and ESR1. The cancer-specific mutation may be a mutation in a gene selected from the group consisting of: CASP8, B2M, PIK3CA, SMC1A, ARID5B, TET2, ALPK2, COL5A1, TP53, DNER, NCOR1, MORC4, CIC, IRF6, MYOCD, ANKLE1, CNKSR1, NF1, SOS1, ARID2, CUL4B, DDX3X, FUBP1, TCP11L2, HLA-A, B or C, CSNK2A1, MET, ASXL1, PD-L1, PD-L2, IDO1, IDO2, ALOX12B and ALO X15B, or copy number gain, does not include whole-chromosome events affecting any of the following chromosome bands: 6q16.1-q21, 6q22.31-q24.1, 6q25.1-q26, 7p11.2-q11.1, 8p23.1, 8p11.23-p11.21 (containing IDO1, IDO2), 9p24.2-p23 (containing PDL1, PDL2), 10p15.3, 10p15.1-p13, 11p14.1, 12p13.32-p13.2, 17p13.1 (containing ALOX12B, ALOX15B), and 22q11.1-q11.21.
[0012] In other embodiments, one or more guide RNAs can be designed to bind to one or more target molecules comprising a loss of heterozygosity (LOH) signature.
[0013] In other embodiments, the one or more guide RNAs can be designed to bind to one or more target molecules comprising a single nucleotide polymorphism (SNP). The disease can be heart disease and the target molecules can be VKORC1, CYP2C9, and CYP2C19.
[0014] In other embodiments, the disease condition can be a pregnancy or childbirth related disease or a genetic disease. The sample can be a blood sample or a mucus sample. The disease can be selected from the group consisting of: trisomy 13, trisomy 16, trisomy 18, Klinefelter syndrome (47, XXY), (47, XYY) and (47, XXX), Turner syndrome (Turner syndrome), Down syndrome (Down syndrome) (trisomy 21), cystic fibrosis, Huntington's disease (Huntington's Disease), beta thalassemia, myotonic dystrophy, sickle cell anemia, porphyria, fragile X syndrome, Robertsonian translocation (Robertsonian translocation), Angelman syndrome (Angelman syndrome), DiGeorge syndrome (DiGeorge syndrome) and Wolf-Hirschhorn syndrome (Wolf-Hirschhorn Syndrome).
[0015] In other embodiments, the infection is caused by a virus, bacteria, or fungus, or the infection is a viral infection. In certain embodiments, the viral infection is caused by a double-stranded RNA virus, a positive-sense RNA virus, a negative-sense RNA virus, a retrovirus, or a combination thereof, or a viral infection is caused by a Coronaviridae virus, a Picornaviridae virus, a Caliciviridae virus, a Flaviviridae virus, a Togaviridae virus, a Bornaviridae virus, a Filoviridae virus, a Paramyxoviridae virus, a Pneumoviridae virus, a Rhabdoviridae virus, an Arenaviridae virus, a Bunyaviridae virus, an Orthomyxoviridae virus, or a Deltavirus virus, or a viral infection is caused by a coronavirus, SARS, poliovirus, rhinovirus, hepatitis A, Norwalk virus, or virus, yellow fever virus, West Nile virus, hepatitis C virus, dengue fever virus, Zika virus, rubella virus, Ross River virus, Sindbisvirus, Chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, measles virus, mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, human respiratory syncytial virus, rabies virus, Lassa virus, Hantavirus, Crimean-Congo hemorrhagic fever virus, influenza, or hepatitis D virus.
[0016] In other embodiments of the invention, the RNA-based masking construct inhibits the generation of a detectable positive signal, or the RNA-based masking construct inhibits the generation of a detectable positive signal by masking the detectable positive signal or alternatively generating a detectable negative signal, or the RNA-based masking construct comprises a silencing RNA that inhibits the production of a gene product encoded by a reporter construct, wherein the gene product generates a detectable positive signal when expressed.
[0017] In other embodiments, the RNA-based masking construct is a ribozyme that produces a negative detectable signal and wherein a positive detectable signal is produced when the ribozyme is inactivated, or the ribozyme converts a substrate to a first color and wherein the substrate converts to a second color when the ribozyme is inactivated.
[0018] In other embodiments, the RNA-based masking agent is an RNA aptamer, or an aptamer chelates an enzyme, wherein the enzyme generates a detectable signal by acting on a substrate upon release from the aptamer, or an aptamer chelates a pair of agents that combine to generate a detectable signal when released from the aptamer.
[0019] In another embodiment, the RNA-based masking construct comprises an RNA oligonucleotide to which a detectable ligand and a masking component are attached. In another embodiment, the detectable ligand is a fluorophore and the masking component is a quencher molecule, or an agent for amplifying a target RNA molecule, such as, but not limited to, NASBA or RPA reagents.
[0020] In another aspect, the present invention provides a diagnostic device comprising one or more individual discrete volumes, each individual discrete volume comprising a CRISPR effector protein, one or more guide RNAs designed to bind to a corresponding target molecule, an RNA-based masking construct, and optionally further comprising a nucleic acid amplification reagent.
[0021] In another aspect, the present invention provides a diagnostic device comprising one or more individual discrete volumes, each individual discrete volume comprising a CRISPR effector protein, one or more guide RNAs designed to bind to a trigger RNA, one or more detection aptamers comprising a masked RNA polymerase promoter binding site or a masked primer binding site, and optionally further comprising nucleic acid amplification reagents.
[0022] In some embodiments, the individual discrete volumes are droplets, or the individual discrete volumes are defined on a solid substrate, or the individual discrete volumes are microwells, or the individual discrete volumes are spots defined on a substrate, such as a paper substrate.
[0023] In certain other exemplary embodiments, the nucleic acid detection system is designed to detect one or more viral targets and is used in conjunction with an antiviral therapeutic. In certain exemplary embodiments, the antiviral therapeutic is a Class 2, Type VI CRISPR-based antiviral system. For example, a nucleic acid detection system can be used in conjunction with an antiviral system to select an appropriate therapeutic agent for the resistance or susceptibility of a viral strain infecting a particular patient or prevalent in a given outbreak. This includes diagnostic systems that can detect novel mutations that arise during therapy as well as mutations that are known to arise that lead to resistance to therapy. Such diagnostic system embodiments disclosed herein can be used as companion diagnostics for antiviral therapeutics to select appropriate initial antiviral therapy and also to modify antiviral therapy in response to potential emergence of resistance mutants. In exemplary embodiments where the antiviral agent is a Class 2, Type VI CRISPR-based antiviral therapeutic, the diagnostic system embodiments disclosed herein can be used to select and / or modify the guide sequence used by the Class 2, Type VI CRISPR-based antiviral therapeutic to direct the effector protein to the target viral agent nucleic acid sequence.
[0024] In one embodiment, the RNA targeting effector protein is a CRISPR type VI RNA targeting effector protein, such as C2c2, Cas13b or Cas13c. In certain exemplary embodiments, the C2c2 effector protein is from an organism selected from the group consisting of Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Freundium, Flavobacterium, Monofilamentous, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacterium, Staphylococcus, Nitrate Lysogeny, Mycoplasma, and Campylobacter, or the C2c2 effector protein is selected from the group consisting of Leptotrichia sabii, Leptotrichia wadeii, Listeria stutzeri, Lachnospiraceae bacterium, Clostridium aminophilum, Gallobacter, Pseudomonas aeruginosa, Listeria wissenii, Listeriaceae bacterium, and Rhodobacter capsulatum. capsulatus), and the C2c2 effector protein is Leptotrichia wadeii F0279 or Leptotrichia wadeii F0279 (Lw2) C2c2 effector protein. In another embodiment, the one or more guide RNAs are designed to bind to one or more target RNA sequences that are diagnostic for a disease condition.
[0025] In certain exemplary embodiments, the RNA-based masking construct inhibits the generation of a detectable positive signal, or the RNA-based masking construct inhibits the generation of a detectable positive signal by masking the detectable positive signal or alternatively generating a detectable negative signal, or the RNA-based masking construct comprises a silencing RNA that inhibits the production of a gene product encoded by a reporter construct, wherein the gene product generates a detectable positive signal when expressed.
[0026] In another exemplary embodiment, the RNA-based masking construct is a ribozyme that produces a negative detectable signal, and wherein a positive detectable signal is produced when the ribozyme is inactivated. In one exemplary embodiment, the ribozyme converts a substrate to a first color, and wherein the substrate converts to a second color when the ribozyme is inactivated. In another exemplary embodiment, the RNA-based masking agent is an aptamer that chelates an enzyme, wherein the enzyme produces a detectable signal by acting on a substrate after being released from the aptamer, or the aptamer chelates a pair of agents that, when released from the aptamer, combine to produce a detectable signal.
[0027] In another exemplary embodiment, the RNA-based masking construct comprises a detectable ligand oligonucleotide and an RNA oligonucleotide to which the masking component is attached. In certain exemplary embodiments, the detectable ligand is a fluorophore and the masking component is a quencher molecule.
[0028] In another aspect, the present invention provides a method for detecting a target RNA in a sample, the method comprising: partitioning the sample or sample group into one or more individual discrete volumes, the individual discrete volumes comprising a CRISPR system comprising an effector protein, one or more guide RNAs, and an RNA-based masking construct; incubating the sample or sample group under conditions sufficient to allow the one or more guide RNAs to bind to the one or more target molecules; activating the CRISPR effector protein via the one or more guide RNAs binding to the one or more target molecules, wherein the activated CRISPR effector protein modifies the RNA-based masking construct to produce a detectable positive signal; and detecting the detectable positive signal, wherein detection of the detectable positive signal indicates the presence of the one or more target molecules in the sample.
[0029] In another aspect, the present invention provides a method for detecting peptides in a sample, the method comprising: distributing the sample or sample group into a set of individual discrete volumes, the individual discrete volumes comprising a peptide detection aptamer, a CRISPR system comprising an effector protein, one or more guide RNAs, and an RNA-based masking construct, wherein the peptide detection aptamer comprises a masked RNA polymerase site and is constructed to bind to one or more target molecules; incubating the sample or sample group under conditions sufficient to allow the peptide detection aptamer to bind to the one or more target molecules, wherein the aptamer binds to the corresponding target molecule to expose the RNA polymerase binding site, thereby facilitating RNA synthesis of the triggering RNA; activating the CRISPR effector protein via binding of the one or more guide RNAs to the triggering RNA, wherein the activated CRISPR effector protein modifies the RNA-based masking construct to produce a detectable positive signal; and detecting the detectable positive signal, wherein detection of the detectable positive signal indicates the presence of one or more target molecules in the sample.
[0030] In certain exemplary embodiments, such methods further comprise amplifying the sample RNA or trigger RNA. In other embodiments, amplifying RNA comprises amplifying by NASBA or RPA.
[0031] In certain exemplary embodiments, the CRISPR effector protein is a CRISPR type VI RNA targeting effector protein, such as C2c2 or Cas13b. In other exemplary embodiments, the C2c2 effector protein is from an organism selected from the group consisting of: Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Fusarium, Flavobacterium, Monofilamentous Shell, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacter, Staphylococcus, Nitrate The genus Haloperidol, Mycoplasma and Campylobacter, or the C2c2 effector protein is selected from the group consisting of: Leptotrichia sabdariffa, Leptotrichia wadeii, Listeria monocytogenes, Lachnospiraceae bacteria, Clostridium aminophilum, Bacillus galli, Bacillus thuringiensis, Listeria wissenii, Listeriaceae bacteria and Rhodobacter capsulatum, in a specific embodiment, the C2c2 effector protein is Leptotrichia wadeii F0279 or Leptotrichia wadeii F0279 (Lw2) C2C2 effector protein.
[0032] In certain exemplary embodiments, the one or more guide RNAs are designed to bind to one or more target molecules that are diagnostic for a disease condition. In certain other exemplary embodiments, the disease condition is an infection, an organ disease, a blood disease, an immune system disease, a cancer, a brain and nervous system disease, an endocrine disease, a pregnancy or childbirth-related disease, a genetic disease or an environmentally acquired disease, a cancer, or a fungal infection, a bacterial infection, a parasitic infection, or a viral infection.
[0033] In certain exemplary embodiments, the RNA-based masking construct inhibits the generation of a detectable positive signal, or the RNA-based masking construct inhibits the generation of a detectable positive signal by masking the detectable positive signal or alternatively generating a detectable negative signal, or the RNA-based masking construct comprises a silencing RNA that inhibits the generation of a gene product encoded by the reporter construct, wherein the gene product generates a detectable positive signal when expressed, or the RNA-based masking construct is a ribozyme that generates a negative detectable signal, and wherein a positive detectable signal is generated when the ribozyme is inactivated. In other exemplary embodiments, the ribozyme converts a substrate to a first state and wherein the substrate converts to a second state when the ribozyme is inactivated, or the RNA-based masking agent is an aptamer, or an aptamer chelates an enzyme, wherein the enzyme generates a detectable signal by acting on a substrate after being released from the aptamer, or an aptamer chelates a pair of agents that, when released from the aptamer, combine to generate a detectable signal. In other embodiments, the RNA-based masking construct comprises an RNA oligonucleotide having a detectable ligand on a first end of the RNA oligonucleotide and a masking component on a second end of the RNA oligonucleotide, or the detectable ligand is a fluorophore and the masking component is a quencher molecule.
[0034] In certain exemplary embodiments, the methods, systems, and devices disclosed herein can be used to detect SNPs associated with fetal microencephaly. Exemplary fetal microencephaly mutations that can be detected using the embodiments disclosed herein are disclosed in Yuan et al. Science 10.1126 / science.aam7120 (2017).
[0035] These and other aspects, objects, features and advantages of the exemplary embodiments will become apparent to those of ordinary skill in the art after considering the following detailed description of the illustrated exemplary embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 - is a schematic diagram of an exemplary C2c2-based CRISPR effector system.
[0037] Figure 2- Provided is (A) a schematic diagram of the CRISPR / C2c2 locus from Leptotrichia wadeii. Representative crRNA structures from the LwC2c2 and LshC2c2 systems are shown. (SEQ.ID No. 142 and 143) (B) Schematic diagram of in vivo bacterial assays for C2c2 activity. The protospacer was cloned upstream of the β-lactamase gene in an ampicillin-resistant plasmid, and this construct was transformed into Escherichia coli (E. coli) expressing C2c2 in combination with a targeting or non-targeting spacer. Successful transformants were counted to quantify activity. (C) Quantification of in vivo activity of LwC2c2 and LshC2c2. (n = 2 biological replicates; bars represent mean ± sem) (D) Final size exclusion gel filtration of LwC2c2. (E) Coomassie blue-stained acrylamide gel of the step-by-step purification of LwC2c2. (F) Activity of LwC2c2 against different PFS targets. LwC2c2 was targeted to fluorescent RNAs with variable 3' PFSs flanked by spacers, and the reaction products were visualized on denaturing gels. LwC2c2 showed a slight preference for the G PFS.
[0038] Figure 3-6 - Shown is the detection of an exemplary masking construct with 4 different amounts of protein / crRNA (1:4, 1:16, 1:32, 1:64) using 1 μg, 100 ng, 10 ng and 1 ng of target at different dilutions with 2 crRNA pools, no crRNA conditions, technical replicates, in (96+48)*2=288 reactions, measured at 5 minute time intervals over 3 hours.
[0039] Figure 7 - Provides a schematic diagram of an exemplary detection scheme using a masking construct and a CRISPR effector protein, according to certain exemplary embodiments.
[0040] Figure 8 - Provides a set of graphs showing changes in fluorescence over time when different pools of guide RNAs are used to detect a target.
[0041] Figure 9 - Provided are graphs showing normalized fluorescence of target RNA detection across different dilutions at different concentrations of CRISPR effector protein.
[0042] Figure 10 - is a schematic diagram showing the general steps of the NASBA amplification reaction.
[0043] Figure 11- Provides a graph showing the detection of the nucleic acid target ssRNA 1 amplified by NASBA with three different primer sets and then subjected to C2c2 incidental detection using a quenched fluorescent probe. (n=2 technical replicates; bars represent mean±sem)
[0044] Figure 12 - Provides a diagram showing that the collateral effect can be used to detect the presence of lentiviral target RNA.
[0045] Figure 13 - Provides a graph demonstrating the collateral effect and that NASBA can detect substances at aM concentrations.
[0046] Figure 14 - Provides figures demonstrating the collateral effect and the rapid discrimination of low-concentration samples by NASBA.
[0047] Figure 15 - shows the normalized fluorescence predicted sample input concentration at a specific time point. Fluorescence measurements from Cas13a detection in the absence of amplification are correlated with input RNA concentration. (n = 2 biological replicates; bars represent mean ± sem)
[0048] Figure 16 - A schematic diagram of the RPA reaction is provided, showing the components involved in the reaction.
[0049] Figure 17 -Schematic diagram of SHERLOCK; provides a schematic diagram showing the detection of DNA or RNA targets via the corresponding incorporation of RPA or RT-RPA steps. After target RNA recognition, a side effect causes C2c2 to cleave the reporter, generating fluorescence. Single-molecule RNA or DNA can be amplified into DNA via recombinase polymerase amplification (RPA) and transcribed to produce RNA, which is then detected by C2c2.
[0050] Figure 18 - Schematic representation of the ssRNA targets detected via C2c2 incidental detection is provided (SEQ. ID No. 144 and 145).
[0051] Figure 19 - A set of graphs demonstrating single molecule DNA detection using RPA is provided (ie, within 15 minutes of C2c2 addition).
[0052] Figure 20 - Provides a set of figures demonstrating that mixing T7 polymerase into RPA reactions can adversely affect DNA detection.
[0053] Figure 21 - Provides a set of figures demonstrating that mixing polymerase into RPA reactions does not adversely affect DNA detection.
[0054] Figure 22 - Provides a graph demonstrating that RPA, T7 transcription, and C2c2 detection reactions are compatible and achieve single-molecule detection when incubated simultaneously. (n=2 technical replicates; bars represent mean ± sem)
[0055] Figure 23 - Provides a set of figures demonstrating the efficacy of rapid RPA-RNA time incubation.
[0056] Figure 24 - Provides a set of graphs demonstrating that increasing the amount of T7 polymerase enhances the sensitivity of RPA-RNA.
[0057] Figure 25 - Provides a set of graphs showing results from a one-pot RPA-DNA detection assay using 1.5x enzyme. Single molecule (2 aM) detection was achieved as early as 30 minutes.
[0058] Figure 26 - Provides a set of graphs showing that a one-pot RPA-DNA reaction demonstrates a quantitative decrease in fluorescence relative to the input concentration. The fitted curve reveals the relationship between the target input concentration and the output fluorescence.
[0059] Figure 27 Provides a set of figures demonstrating that (A) C2c2 detection of RNA without amplification can detect ssRNA targets at concentrations as low as 50 fM (n = 2 technical replicates; bars represent mean ± sem), and (B) RPA-C2c2 reactions are capable of single-molecule DNA detection (n = 4 technical replicates; bars represent mean ± sem).
[0060] Figure 28 - Provides a set of graphs demonstrating that C2c2 signals generated according to certain exemplary embodiments can detect a 20 pM target on a paper substrate.
[0061] Figure 29 - A graph is provided showing that specific RNase inhibitors are able to remove background signals on paper.
[0062] Figure 30 is a set of graphs illustrating inspection on a fiberglass substrate using a system according to certain exemplary embodiments.
[0063] Figure 31- A set of figures is provided, which provides (A) a schematic diagram of Zika RNA detection according to certain exemplary embodiments. Lentivirus is encapsulated with Zika RNA or homologous dengue RNA fragments targeted by C2c2 incidental detection. The culture medium is collected after 48 hours and subjected to thermal lysis, RT-RPA and C2c2 detection. (B) RT-RAP-C2c2 detection enables highly sensitive detection of Zika lentiviral particles (n=4 technical replicates, two-tailed Student t-test; ****, p<0.0001; bars represent mean ± sem) (C) Schematic diagram of Zika RNA detection using freeze-dried C2c2 on paper according to certain exemplary embodiments. (D) Paper-based assay enables highly sensitive detection of Zika lentiviral particles (n-4 technical replicates, two-tailed Student t-test; ****, p<0.0001; **, p<0.01, bars represent mean ± sem)
[0064] Figure 32 - A set of figures is provided showing (A) a schematic diagram of C2c2 detection of Zika RNA isolated from human serum. Zika RNA in serum was subjected to reverse transcription, RNase H degradation of RNA, RPA of cDNA, and C2c2 detection. (B) C2c2 enables highly sensitive detection of human Zika serum samples. The concentrations of Zika RNA shown were verified by qPCR. (n = 4 technical replicates, two-tailed Student t-test; ****, p < 0.0001; bars represent mean ± sem)
[0065] Figure 33 A set of figures is provided, demonstrating that (A) freeze-dried C2c2 enables sensitive detection of ssRNA 1 in the low femtomolar range. C2c2 enables rapid detection of 200 pM ssRNA 1 target in liquid form (B) or freeze-dried on paper (C). The reaction enables sensitive detection of synthesized Zika RNA fragments in solution (D) (n=3) and in freeze-dried form (E) (n=3). (F) Quantification curves for human Zika cDNA detection showing a significant correlation between input concentration and detected fluorescence. (G) C2c2 detection of ssRNA 1 in the presence of varying amounts of human serum. (Unless otherwise noted, n=2 technical replicates; bars represent mean ± sem).
[0066] Figure 34Provided are (A) a schematic diagram of C2c2 detection of the 16S rRNA gene from bacterial genomes using a universal V3 RPA primer set, and (B) the ability of assays performed according to certain exemplary embodiments to achieve sensitive and specific detection of Escherichia coli or Pseudomonas aeruginosa gDNA. (n = 4 technical replicates, two-tailed Student's t-test; ****, p < 0.0001; bars represent mean ± sem). Ec, Escherichia coli; Kp, Klebsiella pneumoniae; Pa, Pseudomonas aeruginosa; Mt, Mycobacterium tuberculosis; Sa, Staphylococcus aureus.
[0067] Figure 35 - Provides a set of graphs showing (A) detection of two different carbapenem resistance genes (KPC and NDM-1) from four different clinical isolates of Klebsiella pneumoniae, and (B) detection of carbapenem resistance genes (part A) normalized to the signal ratio between KPC and NDM-1 crRNA assays. (n = 2 technical replicates, two-tailed Student t-test; ****, p < 0.0001; bars represent mean ± sem)
[0068] Figure 36 - A set of figures is provided showing that (A) C2c2 is insensitive to single mismatches but can distinguish single nucleotide differences in the target when loaded with crRNA with additional mismatches. ssRNA targets 1-3 were detected with 11 crRNAs, of which 10 spacers contained synthetic mismatches at various positions in the crRNA. The mismatched spacers did not show reduced cleavage of target 1, but showed inhibited cleavage of mismatched targets 2 and 3 (SEQ.IDNo.146 to 159). (B) Schematic diagram showing the process of rational design of single-base specific spacers with synthetic mismatches. The synthetic mismatches were placed close to the SNP or base of interest. (SEQ.IDNo.160 to 164) (C) Highly specific detection of strain SNPs allows the use of C2c2 detection with truncated (23 nucleotide) crRNA to distinguish Zika African vs. American RNA targets that differ by only one nucleotide. (n=2 technical replicates, one-tailed Student's t-test; *, p<0.05; ****, p<0.0001; bars represent mean±sem).
[0069] Figure 37A set of figures is provided, showing: (A) Schematic diagram of the Zika strain target region and crRNA sequences used for detection. (SEQ. ID Nos. 165 to 170) SNPs in the target are highlighted in red or blue, and synthetic mismatches in the guide sequence are colored red. (B) Highly specific detection of strain SNPs allows SHERLOCK to distinguish between African and American Zika RNA targets. (n = 2 technical replicates, two-tailed Student t-test; ****, p < 0.0001; bars represent mean ± sem) (SEQ. ID Nos. 171 to 176) (C) Schematic diagram of the dengue strain target region and crRNA sequences used for detection. SNPs in the target are highlighted in red or blue, and synthetic mismatches in the guide sequence are colored red. (D) Highly specific detection of strain SNPs allows SHERLOCK to distinguish between dengue strain 1 and strain 3 RNA targets. (n = 2 technical replicates, two-tailed Student's t-test; ****, p < 0.0001; bars represent mean ± sem) ( Figure 37 )
[0070] Figure 38 - A set of figures is provided, which shows (A) a donut diagram showing the location of human SNPs detected with C2c2. (B) Assays performed according to certain exemplary embodiments can distinguish human SNPs. SHERLOCK can correctly genotype four different individuals at four different SNP sites in the human genome. The identity of the genotype and allele sensing crRNA of each individual is marked below each figure. (n=4 technical replicates; two-tailed Student t-test; *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; bars represent mean ± sem). (C) Schematic diagram of the process of detection of cfDNA (e.g., cell-free DNA detection of cancer mutations) according to certain exemplary embodiments. (D) Exemplary crRNA sequences for detecting EGFR L858R and BRAF V600E. (SEQ. ID No. 177 to 182). Sequences of two genomic loci determined for cancer mutations in cell-free DNA. Shown are the target genomic sequence with SNPs highlighted in blue and the mutant / wild-type sensor crRNA sequence with synthetic mismatches painted in red.
[0071] Figure 39- Provides a set of graphs demonstrating that C2c2 can detect mutant minor alleles in simulated cell-free DNA samples from EGFR L858R (C) or BRAF V600E (B) minor alleles. (n = 4 technical replicates, two-tailed Student's t-test; *, p < 0.05; **, p < 0.01, ****, p < 0.0001; bars represent ± sem)
[0072] Figure 40 - A set of graphs is provided showing that (A) the assay can distinguish genotypes at rs5082. (n = 4 technical replicates; *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001; bars represent mean ± sem) (B) the assay can distinguish genotypes at rs601338 in gDNA directly from centrifuged, denatured, and boiled saliva. (n = 3 technical replicates; *, p < 0.05; bars represent mean ± sem)
[0073] Figure 41 Provided are (A) schematic diagrams of exemplary embodiments of an assay performed on ssDNA 1 in a background of a target that differs from ssDNA 1 by only a single mismatch. (B) The assay achieves single-nucleotide-specific detection of ssDNA 1 in the presence of a background of mismatches (target that differs from ssDNA by only a single mismatch). Various concentrations of target DNA are combined with a background excess of DNA with a single mismatch and detected by the assay.
[0074] Figure 42 is a diagram showing that a masking construct with a different dye, Cy5, also allows efficient detection.
[0075] Figure 43 Schematic diagram of a colorimetric gold nanoparticle-based assay. AuNPs are aggregated using a combination of DNA linkers and RNA bridges. Upon addition of RNase activity, the ssRNA bridges cleave and release the AuNPs, causing a characteristic color shift toward red.
[0076] Figure 44 is a graph showing the ability to detect the red shift of dispersed nanoparticles at 520 nm. The nanoparticles are based on Figure 43 and dispersed using the addition of RNase A at varying concentrations.
[0077] Figure 45 is a graph showing that the RNase colorimetric test is quantitative.
[0078] Figure 46 is a photograph of a microplate showing that the color shift of dispersed nanoparticles is visually detectable.
[0079] Figure 47 is a photograph showing the colorimetric shift visible on a paper substrate. The test was performed on glass fiber 934-AH at 37°C for 10 minutes.
[0080] Figure 48 Schematic diagram of a conformational switching aptamer for protein or small molecule detection according to certain exemplary embodiments. The ligation product (B) serves as an intact target for an RNA-targeting effector that is unable to detect the unligated input product. (SEQ. ID. Nos. 202 and 424).
[0081] Figure 49 This is an image of a gel showing that aptamer-based ligation can create an RPA-detectable substrate. The aptamer was incubated with various levels of thrombin and then ligated to the probe. The ligated construct was used as a template for a 3-minute RPA reaction. 500 nM thrombin resulted in significantly higher levels of amplified target than background.
[0082] Figure 50 The amino acid sequences of the HEPN domains of selected C2c2 orthologs are shown. (SEQ.ID.No.204-233)
[0083] Figure 51 Cas13a detection of RNA using RPA amplification (SHERLOCK) can detect ssRNA targets at concentrations down to approximately 2 aM, more sensitive than Cas13a alone. (n = 4 technical replicates; bars represent mean ± sem)
[0084] Figure 52-C As13a detection can be used to sense viral and bacterial pathogens. (A) Schematic diagram of the SHERLOCK assay for ZIKV RNA isolated from human clinical samples. (B) SHERLOCK enables highly sensitive detection of human ZIKV-positive serum (S) or urine (U) samples. The approximate concentrations of ZIKV RNA shown were determined by qPCR. (n = 4 technical replicates, two-tailed Student t-test; ****, p < 0.0001; bars represent mean ± sem; nd, not detected)
[0085] Figure 53 - by using NASBA of primer set 2 ( Figure 11 ) and SHERLOCK for the detection of ssRNA 1. (n = 2 technical replicates; bars represent mean ± sem)
[0086] Figure 54 Nucleic acid amplification using RPA and single-reaction SHERLOCK. (A) Figure 1(B) Quantification of ssRNA1 by digital droplet PCR of the dilutions used in the experiment. The adjusted concentrations of the dilutions based on the ddPCR results are shown above the bar graph. Figure 1 Digital droplet PCR quantification of ssDNA 1 using the dilutions used in (C). Adjusted concentrations of the dilutions based on the ddPCR results are shown above the bar graph. (C) When incubated simultaneously, RPA, T7 transcription, and Cas13a detection reactions are compatible and achieve single-molecule detection of DNA 2. (n = 3 technical replicates, two-tailed Student's t-test; ns, not significant; **, p < 0.01; ****, p < 0.0001; bars represent mean ± sem)
[0087] Figure 55 - Comparison of SHERLOCK with other sensitive nucleic acid detection tools. (A) Detection analysis of a ssDNA 1 dilution series using digital droplet PCR. (n = 4 technical replicates, two-tailed Student's t-test; ns, not significant; *, p < 0.05; **, p < 0.01; ****, p < 0.0001; red line represents the mean, bars represent the mean ± sem. Samples with measured copies / μl below 10-1 are not shown.) (B) Detection analysis of a ssDNA 1 dilution series using quantitative PCR. (n = 16 technical replicates, two-tailed Student's t-test; ns, not significant; **, p < 0.01; ****, p < 0.0001; red line represents the mean, bars represent the mean ± sem. Samples with relative signals below 10-10 are not shown.) (C) Detection analysis of a ssDNA 1 dilution series using RPA with SYBR Green II. (n = 4 technical replicates, two-tailed Student's t-test; *, p < 0.05; **, p < 0.01; red line indicates the mean, bars indicate the mean ± sem. Samples with relative signals below 100 are not shown.) (D) Detection analysis of a dilution series of ssDNA 1 using SHERLOCK. (n = 4 technical replicates, two-tailed Student's t-test; **, p < 0.01; ****, p < 0.0001; red line indicates the mean, bars indicate the mean ± sem. Samples with relative signals below 100 are not shown.) (E) Percent coefficient of variation of a series of ssDNA 1 dilutions for four types of detection methods. (F) Average percent coefficient of variation of 6e2, 6e1, 6e0, and 6e-1 ssDNA 1 dilutions for four types of detection methods. (Bars indicate the mean ± sem) Figure 56Detection of carbapenem resistance in clinical bacterial isolates. Five clinical isolates of Klebsiella pneumoniae and an Escherichia coli control were tested for two different carbapenem resistance genes (KPC and NDM-1). (n = 4 technical replicates, two-tailed Student's t-test; ****, p < 0.0001; bars represent mean ± SEM; nd, not detected)
[0088] Figure 57 - Characterization of LwCas13a sensitivity to truncated spacers and single mismatches in target sequences. (A) Sequences of truncated spacer crRNAs used in (B)-(G) (SEQ.ID.No.425-436). Sequences of ssRNA 1 and 2 are also shown, with single base pair differences highlighted in red. CrRNAs containing synthetic mismatches are displayed with mismatch positions painted red. (B) Incidental cleavage activity of 28nt spacer crRNAs with synthetic mismatches at positions 1-7 against ssRNA 1 and 2. (n=4 technical replicates; bars represent mean ± sem) (C) Specificity ratios of crRNAs tested in (B). The specificity ratio is calculated as the ratio of incidental cleavage of the on-target RNA (ssRNA 1) to incidental cleavage of the off-target RNA (ssRNA 2). (n = 4 technical replicates; bars represent mean ± sem) (D) Incidental cleavage activity of 23nt spacer crRNAs with synthetic mismatches at positions 1-7 against ssRNAs 1 and 2. (n = 4 technical replicates; bars represent mean ± sem) (E) Specificity ratios of the crRNAs tested in (D). Specificity ratios were calculated as the ratio of incidental cleavage of the on-target RNA (ssRNA 1) to incidental cleavage of the off-target RNA (ssRNA 2). (n = 4 technical replicates; bars represent mean ± sem) (F) Incidental cleavage activity of 20nt spacer crRNAs with synthetic mismatches at positions 1-7 against ssRNAs 1 and 2. (n = 4 technical replicates; bars represent mean ± sem) (G) Specificity ratios of the crRNAs tested in (F). Specificity ratios were calculated as the ratio of incidental cleavage of the on-target RNA (ssRNA 1) to incidental cleavage of the off-target RNA (ssRNA 2). (n = 4 technical replicates; bars represent mean ± sem)
[0089] Figure 58.-Identification of ideal synthetic mismatch positions relative to mutations in the target sequence. (A) Sequences (SEQ.ID.No.437-462) used to evaluate ideal synthetic mismatch positions to detect mutations between ssRNA 1 and ssRNA 2. On each target, crRNAs with synthetic mismatches at the colored (red) positions were tested. Each set of synthetic mismatch crRNAs was designed so that the mutation position was positionally offset relative to the sequence of the spacer. The spacer was designed so that mutations were evaluated at positions 3, 4, 5, and 6 within the spacer. (B) Incidental cleavage activity of crRNAs with synthetic mismatches against ssRNA 1 and 2 at different positions. There are four groups of crRNAs that have mutations at any position 3, 4, 5, or 6 within the spacer:target duplex region. (n=4 technical replicates; bars represent mean ± sem) (C) Specificity ratios of the crRNAs tested in (B). The specificity ratio is calculated as the ratio of incidental cleavage of the on-target RNA (ssRNA 1) to incidental cleavage of the off-target RNA (ssRNA 2). (n = 4 technical replicates; bars represent mean ± sem)
[0090] Figure 59 - Genotyping at additional loci using SHERLOCK and direct genotyping from boiled saliva. SHERLOCK can distinguish genotypes at the rs601338 SNP site in genomic DNA directly from centrifuged, denatured, and boiled saliva. (n = 4 technical replicates, two-tailed Student t-test; **, p < 0.01; ****, p < 0.001; bars represent mean ± sem)
[0091] Figure 60-Development of synthetic genotyping standards for accurate genotyping of human SNPs. (A) Genotyping performed on each of four individuals at the rs601338 SNP site using SHERLOCK compared to the genotyping standard of PCR amplification. (n=4 technical repeats; bars represent mean ± sem) (B) Genotyping performed on each of four individuals at the rs4363657 SNP site using SHERLOCK compared to the genotyping standard of PCR amplification. (n=4 technical repeats; bars represent mean ± sem) (C) Heat map of the calculated p value between the SHERLOCK result of each individual and the synthetic standard at the rs601338 SNP site. A heat map of each of the allele sensing crRNAs is shown. The heat map color table is scaled so that non-significant (p>0.05) is red and significant (p<0.05) is blue. (n=4 technical repeats, single-factor ANOVA). (D) Heat map of the calculated p value between the SHERLOCK result of each individual and the synthetic standard at the rs4363657SNP site. A heat map of each of the allele sensing crRNAs is shown. The heat map color table is scaled so that non-significance (p>0.05) is red and significance (p<0.05) is blue. (n=4 technical repeats, single-factor ANOVA) (E) A guide for understanding the p value heat map results of SHERLOCK genotyping. Genotyping can be easily called by selecting the allele corresponding to the p value>0.05 between the individual and the allele synthetic standard. The red block corresponds to the non-significant difference between the synthetic standard and the individual SHERLOCK result and is therefore a genotype positive result. The blue block corresponds to the significant difference between the synthetic standard and the individual SHERLOCK result and is therefore a genotype negative result.
[0092] Figure 61 - Detection of ssDNA 1 as a minor mismatched background target. SHERLOCK assay of a dilution series of ssDNA 1 against a background of human genomic DNA. Note that there should be no sequence similarity between the detected ssDNA 1 target and the background genomic DNA. (n = 2 technical replicates; bars represent mean ± sem)
[0093] Figure 62 - Urine (A) or serum (B) samples from patients with Zika virus were heat inactivated at 95°C (urine) or 65°C (serum) for 5 minutes. According to an exemplary embodiment, 1 microliter of inactivated urine or serum was used as input for a 2-hour RPA reaction followed by a 3-hour C2c2 / Cas13a detection reaction. Error bars indicate 1SD based on n=4 technical replicates of the detection reaction.
[0094] Figure 63 - Urine samples from patients with Zika virus were heat inactivated at 95°C for 5 minutes. According to an exemplary embodiment, 1 microliter of inactivated urine was used as input for a 30-minute RPA reaction followed by a 3-hour (A) or 1-hour (B) C2c2 / Cas13 detection reaction. Error bars indicate 1SD based on n=4 technical replicates of the detection reaction.
[0095] Figure 64 Urine samples from patients with Zika virus were heat-inactivated at 95°C for 5 minutes. One microliter of inactivated urine was used as input for a 20-minute RPA reaction followed by a 1-hour C2c2 / Cas13a detection reaction. Healthy human urine was used as a negative control. Error bars indicate 1SD based on n=4 technical replicates or detection reactions.
[0096] FIG65 — Urine samples from patients with Zika virus were heat inactivated at 95° C. for 5 minutes. One microliter of inactivated urine was used as input for a 20-minute RPA reaction followed by a 1-hour C2c2 / Cas13a detection reaction in the presence or absence of guide RNA. Data were normalized by subtracting the mean fluorescence value of the guideless detection reaction from the detection reaction containing the guide. Healthy human urine was used as a negative control. Error bars indicate 1SD based on n=4 technical replicates of the detection reaction.
[0097] Figure 66 - shows the detection of two malaria-specific targets using four different guide RNA designs according to an exemplary embodiment. (SEQ.ID.No.463-474).
[0098] Figure 67 - Shown are the positioning of designed guide RNAs along the segmented LCMV genome. Guide RNAs S1-S6 are complementary to MCMV S RNA (where S1 and S6 bind to the 5'UTR and 3'UTR, respectively). Guide RNAs L1-L6 are complementary to MCMV L RNA (where L1 and L6 bind to the 5'UTR and 3'UTR, respectively). All guide RNAs bind to the coding strand.
[0099] Figure 68-CExpression of as13a and LCMV-specific guide RNA reduces LCMV replication in cell culture. (A) HEK293FT cells were transfected with a plasmid expressing Cas13a and a single guide RNA targeting LCMV or a non-targeting control. 24 hours after transfection, cells were infected with LCMV at an MOI of 5, and viral titers were measured using RT-qPCR of viral RNA in the culture supernatant 48 hours after infection. (B) Inhibition of viral replication. Empty vector, off-target #1, and off-target #2 were considered negative controls. S1-S5 and L1-L6 target various regions of the LCMV genome. Error bars indicate 1 standard deviation based on n=3-6 biological replicates.
[0100] Figure 69 Inhibition of viral replication. LCMV-infected mammalian 293FT cells were transfected with the indicated C2c2 and guide plasmids. Graphs represent RT-qPCR values per microliter of genome equivalents, with bars representing each transfected guide plasmid. Empty vector, off-target #1, and off-target #2 were used as negative controls. S1-S5 and L1-L6 target various regions of the LCMV genome. Error bars indicate 1 standard deviation based on n=6 biological replicates.
[0101] Figure 70 -The combination of multiple guides enhances Cas13a-mediated inhibition of LCMV replication. HEK293FT cells were transfected with a plasmid expressing Cas13a and one or more guide RNAs targeting LCMV or a non-targeting control. LCMV infection was performed 24 hours after transfection at an MOI of 5, and viral titers were measured using RT-qPCR of viral RNA in the culture supernatant 48 hours after infection. Empty vector, off-target #1, and off-target #2 were considered negative controls. Error bars indicate 1 standard deviation based on n=6 biological replicates.
[0102] Figure 71 -The fraction of guides that reduce viral replication. The average GFP fluorescence 48 hours after LCMV infection was calculated for all guides from 3 replicates. The fold change of each LCMV-targeted guide was calculated as the ratio of the average fluorescence of the control guide versus the LCMV-targeted guide. A two-tailed, unpaired t-test was used to calculate the p-value. A targeted guide was considered to be any guide with a p-value less than or equal to 0.05 and a fold change (FC) greater than or equal to 2. The pie chart plots the data shown in the table, with the wedges corresponding to the non-coding and coding regions of the four proteins of LCMV. The remaining guides are those LCMV-targeted guides that did not pass the p-value and FC cutoffs.
[0103] Figure 72- Distribution of targeting efficiency of targeting guides. Distribution of fold change in GFP fluorescence (control guides vs. LCMV-targeted guides) for guides passing a p-value cutoff of 0.05. Not shown in this figure are the 8 guides with a greater than 50-fold reduction in GFP fluorescence (*8 guides showed a >50-fold reduction).
[0104] Figure 73 - Representative images illustrating the reduction in GFP (i.e., LCMV replication) for guides targeting the coding region of L(#104) compared to controls (empty guide vector) (three replicates per guide). Images were acquired at 4x magnification 48 hours after LCMV infection. Fold change 2.72, p-value 0.047.
[0105] Figure 74 - Fold change in GFP fluorescence 48 hours post-infection of control guides versus LCMV-targeted guides for all guides that passed a p-value cutoff of 0.05 and a fold change cutoff of 2. Each position on the x-axis is a guide tested in the LCMV whole genome screen. Any guide that did not pass this cutoff was plotted as 1. For any guide whose fluorescence was less than background or above background, the fold change was set to the maximum fold change observed.
[0106] Figure 75 - Cas13a-based diagnosis can sensitively detect Zika virus nucleic acid. Zika virus cDNA was serially diluted in healthy human urine and water to inactivate endogenous human RNase, and the SHERLOCK protocol was used to quantify viral cDNA (a). Several cDNA samples were also tested from patient urine or serum (b), and a combination of guide RNAs was used to distinguish patient samples collected from different countries during the Zika virus outbreak (c). Error bars indicate 1 standard deviation. Abbreviations: DOM = Dominican Republic, DOMUSA = Dominican Republic / United States, HND = Honduras, USA = United States.
[0107] Figure 76 - provides a diagram illustrating single copy detection of Zika according to certain exemplary embodiments.
[0108] Figure 77 - Graph illustrating the detection limits of Zika cDNA (a), RNA (b), and viral particles (c) using the SHERLOCK method with Zika virus-specific RPA primers and Zika virus-specific crRNA. Error bars represent 1 S.D. of three technical replicates. No input was nuclease-free water added to water or urine.
[0109] Figure 78Panel A is a schematic diagram of detecting single nucleotide variants in viral samples. Panel B is a schematic diagram showing the genomic locations of three SNPs tested by the SHERLOCK method. Panel C shows a graph showing the SNPs that appeared during the 2015 Zika virus outbreak and the locations where the SNPs appeared. Panel D shows the fluorescence ratio between mutant cRNA and wild-type cRNA at the 1 hour time point. Panel E shows the log2 transformed fluorescence of each sample for each crRNA. Figure 78 Heatmap of fluorescence ratios shown in D. Values greater than 0 indicate the presence of the mutant variant. Panel F is a graph showing data for the S139N variant. Darker shaded bars represent fluorescence measured when the S139N-targeting crRNA was used in the detection reaction, and lighter shaded bars represent fluorescence measured when the N139S-targeting crRNA was used. Error bars represent 1 S.D. of three technical replicates.
[0110] Figure 79 Panel A shows a schematic diagram illustrating how the multi-serotype dengue SHERLOCK panel works. In panel B, each tick on the x-axis represents a gblock template used as input for the SHERLOCK reaction. Each purple shading designates a serotype-specific crRNA. Error bars represent the 1 S.D. of three technical replicates. Panel C shows an alternative representation of the bar graph in (b) of fluorescence on a log10 scale.
[0111] Figure 80 A schematic diagram showing how the flavivirus SHERLOCK panel works is shown in panel A. In panel B, each tick on the x-axis represents a gblock template used as input for the SHERLOCK reaction. In panel C, each tick on the x-axis represents two gblock templates used as input for the SHERLOCK reaction to simulate SHERLOCK's ability to detect co-infections. Within each alternating white and gray block, each bar represents the fluorescence generated by a guide tested in the order of ZIKV crRNA, WNV crRNA, DENV crRNA, and YFV crRNA retained in each block. In panels B and C, each color designates a virus-specific crRNA. Error bars represent the ±SD of three technical replicates.
[0112] Figure 81 - Panels A and B show Figure 80 Alternative representation of measured fluorescence shown in the bar graphs of B and 80 C. The gradient is fluorescence at 3 hours on a log10 scale.
[0113] Figure 82-Sensitive ZIKV detection from clinical samples and mosquito banks. (A) Schematic diagram of SHERLOCK applied to clinical samples. Nucleic acids were extracted from clinical samples and target molecules were amplified by recombinase polymerase amplification (RPA). RNA samples were reverse transcribed (RT) before RPA. RPA products were detected using a reaction containing T7 RNA polymerase (for in vitro transcription of dsDNA RPA products), purifying Cas13a, crRNA, and an RNA reporter that fluoresces when cleaved. (B) SHERLOCK was tested on 40 samples collected during the 2016 ZIKV outbreak. cDNA was SHERLOCKed using a 20-minute RPA reaction and a 1-hour Cas13a detection. The blue dotted line indicates the critical value for the presence or absence of ZIKV (see Methods for details). (C) Comparison of SHERLOCK fluorescence with amplicon PCR yields. SHERLOCK and amplicon PCR were performed on the 40 ZIKV cDNA samples shown in (B). Amplicon PCR yield is the minimum concentration (ng / μL) of two independent amplification reactions using a primer pool of the patched ZIKV genome. Dashed lines indicate the cutoff values used to determine the presence or absence of ZIKV: blue for SHERLOCK and red for amplicon PCR. A Venn diagram shows the number of samples that passed these cutoff values for each method. In some cases, data points nearly overlap, indicated by numbers in parentheses. ND: Not detected.
[0114] Figure 83 - Direct detection of ZIKV cDNA, RNA, and particles from urine. (A) Detection of diluted ZIKV cDNA in untreated healthy human urine (red) using SHERLOCK. (B) Detection of diluted ZIKV RNA in untreated (red) or treated (blue) healthy human urine using SHERLOCK. (C) Detection of diluted ZIKV particles in PBS (grey) or untreated healthy human urine (red) using SHERLOCK. Undiluted viral stock is shown in black. Fluorescence at the most dilute sample and no input at 3 hours is shown (inset). In all panels, samples were treated with TCEP / EDTA and heated immediately after dilution to inactivate both the virus and RNase. The duration of heat treatment is indicated in the schematic. Error bars indicate 1 S.D. based on 3 technical replicates.
[0115] Figure 84 - SHERLOCK plates can distinguish between virus species and serotypes. (A) Detection of four related flaviviruses using SHERLOCK. (B) Target-specific fluorescence at 3 hours is shown for each crRNA for each virus in a bar graph and heat map. (C) Target-specific fluorescence at 3 hours is shown when two viral targets are present in a single sample. (D) Detection of DENV serotypes 1-4 using SHERLOCK. (E) Target-specific fluorescence at 3 hours is shown for serotype-specific crRNAs for each of the DENV serotypes. Target-specific fluorescence is the fluorescence for each target of the crRNA relative to the fluorescence of the crRNA without input. In all plates, error bars indicate 1 S.D. based on 3 technical replicates.
[0116] Figure 85 - Identification of adaptive and functional ZIKV mutations from an outbreak. (A) A schematic diagram illustrating how to design a SHERLOCK assay for SNP identification. Light colors are used to refer to ancestral crRNAs and dark colors are used to refer to derived crRNAs. (B) SHERLOCK assays for three SNPs from the 2016 ZIKV outbreak. The applicant illustrates the genomic location of each SNP and a simplified phylogenetic tree describing its evolutionary relationship. (C) SNP identification was tested using synthetic targets. Fluorescence values for derived crRNAs (dark colors) and ancestral crRNAs (light colors) are shown for each of the three region-specific SNPs. (D) Identification of region-specific SNPs in samples from the 2016 ZIKV outbreak. Three SNP identification assays were used to evaluate cDNA samples from the Dominican Republic (DOM), the United States (USA), and Honduras (HND). The applicant illustrates the fluorescence ratio (derivative crRNA fluorescence divided by ancestral crRNA fluorescence) of each SNP and each sample. (E) Visualization of log2-transformed data from (D) as a heat map. (F) Identification of ZIKV SNPs associated with microcephaly. As in (C), dark colors indicate derived crRNAs and light colors indicate ancestral crRNAs. In all panels, error bars indicate 1 S.D. based on three technical replicates.
[0117] Figure 86 SHERLOCK can detect ZIKV cDNA with high sensitivity. Applicants show SHERLOCK fluorescence values after 20 minutes of RPA and 1 hour of detection of serial dilutions of ZIKV cDNA. Error bars indicate 1 S.D. based on three technical replicates. In this experiment, RNase Alert v1 (IDT) was used as the RNA reporter.
[0118] Figure 87-(AD) SHERLOCK fluorescence data at 1 hour for 40 cDNA samples from the 2016 ZIKV outbreak. The sample name indicates the country of origin, the year of sample collection, followed by the sample name and sample type. The sample type is indicated as follows: PLA: plasma sample, SER: serum sample, URI: urine sample, MOS: mosquito reservoir. The country of origin is indicated using the following abbreviations: HND: Honduras, DOM: Dominican Republic, USA: United States. The error bars indicate 1S.D. based on 3 technical replicates. The positive control (purple) shown in each figure is a cultured virus seed stock solution (PE243). The negative control is shown in orange.
[0119] Figure 88 - Amplicon PCR primer library data and critical values. (A) Scatter plot of ng / μL concentration (measured by Agilent electrophoresis workstation (tapestation)) from each of the two amplicon PCR primer libraries for each cDNA sample. In some cases, the data points almost overlap, as indicated by the numbers in brackets. ND: Not detected. The positive control (purple cross) is a cultured viral seed stock (PE243), and the negative control (orange x) includes 1 no input control and 4 single donor healthy urine samples. (B) Scatter plot of amplicon PCR yield (ng / μl) versus genome coverage from the latest Zika sequencing work (Metsky et al. 2017). Amplicon PCR yield is defined as the minimum amplicon DNA concentration (measured by Agilent electrophoresis workstation) of the two amplicon PCR libraries. Genome coverage is normalized to 1. Technical replicates of the sequencing libraries are shown in separate circles. (C) Applicants show precision (true positives divided by the sum of true positives and false positives), recall (sensitivity), and F for different amplicon PCR yield cutoffs. 0.5 Statistics. The critical value of amplicon PCR yield was selected so that F 0.5 Statistics maximized.
[0120] Figure 89 - RNase inactivation using heat and chemical treatment. Serial 1:4 dilutions of RNase A (1 μg / ml) or healthy human urine were treated with TCEP and EDTA at final concentrations of 100 mM and 1 mM, respectively. Samples were incubated at 95°C for 10 minutes, then RNase Alert v1 (IDT) was added to each sample and fluorescence was monitored to determine nuclease activity. Fluorescence values are shown after 1 hour of incubation at 37°C. Error bars indicate 1S.D. based on 3 technical replicates.
[0121] Figure 90 - (A) Pretreatment of urine allows sensitive RNA detection using SHERLOCK. Applicants show fluorescence data after 1 hour of detection for RNA diluted in water (blue) and RNA diluted in urine pretreated with 100mM TCEP and 1mM EDTA at 95°C for 10 minutes (light red). (B) Carrier RNA does not improve SHERLOCK sensitivity. Applicants diluted ZIKV RNA in partially inactivated healthy human urine in the presence or absence of 100ng carrier RNA (see Methods section for details). As in (A), 1 hour detection was used. Error bars indicate 1S.D. based on 3 technical replicates.
[0122] Figure 91 - RNase inactivation at lower temperatures. Applicants tested a two-step heat inactivation protocol in which healthy human urine was incubated at 50°C for 20 minutes, followed by incubation at 95°C for 5 minutes. RNA was diluted in urine after the 50°C step but before the 95°C step. Error bars indicate 1 S.D. based on three technical replicates.
[0123] Figure 92 - Flavivirus plate time course. Each plate shows background-corrected fluorescence of virus-specific crRNA for each flavivirus target and a no-input control over a 3-hour time course, with fluorescence measurements taken every 5 minutes. Error bars are 1 S.D. based on 3 technical replicates.
[0124] Figure 93 - Flavivirus plate co-infection time course. Each plate shows background-corrected fluorescence for all crRNAs in samples with two flavivirus targets over a 3-hour time course, with fluorescence measurements taken every 5 minutes. Each plate also includes background-corrected fluorescence observed for each crRNA against a no-input control. Error bars are 1 S.D. based on 3 technical replicates.
[0125] Figure 94 -Dengue plate time course. Each plate shows background-corrected fluorescence of DENV serotype-specific crRNA for all DENV serotypes and no input control over a 3-hour time course, with fluorescence measurements taken every 5 minutes. Error bars are 1 S.D. based on 3 technical replicates.
[0126] Figure 95 - SNP Design Timeline. Applicants show the steps required to design, create, and test a SHERLOCK-based SNP identification assay. The total turnaround time is less than 1 week.
[0127] Figure 96- Identification of ZIKV microcephaly-associated SNPs using alternative crRNA design. The SNP is at position 7 of the crRNA and there are no synthetic mismatches introduced into the crRNA. Dark colors indicate derived crRNAs and light colors indicate ancestral crRNAs. Error bars indicate 1 S.D. based on 3 technical replicates.
[0128] Figure 97 - The SHERLOCK assay can identify six drug-resistant mutations in HIV reverse transcriptase. Applicants show a SNP discrimination index calculated by dividing the fluorescence ratio of the derived template by the fluorescence ratio of the ancestral template (see the Methods section for details). If there is no ability to distinguish between ancestral and derived alleles, then this index is equal to 1 and increases as the ability to distinguish the two alleles increases. Error bars indicate 1 S.D. based on 3 technical replicates.
[0129] Figure 98 This graph illustrates that SHERLOCK can detect ZIKV cDNA with high sensitivity. Shown are SHERLOCK fluorescence values after 20 minutes of RPA and 1 hour of detection of serial dilutions of ZIKV cDNA. A sensitivity of 0.9 aM is equivalent to a single-copy sensitivity of 2 aM = 1 cp / μl, with 2 μl of sample used as input. Error bars indicate 1 S.D. based on three technical replicates.
[0130] Figure 99 - Detection of ZIKV and DENV from patient samples and clinical isolates is shown. (A) Schematic diagram of SHERLOCK. Nucleic acids are extracted from clinical samples, and targets are amplified by RPA using RNA or DNA as input (RT-RPA or RPA, respectively). RPA products are detected in reactions containing T7 RNA polymerase, Cas13, target-specific crRNA, and an RNA reporter that fluoresces when cleaved. We tested SHERLOCK on (B) cDNA from 37 patient samples collected during the 2015-2016 ZIKV epidemic and (C) cDNA from 16 patient samples compared head-to-head using the Altona RealStar Zika virus RT-PCR assay. +: ZIKV seed stock cDNA (3x102 cp / μl) and ×: no input. (D) SHERLOCK on RNA extracted from 24 DENV-positive patient samples and clinical isolates. Blue dashed line: cutoff value for the presence or absence of ZIKV or DENV (see Methods).
[0131] Figure 100- Shown is a comparison between SHERLOCK and other nucleic acid amplification tests. Shown is a Venn diagram comparing the results of: (A) SHERLOCK versus the Altona RealStar Zika Virus RT-PCR Assay, and (B) SHERLOCK versus the Altona RealStar Zika Virus RT-PCR Assay and the Hologic Aptima Zika Virus Assay.
[0132] Figure 101 - Schematic diagram of the ZIKV genome regions targeted by SHERLOCK and other diagnostic methods. PCR amplicons collage the entire ZIKV genome, while the SHERLOCK ZIKV assay targets only a region of the ZIKV genome with shorter amplicons. The Altona RealStar RT-PCR assay and the Hologic Aptima TMA assay also target individual short amplicons in the ZIKV genome (the location and size of these amplicons are proprietary and therefore not shown in the schematic diagram). It is possible to have clinical samples with highly fragmented RNA that cannot be amplified by PCR primers (which have product lengths of approximately 400nt). Conversely, it is possible to have clinical samples with partial ZIKV genomes that do not contain the approximately 120nt SHERLOCK amplicon.
[0133] Figure 102 - Graphs illustrating the detection limit of pan-dengue SHERLOCK for RNA from four DENV serotypes are shown. (AD) SHERLOCK fluorescence values after 20 minutes of RPA and 1 hour of detection of serial dilutions of DENV RNA derived from synthetic templates. 1 μl of sample was used as input. Error bars indicate 1 S.D. based on three technical replicates.
[0134] Figure 103 Illustration of pan-dengue SHERLOCK applied to patient samples and clinical isolates. (A) Pan-dengue SHERLOCK fluorescence of RNA extracted from 24 samples and four seed stocks designated by DENV serotype. (B) Pan-dengue SHERLOCK fluorescence of RNA extracted from 14 human serum samples (B), from 10 cultured clinical isolates (C), and from four DENV seed stocks (D) at 1 hour of Cas13 detection.
[0135] Figure 104- Direct detection of ZIKV and DENV in body fluids using HUDSON and SHERLOCK. (A) Schematic diagram of direct virus detection using HUDSON and SHERLOCK. (BC) Detection of ZIKV RNA in particles diluted in healthy human serum (pink, B) or healthy human saliva (blue, C). Because the experiments were performed together, the same PBS control was used in A and B. (D) Detection of ZIKV RNA in particles diluted in healthy human urine (yellow). Black: undiluted virus stock solution. Gray: dilution in PBS. Error bars indicate 1S.D. based on 3 technical replicates. (EF) Detection of DENV RNA directly from patient serum (E) and saliva samples (F). (G) Lateral flow detection of DENV from the samples shown in (EF). All samples were treated with TCEP / EDTA before heating.
[0136] Figure 105 - A graph illustrating the detection of ZIKV cDNA directly from blood products using SHERLOCK, wherein ZIKV cDNA was diluted in healthy human whole blood (red), healthy human plasma (purple), healthy human serum (pink), or water (grey). Immediately after dilution, the body fluids were treated with 100 mM TCEP and 1 mM EDTA at 50°C for 5 minutes, followed by treatment at 64°C for 5 minutes. Error bars indicate 1 S.D. based on 3 technical replicates.
[0137] Figure 106 - A graph illustrating the detection of ZIKV cDNA directly from saliva using SHERLOCK, wherein ZIKV cDNA was diluted in healthy human saliva (blue) or water (grey). Immediately after dilution, the body fluid was treated with 100 mM TCEP and 1 mM EDTA at 50°C for 5 minutes, followed by treatment at 64°C for 5 minutes. Error bars indicate 1 S.D. based on 3 technical replicates.
[0138] Figure 107 - A graph illustrating rapid RNase inactivation of whole blood, plasma, and urine is shown. Healthy human whole blood, plasma, and urine were diluted as indicated and inactivated with 100 mM TCEP and 1 mM EDTA at 50°C for 5 minutes. RNase activity was measured using RNase Alert v2 (Thermo) in the presence of 2 U / μl murine RNase inhibitor (NEB) after incubation for 1 hour at 37°C. Two technical replicates (orange and black bars) are shown for each condition.
[0139] Figure 108- Graph illustrating the detection of Zika virus diluted in whole blood. Detection of ZIKV RNA in pellets diluted in healthy human whole blood (red) 1 hour after detection. Samples were heated with 100 mM TCEP and 1 mM EDTA at 50°C for 5 minutes plus at 64°C for 5 minutes. Because the experiments were performed together, Figure 104 A and Figure 104 The same PBS control was used as in B. Error bars indicate 1 S.D. based on 3 technical replicates.
[0140] Figure 109 Diagram illustrating body temperature heat inactivation of body fluids. Healthy human whole blood, serum, saliva, and urine were diluted as indicated and inactivated with 100 mM TCEP and 1 mM EDTA at 37°C for 20 minutes. RNase activity was measured using RNase Alert v2 (Thermo) in the presence of 2 U / μl murine RNase inhibitor (NEB) after incubation for 1 hour at 37°C. Two technical replicates are shown for each condition (orange and black bars).
[0141] Figure 110 - Graph illustrating the detection of dengue virus diluted in whole blood, serum, and saliva. Detection of DENV RNA in particles diluted in healthy human whole blood (red, A), serum (pink, B), or healthy human saliva (blue, C) after 1 hour of detection. The samples were heated at 37°C for 20 minutes with 100mM TCEP and 1mM EDTA, plus 5 minutes at 64°C. Because the experiments were performed together, the same PBS control was used in all plates. DENV titers are indicated in focus-forming units per milliliter (FFU / ml). Error bars indicate 1S.D. based on 3 technical replicates.
[0142] Figure 111 Bar graphs showing RNA serotypes of dengue clinical samples. (A-D) SHERLOCK DENV plates showing serotype differentiation using RNA extracted from one DENV1 sample (A), two DENV2 samples, two samples containing both DENV2 and DENV3 (B), four DENV3 samples (C), and three DENV4 samples (D). Fluorescence values are shown after 3 hours of Cas13 detection. Error bars indicate ±SD based on three technical replicates.
[0143] Figure 112 - Illustration of the identification of adaptive and functional ZIKV mutations. (A) SHERLOCK assay for SNP identification. Dark: derived crRNA, light: ancestral crRNA. (B-C) Using synthetic target (104 cp / μl) and viral seed stock cDNA (3x102 cp / μl) tested for three region-specific SNPs from the 2015-2016 ZIKV epidemic, including the genomic location of the SNPs and a simplified phylogenetic tree. (DE) Identification of region-specific SNPs in ZIKV cDNA samples from the Dominican Republic (DOM), the United States (USA), and Honduras (HND). The fluorescence ratio (derived crRNA fluorescence divided by ancestral crRNA fluorescence) for each SNP in each sample is shown in the bar graph (log2-transformed data in the heat map). (F) Timeline for the development of the SHERLOCK assay for new SNPs (more details in Figure 113 (G-H) Identification of a microcephaly-associated ZIKV mutation (PrM S139N) by fluorescence and colorimetric detection. In all panels, error bars indicate ±SD based on three technical replicates.
[0144] Figure 113 - Illustrated SNP design timeline. We show the steps required to design, create, and test a SHERLOCK-based SNP identification assay, along with the actual time required for each step. The total turnaround time is less than 1 week.
[0145] Figure 114 - Illustration of a lateral flow assay for Zika virus diluted in urine using visual readout. We show a lateral flow assay for Zika virus diluted in urine ( Figure 104 C) The upper band is the test band and the lower band is the control band. A faint band is visible at 10 copies / μl in PBS and urine dilution after 1 hour of detection. DETAILED DESCRIPTION
[0146] General Definition
[0147] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Definitions of commonly used terms and techniques in molecular biology can be found in the following: Molecular Cloning: A Laboratory Manual, 2nd Edition (1989) (Sambrook, Fritsch and Maniatis); Molecular Cloning: A Laboratory Manual, 4th Edition (2012) (Green and Sambrook); Current Protocols in Molecular Biology (1987) (FM Ausubel et al., eds.); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (1995) (MJ MacPherson, BD Hames and GR Taylor, eds.); Antibodies, A Laboraotry Manual (1988) (Harlow and Lane, eds.); Antibodies A Laboraotry Manual, 2nd Edition 2013 (E.A. Greenfield, ed.); Animal Cell Culture (1987) (RI Freshney, ed.); Benjamin Lewin, Genes IX, published by Jones and Bartlet, 2008 (ISBN 0763752223); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0632021829); Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 9780471185710); Singleton et al., Dictionary of Microbiology and Molecular Biology 2nd ed., J. Wiley & Sons (New York, NY1994), March, Advanced Organic Chemistry Reactions, Mechanisms and Structure, 4th edition, John Wiley & Sons (New York, NY 1992); and Marten H. Hofker and Jan van Deursen, Transgenic Mouse Methods and Protocols, 2nd edition (2011).
[0148] As used herein, the singular forms "a," "an," and "the" include singular and plural referents unless the context clearly dictates otherwise.
[0149] The term "optional" or "optionally" means that the subsequently described event, circumstance, or alternative may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0150] The recitation of numerical ranges by endpoints includes all numbers and fractions subsumed within the corresponding ranges, as well as the recited endpoints.
[0151] As used herein, the terms "about" or "approximately" when referring to a measurable value such as a parameter, amount, time interval, etc., are intended to encompass variations from the specified value and variations therefrom, such as the specified value and variations of + / -10% or less, + / -5% or less, + / -1% or less, and + / -0.1% or less, so long as such variations are suitable for performing the disclosed invention. It should be understood that the value to which the modifier "about" or "approximately" refers is itself also specifically and preferably disclosed.
[0152] References throughout this specification to "one embodiment," "an embodiment," or "an exemplary embodiment" mean that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, appearances of the phrases "in one embodiment," "in an embodiment," or "an exemplary embodiment" throughout this specification are not necessarily all referring to the same embodiment, but may be. Furthermore, as will be apparent to those skilled in the art from this disclosure, in one or more embodiments, the particular features, structures, or characteristics may be combined in any suitable manner. Furthermore, while some embodiments described herein include some features included in other embodiments but not other features, combinations of features from different embodiments are intended to be within the scope of the present invention. For example, in the appended claims, any of the claimed embodiments may be used in any combination.
[0153] All publications, published patent documents, and patent applications cited herein are hereby incorporated by reference to the same extent as if each individual publication, published patent document, or patent application was specifically and individually indicated to be incorporated by reference.
[0154] Overview
[0155] Microbial Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (CRISPR-Cas) adaptive immune systems contain programmable nucleases, such as Cas9 and Cpf1 (Shmakov et al., 2017; Zetsche et al., 2015). Although both Cas9 and Cpf1 target DNA, single-effector RNA-guided RNases have recently been discovered (Shmakov et al., 2015) and characterized (Abudayyeh et al., 2016; Smargon et al., 2017), including C2c2, which provide a platform for specific RNA sensing. RNA-guided RNases can be easily and conveniently reprogrammed using CRISPR RNA (crRNA) to cleave target RNA. Unlike DNA endonucleases Cas9 and Cpf1, which only cleave DNA targets, RNA-guided RNases, such as C2c2, remain active after cleaving their RNA targets, causing "collateral" cleavage of nearby non-target RNAs (Abudayyeh et al., 2016). This crRNA-programmed collateral RNA cleavage activity provides the opportunity to use RNA-guided RNases to detect the presence of specific RNAs by triggering programmed cell death in vivo or non-specific RNA degradation in vitro, which can serve as readouts (Abudayyeh et al., 2016; East-Seletsky et al., 2016).
[0156] The embodiments disclosed herein utilize RNA targeting effectors to provide robust CRISPR-based diagnostics with attomolar sensitivity. The embodiments disclosed herein can detect broth DNA and RNA at comparable levels of sensitivity and can distinguish targets from non-targets based on single base pair differences. In addition, the embodiments disclosed herein can be prepared in a freeze-dried format for convenient distribution and point-of-care (POC) applications. Such embodiments are applicable to a variety of situations in human health, including, for example, virus detection, strain typing, sensitive genotyping, and detection of disease-related cell-free DNA.
[0157] In order to diagnose infectious microorganisms worldwide, there is a need for assays that are fast, sensitive, low-cost, user-friendly, and can be quickly adapted to detect new discriminants. The embodiments disclosed herein demonstrate that the Cas13-based SHERLOCK platform can detect Zika virus (ZIKV) in clinical samples and mosquito banks at single-copy sensitivity, and show that it can detect ZIKV directly from urine in <2 hours. The applicant further developed an assay to simultaneously detect 4 flaviviruses, distinguish dengue virus serotypes 1-4, and use regional specific variants to distinguish strains from the ZIKV outbreak in 2016. Finally, the applicant developed an assay and tested it to identify ZIKV variants associated with fetal microcephaly within 1 week of its publication. This demonstrates that SHERLOCK can detect viruses directly from body fluids, distinguish a variety of pathogenic viruses, and can be quickly updated to identify mutations that cause clinically important phenotypes.
[0158] In one aspect, the embodiments disclosed herein relate to a nucleic acid detection system comprising a CRISPR system, one or more guide RNAs designed to bind to corresponding target molecules, a masking construct, and optionally an amplification reagent for amplifying the target nucleic acid molecules in the sample. In certain exemplary embodiments, the system may further comprise one or more detection aptamers. The one or more detection aptamers may comprise an RNA polymerase site or a primer binding site. The one or more detection aptamers specifically bind to the one or more target polypeptides and are configured so that the RNA polymerase site or the primer binding site is exposed only after the detection aptamer binds to the target peptide. The exposure of the RNA polymerase site contributes to the generation of trigger RNA oligonucleotides using the aptamer sequence as a template. Therefore, in such embodiments, the one or more guide RNAs are configured to bind to the trigger RNA.
[0159] In another aspect, embodiments disclosed herein relate to a diagnostic device comprising a plurality of individual discrete volumes. Each individual discrete volume comprises a CRISPR effector protein, one or more guide RNAs designed to bind to a corresponding target molecule, and a masking construct. In certain exemplary embodiments, RNA amplification reagents can be preloaded into the individual discrete volumes or added to the individual discrete volumes simultaneously with or after the sample is added to each individual discrete volume. The device can be a microfluidic-based device, a wearable device, or a device comprising a flexible material substrate on which the individual discrete volumes are defined.
[0160] In another aspect, the embodiments disclosed herein relate to a method for detecting a target nucleic acid in a sample, the method comprising distributing a sample or sample group into a set of individual discrete volumes, each individual discrete volume comprising a CRISPR effector protein, one or more guide RNAs designed to bind to a target oligonucleotide, and a masking construct. The sample group is then maintained under conditions sufficient to allow the one or more guide RNAs to bind to the one or more target molecules. The one or more guide RNAs bind to the target nucleic acid and then activate the CRISPR effector protein. Once activated, the CRISPR effector protein then inactivates the masking construct, for example, by cleaving the masking construct to demask, release, or generate a detectable positive signal. Detection of a positive detectable signal in the individual discrete volumes indicates the presence of the target molecule.
[0161] In another aspect, the embodiments disclosed herein relate to a method for detecting a polypeptide. The method for detecting a polypeptide is similar to the method for detecting a target nucleic acid described above. However, peptide detection aptamers are also included. The peptide detection aptamers function as described above and facilitate the generation of a trigger oligonucleotide after binding to a target polypeptide. The guide RNA is designed to recognize the trigger oligonucleotide, thereby activating the CRISPR effector protein. Inactivation of the masking construct by the activated CRISPR effector protein facilitates the unmasking, release, or generation of a detectable positive signal.
[0162] CRISPR effector proteins
[0163] In general, CRISPR-Cas or CRISPR systems as used herein and in documents such as WO 2014 / 093622 (PCT / US2013 / 074667) collectively refer to transcripts and other elements involved in the expression of or directing the activity of a CRISPR-associated ("Cas") gene, including sequences encoding the Cas gene, a tracr (trans-activating CRISPR) sequence (e.g., a tracrRNA or an active partial tracrRNA), a tracr-mate sequence (encompassing "direct repeats" and tracrRNA-processed partial direct repeats in the context of an endogenous CRISPR system), a guide sequence (also referred to as a "spacer" in the context of an endogenous CRISPR system), or, as that term is used herein, "RNA(s)" (e.g., RNA(s) to guide Cas, e.g., Cas9, e.g., a CRISPR RNA and a trans-activating (tracr) RNA or a single guide RNA (sgRNA) (chimeric RNA), or other sequences and transcripts from a CRISPR locus. In general, CRISPR systems are characterized by elements that promote the formation of CRISPR complexes at the site of the target sequence (also referred to as protospacers in the case of endogenous CRISPR systems). When the CRISPR protein is a C2c2 protein, tracrRNA is not required. C2c2 has been described in the following literature: Abudayyeh et al. (2016) "C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector"; Science; DOI: 10.1126 / science.aaf5573; and Shmakov et al. (2015) "Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems", Molecular Cell, DOI: dx.doi.org / 10.1016 / j.molcel.2015.10.008; the literature is incorporated herein by reference in its entirety.Cas13b has been described in the following literature: Smargon et al. (2017) "Cas13bIs a Type VI-B CRISPR-Associated RNA-Guided RNases Differentially Regulatedby Accessory Proteins Csx27 and Csx28", Molecular Cell. 65, 1-13; dx.doi.org / 10.1016 / j.molcel.2016.12.023., which is incorporated herein by reference in its entirety.
[0164] In certain embodiments, a protospacer adjacent motif (PAM) or PAM-like motif directs binding of an effector protein complex as disclosed herein to a target locus of interest. In some embodiments, the PAM may be a 5' PAM (i.e., located upstream of the 5' end of the protospacer). In other embodiments, the PAM may be a 3' PAM (i.e., located downstream of the 5' end of the protospacer). The term "PAM" may be used interchangeably with the term "PFS" or "protospacer flanking site" or "protospacer flanking sequence."
[0165] In preferred embodiments, the CRISPR effector protein can recognize a 3' PAM. In certain embodiments, the CRISPR effector protein can recognize a 3' PAM that is 5'H, wherein H is A, C, or U. In certain embodiments, the effector protein can be Leptotrichia saburoi C2c2p, more preferably Leptotrichia saburoi DSM 19757 C2c2, and the 3' PAM is 5'H.
[0166] In the context of forming a CRISPR complex, a "target sequence" refers to a sequence to which a guide sequence is designed to have complementarity, wherein hybridization between the target sequence and the guide sequence promotes the formation of a CRISPR complex. The target sequence may comprise an RNA polynucleotide. The term "target RNA" refers to an RNA polynucleotide that serves as a target sequence or comprises a target sequence. In other words, the target RNA may be part of a gRNA, i.e., an RNA polynucleotide or a portion of an RNA polynucleotide to which a guide sequence is designed to have complementarity and to which the effector function mediated by a complex comprising a CRISPR effector protein and a gRNA is directed. In some embodiments, the target sequence is located in the nucleus or cytoplasm of the cell.
[0167] The nucleic acid molecule encoding the CRISPR effector protein, in particular C2c2, is advantageously a codon-optimized CRISPR effector protein. In this case, an example of a codon-optimized sequence is a sequence optimized for expression in a eukaryote, such as a human (i.e., optimized for expression in a human), or for another eukaryote, animal, or mammal as discussed herein; see, for example, the SaCas9 human codon-optimized sequence in WO 2014 / 093622 (PCT / US2013 / 074667). Although this is preferred, it will be appreciated that other examples may exist, and codon optimization for host species other than humans or for specific organs is known. In some embodiments, the enzyme coding sequence encoding the CRISPR effector protein is codon-optimized for expression in a specific cell, such as a eukaryotic cell. Eukaryotic cells can be those of a specific organism or derived from a specific organism, such as a plant or a mammal, including but not limited to people, or non-human eukaryotic organisms or animals or mammals as discussed herein, such as mice, rats, rabbits, dogs, livestock or non-human mammals or primates. In some embodiments, the process of modifying the germline genetic identity of the person who may not bring any substantial medical benefit to humans or animals and / or the process of modifying the genetic identity of the animal, as well as the animal produced by such process, can be excluded. In general, codon optimization refers to the process of modifying nucleic acid sequences for enhancing the expression in the host cell of interest, and this process is by replacing at least one codon (such as about or greater than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) of the native sequence with a codon that is more frequent or most frequently used in the gene of the host cell, while maintaining the native amino acid sequence. Each species exhibits a specific bias to certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) is often associated with the efficiency of translation of messenger RNA (mRNA), which is believed to depend, in turn, on the properties of the codons translated and the availability of specific transfer RNA (tRNA) molecules. The dominance of the selected tRNA in a cell generally reflects the most frequently used codons in peptide synthesis. Therefore, genes can be adjusted for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, in the "Codon Usage Database" available at kazusa.orjp / codon / , and these tables can be adapted in many ways.See Nakamura, Y. et al. "Codon usage tabulated from the international DNA sequence databases: status for the year 2000" Nucl. Acids Res. 28:292 (2000). Computer algorithms for codon optimization of specific sequences for expression in specific host cells are also available, such as Gene Forge (Aptagen; Jacobus, PA). In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more or all codons) in the sequence encoding Cas correspond to the most frequently used codons for a specific amino acid.
[0168] In certain embodiments, the methods described herein may include providing a Cas transgenic cell, particularly a C2c2 transgenic cell, wherein one or more nucleic acids encoding one or more guide RNAs are provided or introduced, which are operably linked to a regulatory element comprising a promoter of one or more genes of interest in the cell. As used herein, the term "Cas transgenic cell" refers to a cell, such as a eukaryotic cell, in which the Cas gene has been integrated into the genome. The nature, type or origin of the cell is not particularly limited according to the present invention. Moreover, the manner in which the Cas transgene is introduced into the cell may vary and may be any method known in the art. In certain embodiments, the Cas transgenic cell is obtained by introducing the Cas transgene into an isolated cell. In certain other embodiments, the Cas transgenic cell is obtained by isolating cells from a Cas transgenic organism. By way of example and not limitation, the Cas transgenic cell as mentioned herein may be derived from a Cas transgenic eukaryote, such as a Cas knock-in eukaryote. Reference is made to WO 2014 / 093622 (PCT / US13 / 74667), which is incorporated herein by reference. The methods of U.S. Patent Publication Nos. 20120017290 and 20110265198 assigned to Sangamo BioSciences, Inc. for targeting the Rosa locus can be modified to utilize the CRISPR Cas system of the present invention. The methods of U.S. Patent Publication No. 20130236946 assigned to Cellectis for targeting the Rosa locus can also be modified to utilize the CRISPR Cas system of the present invention. By way of another example, reference is made to Platt et al. (Cell; 159(2):440-455(2014)), which describe Cas9 knock-in mice, incorporated herein by reference. The Cas transgene can also include a Lox-Stop-polyA-Lox (LSL) box, thereby facilitating Cas expression inducible by the Cre recombinase. Alternatively, Cas transgenic cells can be obtained by introducing the Cas transgene into isolated cells. Delivery systems for transgenics are well known in the art. By way of example, the Cas transgene can be delivered, e.g., in eukaryotic cells, by means of vectors (e.g., AAV, adenovirus, lentivirus) and / or particle and / or nanoparticle delivery as also described elsewhere herein.
[0169] The skilled artisan will appreciate that cells as referred to herein, e.g., Cas transgenic cells, may comprise genomic alterations in addition to having an integrated Cas gene or mutations resulting from the sequence-specific action of Cas when complexed with RNA capable of directing Cas to a target locus.
[0170] In certain aspects, the present invention relates to vectors for delivering or introducing Cas and / or RNA capable of directing Cas to a target locus (i.e., guide RNA) into cells and for propagating these components (e.g., in prokaryotic cells). As used herein, a "vector" is a tool that allows or facilitates the transfer of an entity from one environment to another. A vector is a replicon, such as a plasmid, phage, or cosmid, into which another DNA segment can be inserted to achieve replication of the inserted segment. In general, a vector is capable of replication when associated with appropriate control elements. In general, the term "vector" refers to a nucleic acid molecule that is capable of transporting another nucleic acid to which it has been connected. Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules comprising one or more free ends, no free ends (e.g., circular); nucleic acid molecules comprising DNA, RNA, or both; and other species of polynucleotides known in the art. One type of vector is a "plasmid," which refers to a circular double-stranded DNA loop into which additional DNA segments can be inserted, such as by standard molecular cloning techniques. Another type of vector is a viral vector, in which there is a virally derived DNA or RNA sequence in the vector for encapsulation into a virus (such as a retrovirus, a replication-defective retrovirus, adenovirus, a replication-defective adenovirus, and adeno-associated virus (AAV)). Viral vectors also include polynucleotides carried by the virus for transfection into a host cell. Some vectors can replicate autonomously (such as bacterial vectors with bacterial replication origins, and additional mammalian vectors) in the host cell it introduces. Other vectors (such as non-additional mammalian vectors) are integrated into the genome of the host cell after being introduced into the host cell, and thus replicate together with the host genome. In addition, some vectors can guide the expression of the gene that is operatively connected. Such vectors are referred to as "expression vectors" in this article. Commonly used expression vectors that are effective in recombinant DNA technology are often in the form of plasmids.
[0171] The recombinant expression vector may comprise a nucleic acid of the present invention in a form suitable for expressing nucleic acid in a host cell, which means that the recombinant expression vector includes one or more regulatory elements that can be selected on the basis of the host cell to be used for expression and operably connected to the nucleic acid sequence to be expressed. Within the recombinant expression vector, "operably connected" is intended to mean that the nucleotide sequence of interest is connected to one or more regulatory elements in a manner that allows the nucleotide sequence to be expressed (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into a host cell). Regarding recombination and cloning methods, reference is made to U.S. patent application 10 / 815,730, published as US 2004-0171156A1 on September 2, 2004, the contents of which are incorporated herein by reference in their entirety. Therefore, the embodiments disclosed herein may also include transgenic cells comprising a CRISPR effector system. In certain exemplary embodiments, transgenic cells may serve as individual discrete volumes. In other words, a sample comprising a masking construct may be delivered to a cell, for example, in a suitable delivery vesicle, and if a target is present in the delivery vesicle, the CRISPR effector is activated and a detectable signal is generated.
[0172] One or more vectors may include one or more regulatory elements, such as one or more promoters. One or more vectors may contain a Cas encoding sequence and / or a single, but may also contain at least 3 or 8 or 16 or 32 or 48 or 50 guide RNA (e.g., sgRNA) encoding sequences, such as 1-2, 1-3, 1-4, 1-5, 3-6, 3-7, 3-8, 3-9, 3-10, 3-8, 3-16, 3-30, 3-32, 3-48, 3-50 RNAs (e.g., sgRNAs). In a single vector, a promoter for each RNA (e.g., sgRNA) may be present, advantageously when there are at most about 16 RNAs; and when a single vector provides more than 16 RNAs, one or more promoters may drive the expression of more than one RNA, for example, when there are 32 RNAs, each promoter may drive the expression of two RNAs, and when there are 48 RNAs, each promoter may drive the expression of three RNAs. By simple arithmetic and perfect cloning scheme and the teachings in the present disclosure, those skilled in the art can easily implement the present invention with respect to one or more RNAs of suitable exemplary vectors (e.g., AAV) and suitable promoters such as U6 promoters. For example, the encapsulation limit of AAV is about 4.7kb. The length of a single U6-gRNA (plus the restriction sites for cloning) is 361bp. Therefore, technicians can easily assemble about 12-16, for example, 13 U6-gRNA boxes into a single vector. This can be assembled by any suitable means, such as the Golden Gate strategy (genome-engineering.org / taleffectors / ) for TALE assembly. Technicians can also use a series guide strategy to increase the number of U6-gRNA by about 1.5 times, for example, from 12-16, for example, 13 to about 18-24, for example, about 19 U6-gRNAs. Thus, those skilled in the art can easily reach about 18-24, for example about 19 promoter-RNAs, such as U6-gRNAs, in a single vector, such as an AAV vector. A further way to increase the number of promoters and RNAs in a vector is to use a single promoter (e.g., U6) to express an RNA array separated by a cleavable sequence. Also, a further way to increase the number of promoter-RNAs in a vector is to express a promoter-RNA array separated by a cleavable sequence in an intron of a coding sequence or gene; and in this case, it is advantageous to use a polymerase II promoter, which can have increased expression and can transcribe long RNAs in a tissue-specific manner.(See, e.g., nar.oxfordjournals.org / content / 34 / 7 / e53.short and nature.com / mt / journal / v16 / n9 / abs / mt2008144a.html.) In advantageous embodiments, AAV can encapsulate U6 tandem gRNAs targeting up to about 50 genes. Thus, from the knowledge in the art and the teachings of the present disclosure, one can readily make and use one or more vectors, e.g., a single vector, expressing multiple RNAs or guides under control or operatively or functionally linked to one or more promoters—particularly with respect to the number of RNAs or guides discussed herein—without undue experimentation.
[0173] The guide RNA coding sequence and / or the Cas coding sequence can be functionally or operably connected to one or more regulatory elements, and thus one or more regulatory elements drive expression. One or more promoters can be one or more constitutive promoters and / or one or more conditional promoters and / or one or more inducible promoters and / or one or more tissue-specific promoters. The promoter can be selected from the group consisting of RNA polymerase, pol I, pol II, pol III, T7, U6, H1, retrovirus Rous sarcoma virus (RSV) LTR promoter, cytomegalovirus (CMV) promoter, SV40 promoter, dihydrofolate reductase promoter, β-actin promoter, phosphoglycerol kinase (PGK) promoter and EF1α promoter. Advantageous promoter is promoter U6.
[0174] In some embodiments, one or more elements of the nucleic acid targeting system are derived from a specific organism that contains an endogenous CRISPR RNA targeting system. In certain exemplary embodiments, the effector protein CRISPR RNA targeting system comprises at least one HEPN domain, including but not limited to the HEPN domains described herein, HEPN domains known in the art, and domains identified as HEPN domains by comparison with consensus sequence motifs. Several such domains are provided herein. In a non-limiting example, the consensus sequence can be derived from the sequence of a C2c2 or Cas13b ortholog provided herein. In certain exemplary embodiments, the effector protein comprises a single HEPN domain. In certain other exemplary embodiments, the effector protein comprises two HEPN domains.
[0175] In an exemplary embodiment, the effector protein comprises one or more HEPN domains comprising an RxxxxH motif sequence. The RxxxxH motif sequence can be, but is not limited to, derived from a HEPN domain described herein or a HEPN domain known in the art. The RxxxxH motif sequence also includes a motif sequence created by combining portions of two or more HEPN domains. As noted, the consensus sequence can be derived from sequences of orthologs disclosed in U.S. Provisional Patent Application 62 / 432,240, entitled "Novel CRISPR Enzymes and Systems," U.S. Provisional Patent Application 62 / 471,710, filed March 15, 2017, entitled "Novel Type VI CRISPR Orthologs and Systems," and U.S. Provisional Patent Application 62 / 471,710, filed April 12, 2017, entitled "Novel Type VI CRISPR Orthologs and Systems," and attorney docket number 47627-05-2133.
[0176] In embodiments of the present invention, the HEPN domain comprises at least one RxxxxH motif comprising the sequence R{N / H / K}XXXX3H. In embodiments of the present invention, the HEPN domain comprises an RxxxxH motif comprising the sequence R{N / H}XXXX3H. In embodiments of the present invention, the HEPN domain comprises the sequence R{N / K}XXXX3H. In certain embodiments, X1 is R, S, D, E, Q, N, G, Y, or H. In certain embodiments, X2 is I, S, T, V, or L. In certain embodiments, X3 is L, F, N, Y, V, I, S, D, E, or A.
[0177] Additional effectors for use in accordance with the present invention can be identified by their proximity to the cas1 gene, for example, but not limited to, within 20 kb from the beginning of the cas1 gene and 20 kb from the end of the cas1 gene. In certain embodiments, the effector protein comprises at least one HEPN domain and at least 500 amino acids, and wherein the C2c2 effector protein is naturally present in a prokaryotic genome within 20 kb upstream or downstream of a Cas gene or CRISPR array. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csx12), Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, homologs thereof, or modified versions thereof. In certain exemplary embodiments, the C2c2 effector protein is naturally present in a prokaryotic genome within 20 kb upstream or downstream of the Cas 1 gene. The terms "orthologue" (also referred to herein as "ortholog") and "homologue" (also referred to herein as "homolog") are well known in the art. By way of further guidance, a "homologue" of a protein as used herein is a protein of the same species that performs the same or similar function as a protein that is its homolog. Homologous proteins may, but need not, be structurally related, or only partially structurally related. An "orthologue" of a protein as used herein is a protein of a different species that performs the same or similar function as a protein that is its ortholog. Orthologous proteins may, but need not, be structurally related, or only partially structurally related.
[0178] In certain embodiments, the type VI RNA-targeted Cas enzyme is C2c2. In other exemplary embodiments, the type VI RNA-targeted Cas enzyme is Cas 13b. In certain embodiments, a homologue or orthologue of a Type VI protein as referred to herein, such as C2c2, is conjugated to a Type VI protein, such as C2c2 (e.g., a wild-type sequence based on any of the following: Leptotrichia sabii C2c2, Lachnospiraceae MA2020 C2c2, Lachnospiraceae NK4A179 C2c2, Clostridium aminophila (DSM 10710) C2c2, Bacillus galliformis (DSM 4847) C2c2, Paenibacillus genistein (WB4) C2c2, Listeria wissenii (FSL R9-0317) C2c2, Listeriaceae (FSL M6-0635) C2c2, Listeria newyorkensis (FSLM6-0635) C2c2, Leptotrichia wadeii (F0279) C2c2, Rhodobacter capsulatum (SB 1003) C2c2, Rhodobacter capsulatum (R121) C2c2, Rhodobacter capsulatum (DE442) C2c2, Leptotrichia wadeii (Lw2) C2c2 or Listeria stutzeri C2c2) have a sequence homology or identity of at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, more preferably at least 85%, even more preferably at least 90%, for example at least 95%. In other embodiments, homologs or orthologs of type VI proteins, such as C2c2, as referred to herein, are compared to wild-type C2c2 (e.g., a wild-type sequence based on any of the following: Leptotrichia sabii C2c2, Lachnospiraceae MA2020 C2c2, Lachnospiraceae NK4A179 C2c2, Clostridium aminophila (DSM 10710) C2c2, Bacillus galliformis (DSM 4847) C2c2, Paenibacillus genistein (WB4) C2c2, Listeria monocytogenes (FSL R9-0317) C2c2, Listeriaceae (FSL M6-0635) C2c2, Listeria nycopene (FSLM6-0635) C2c2, Leptotrichia wadeii (F0279) C2c2, Rhodobacter capsulatum (SB) C2c2, or a wild-type sequence based on any of the following: 1003) C2c2, Rhodobacter capsulatum (R121) C2c2, Rhodobacter capsulatum (DE442) C2c2, Leptotrichia wadeii (Lw2) C2c2 or Listeria stutzeri C2c2) have a sequence identity of at least 30%, or at least 40%, or at least 50%, or at least 60%, or at least 70%, or at least 80%, more preferably at least 85%, even more preferably at least 90%, for example at least 95%.
[0179] In certain other exemplary embodiments, the CRISPR system effector protein is a C2c2 nuclease. The activity of C2c2 may depend on the presence of two HEPN domains. These have been shown to be RNase domains, i.e., nucleases (especially endonucleases) that cut RNA. The C2c2 HEPN can also target DNA, or potentially DNA and / or RNA. On the basis that the HEPN domain of C2c2 is at least able to bind to RNA and cut RNA in its wild-type form, it is preferred that the C2c2 effector protein has RNase function. Regarding the C2c2 CRISPR system, reference is made to U.S. Provisional Case 62 / 351,662 filed on June 17, 2016 and U.S. Provisional Case 62 / 376,377 filed on August 17, 2016. Reference is also made to U.S. Provisional Case 62 / 351,803 filed on June 17, 2016. Reference is also made to the U.S. provisional case entitled “Novel Crispr Enzymes and Systems,” filed December 8, 2016, bearing Broad Institute No. 10035.PA4 and attorney docket No. 47627.03.2133. Reference is also made to East-Seletsky et al., “Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection,” Nature doi:10 / 1038 / nature19802 and Abudayyeh et al., “C2c2 is a single-component programmable RNA-guided RNA targeting CRISPR effector,” bioRxiv doi:10.1101 / 054742.
[0180] RNase function in CRISPR systems is known, for example, mRNA targeting has been reported for certain type III CRISPR-Cas systems (Hale et al., 2014, Genes Dev, Vol. 28, 2432-2443; Hale et al., 2009, Cell, Vol. 139, 945-956; Peng et al., 2015, Nucleic acids research, Vol. 43, 406-417) and provides significant advantages. In the Staphylococcus epidermis type III-A system, trans-target transcription results in cleavage of the target DNA and its transcript, which is mediated by independent active sites within the Cas10-Csm ribonucleoprotein effector protein complex (see Samai et al., 2015, Cell, Vol. 151, 1164-1174). Thus, a CRISPR-Cas system, composition, or method for targeting RNA via an effector protein of the present invention is provided.
[0181] In an embodiment, the Cas protein can be a C2c2 ortholog of an organism of the following genera: including but not limited to Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Fusarium, Flavobacterium, Monofilamentous Shell, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacter, Staphylococcus, Nitrolyticus, Mycoplasma, and Campylobacter. The types of organisms of this genus can be as discussed elsewhere herein.
[0182] Some methods for identifying orthologs of CRISPR-Cas system enzymes can involve identifying tracr sequences in the genome of interest. Identification of tracr sequences can involve the following steps: searching a database for direct repeats or tracr mate sequences to identify CRISPR regions containing CRISPR enzymes. Searching for homologous sequences in the CRISPR regions flanking the CRISPR enzymes in both the sense and antisense directions. Searching for transcription terminators and secondary structures. Identifying any sequence that is not a direct repeat or tracr mate sequence but has greater than 50% identity to a direct repeat or tracr mate sequence as a potential tracr sequence. Obtaining a potential tracr sequence and analyzing the transcription terminator sequence associated with it.
[0183] It will be appreciated that any functionality described herein can be engineered into CRISPR enzymes from other orthologs, including chimeric enzymes comprising fragments from multiple orthologs. Examples of such orthologs are described elsewhere herein. Thus, a chimeric enzyme may comprise a fragment of a CRISPR enzyme ortholog from an organism including, but not limited to, Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Trichoderma, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Fusarium, Flavobacterium, Monofilamentosa, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacter, Staphylococcus, Nitrate Lysinus, Mycoplasma, and Campylobacter. The chimeric enzyme may comprise a first fragment and a second fragment, and the fragments may be fragments of a CRISPR enzyme ortholog of an organism of the genus mentioned herein or of the species mentioned herein; advantageously, the fragments are from CRISPR enzyme orthologs of different species.
[0184] In an embodiment, the C2c2 protein as referred to herein also encompasses functional variants of C2c2 or its homologs or orthologs. As used herein, a "functional variant" of a protein refers to a variant of such a protein that at least partially retains the activity of the protein. Functional variants may include mutants (which may be insertion, deletion or substitution mutants), including polymorphs, etc. Functional variants also include fusion products of such a protein with another, generally unrelated, nucleic acid, protein, polypeptide or peptide. Functional variants may be naturally occurring or may be artificial. Advantageous embodiments may involve engineered or non-naturally occurring Type VI RNA targeting effector proteins.
[0185] In embodiments, one or more nucleic acid molecules encoding C2c2 or an ortholog or homolog thereof can be codon-optimized for expression in eukaryotic cells. The eukaryotic organism can be as discussed herein. The one or more nucleic acid molecules can be engineered or non-naturally produced.
[0186] In an embodiment, C2c2 or its ortholog or homolog may comprise one or more mutations, and thus one or more nucleic acid molecules encoding it may have one or more mutations. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain. Examples of catalytic domains of the Cas9 enzyme may include, but are not limited to, RuvC I, RuvC II, RuvC III, and HNH domains.
[0187] In an embodiment, C2c2 or its ortholog or homolog may comprise one or more mutations. The mutation may be an artificially introduced mutation and may include, but is not limited to, one or more mutations in the catalytic domain. Examples of catalytic domains of Cas enzymes may include, but are not limited to, a HEPN domain.
[0188] In an embodiment, C2c2 or its orthologs or homologs can be used as universal nucleic acid binding proteins fused to or operably linked to functional domains. Exemplary functional domains can include, but are not limited to, translation initiators, translation activators, translation repressors, nucleases (particularly ribonucleases), spliceosomes, beads, light-inducible / controllable domains, or chemically inducible / controllable domains.
[0189] In certain exemplary embodiments, the C2c2 effector protein may be from an organism selected from the group consisting of Leptotrichia, Listeria, Corynebacterium, Sutterella, Legionella, Treponema, Trichoderma, Eubacterium, Streptococcus, Lactobacillus, Mycoplasma, Bacteroides, Fusarium, Flavobacterium, Monofilamentous, Azospirillum, Gluconacetobacter, Neisseria, Roseburia, Parvibacter, Staphylococcus, Nitrolyticus, Mycoplasma, and Campylobacter.
[0190] In certain embodiments, the effector protein can be Listeria sp. C2c2p, preferably Listeria monocytogenes C2c2p, more preferably Listeria monocytogenes serovar 1 / 2bstr. SLCC3954 C2c2p, and the crRNA sequence can be 44 to 47 nucleotides in length with a 5' 29-nt direct repeat (DR) and a 15-nt to 18-nt spacer.
[0191] In certain embodiments, the effector protein can be Leptotrichia sp. C2c2p, preferably Leptotrichia sabdariffa C2c2p, more preferably Leptotrichia sabdariffa DSM 19757 C2c2p, and the crRNA sequence can be 42 to 58 nucleotides in length, having a 5' direct repeat of at least 24 nt, such as a 5' 24-28-nt direct repeat (DR), and a spacer of at least 14 nt, such as a 14-nt to 28-nt spacer, or a spacer of at least 18 nt, such as 19, 20, 21, 22 or more nt, such as 18-28, 19-28, 20-28, 21-28, or 22-28 nt.
[0192] In certain exemplary embodiments, the effector protein may be of the genus Leptotrichia, Leptotrichia wadeii F0279, or Listeria, preferably Listeria nycteris FSL M6-0635.
[0193] In certain exemplary embodiments, the C2c2 effector proteins of the invention include, but are not limited to, the following 21 orthologous species (including multiple CRISPR loci): Leptotrichia sabii; Leptotrichia wadeii (Lw2); Listeria stutzeri; Lachnospiraceae MA2020; Lachnospiraceae NK4A179; Clostridium aminophilum DSM 10710; Bacillus galliformis DSM 4847; Bacillus galliformis DSM 4847 (second CRISPR locus); Paenibacillus rhizogenes WB4; Listeria wissenii FSL R9-0317; Listeriaceae FSL M6-0635; Leptotrichia wadeii F0279; Rhodobacter capsulatum SB 1003; Rhodobacter capsulatum R121; Rhodobacter capsulatum DE442; Leptotrichia buccal buccalis) C-1013-b; Herbinix hemicellulosilytica; Eubacterium rectale; Eubacteriaceae bacterium CHKCI004; Blautia sp. Marseille-P2398; and oral taxon 879str.F0557. Twelve (12) other non-limiting examples are: Lachnospiraceae bacterium NK4A144; Chloroflexus aggregans; Demequinaurantiaca; Thalassospira sp. TSL5-1; Pseudobutyrivibrio sp. OR37; Butyrivibrio sp. YAB3001; Blautiae Marseille-P2398; Leptotrichia Marseille-P3007; Bacteroides ihuae; Porphyromonadaceae bacterium KH3CP3RA; Listeria riparia; and Insolitispirillum peregrinum.
[0194] In certain embodiments, a C2c2 protein according to the present invention is or is derived from one of the orthologs described in the following table, or is a chimeric protein of two or more of the orthologs described in the following table, or is a mutant or variant (or chimeric mutant or variant) of one of the orthologs described in the following table, including dead C2c2, shed C2c2, destabilized C2c2, etc. as defined elsewhere herein, with or without fusion to a heterologous / functional domain.
[0195] In certain exemplary embodiments, the C2c2 effector protein is selected from Table 1 below. (Also including SEQ.ID.Nos. 600-615)
[0196] Table 1
[0197]
[0198]
[0199] The wild-type protein sequences of the above species are listed below in Table 2. In certain embodiments, nucleic acid sequences encoding C2c2 proteins are provided.
[0200] Table 2
[0201]
[0202]
[0203]
[0204] In an embodiment of the present invention, an effector protein is provided, comprising an amino acid sequence having at least 80% sequence homology to the wild-type sequence of any one of the following bacteria: Leptotrichia sabii C2c2, Lachnospiraceae MA2020 C2c2, Lachnospiraceae NK4A179 C2c2, Clostridium aminophila (DSM 10710) C2c2, Bacillus galliformis (DSM4847) C2c2, Pseudomonas aeruginosa (WB4) C2c2, Listeria monocytogenes (FSL R9-0317) C2c2, Listeriaceae (FSL M6-0635) C2c2, Listeria nycnidium (FSL M6-0635) C2c2, Leptotrichia wadeii (F0279) C2c2, Rhodobacter capsulatum (SB 1003) C2c2, Rhodobacter capsulatum (R121) C2c2, Rhodobacter capsulatum (DE442) C2c2, Leptotrichia wadeii (Lw2) C2c2 or Listeria monocytogenes C2c2.
[0205] In embodiments of the invention, the effector protein comprises an amino acid sequence having at least 80% sequence homology to a Type VI effector protein consensus sequence, including but not limited to the consensus sequences described herein.
[0206] According to the present invention, consensus sequences can be generated from a variety of C2c2 orthologs that can help locate conserved amino acid residues and motifs, including but not limited to catalytic residues and HEPN motifs that mediate C2c2 function among C2c2 orthologs. One such consensus sequence generated from the 33 orthologs mentioned above using Geneious alignment is SEQ ID NO: 325.
[0207] In another non-limiting example, a sequence alignment tool used to aid consensus sequence generation and identification of conserved residues is the MUSCLE alignment tool (www.ebi.ac.uk / Tools / msa / muscle / ). For example, using MUSCLE, the following amino acid positions can be identified in Leptotrichia wadeii C2c2 that are conserved among C2c2 orthologs: K2; K5; V6; E301; L331; I335; N341; G351; K352; E375; L392; L396; D403; F446; I466; I470; R474 (HEPN); H475; H479 (HEPN); E508; P556; L561; I595; Y59 6; F600; Y669; I673; F681; L685; Y761; L676; L779; Y782; L836; D847; Y863; L869; 958; R961; Y965; E970; R971; D972; R1046(HEPN); H1051(HEPN); Y1075;
[0208] An exemplary sequence alignment of HEPN domains showing highly conserved residues is shown in Figure 50 Shown in
[0209] In certain exemplary embodiments, the RNA-targeting effector protein is a type VI-B effector protein, such as Cas13b and a protein from Group 29 or Group 30. In certain exemplary embodiments, the RNA-targeting effector protein comprises one or more HEPN domains. In certain exemplary embodiments, the RNA-targeting effector protein comprises a C-terminal HEPN domain, an N-terminal HEPN domain, or both domains. For exemplary Type VI-B effector proteins that can be used in the context of the present invention, reference is made to U.S. Application No. 15 / 331,792, entitled “Novel CRISPR Enzymes and Systems,” filed October 21, 2016, International Patent Application No. PCT / US2016 / 058302, entitled “Novel CRISPR Enzymes and Systems,” filed October 21, 2016, and Smargon et al., “Cas13b is a Type VI-B CRISPR-associated RNA-Guided RNase differentially regulated by accessory proteins Csx27 and Csx28,” Molecular Cell, 65, 1-13 (2017); dx.doi.org / 10.1016 / j.molcel.2016.12.023, and International Patent Application No. PCT / US2016 / 058302, filed March 15, 2017. System" is assigned to U.S. Provisional Application No. 479-566. In certain embodiments, the Cas13b enzyme is derived from Bergeyella zoohelcum. In certain other exemplary embodiments, the effector protein is or comprises an amino acid sequence having at least 80% sequence homology to any one of the sequences listed in Table 3. (Also referred to are SEQ.ID.Nos. 479-566)
[0210] Table 3
[0211]
[0212]
[0213]
[0214]
[0215]
[0216] In certain exemplary embodiments, the Class 2 Type VI CRISPR system is a Cas13c system. In certain exemplary embodiments, the Cas13c ortholog is selected from Table 4 below, which comprises Cas13c orthologs for expression in mammalian cells.
[0217] Table 4
[0218]
[0219] In certain exemplary embodiments, the RNA targeting effector protein is a Cas13c effector protein as disclosed in U.S. Provisional Patent Application No. 62 / 525,165, filed on June 26, 2017, and PCT Application No. US2017 / 047193, filed on August 16, 2017. Exemplary wild-type ortholog sequences of Cas13c are provided in Table 5 below.
[0220] Table 5
[0221]
[0222]
[0223] guide RNA
[0224] As used herein, the terms "crRNA" or "guide RNA" or "single guide RNA", "gRNA" refer to a polynucleotide comprising any polynucleotide sequence having sufficient complementarity to a target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide sequence-specific binding of an RNA-targeting complex comprising the gRNA and a CRISPR effector protein to the target nucleic acid sequence. In general, a gRNA can be any polynucleotide sequence that: (i) is capable of forming a complex with a CRISPR effector protein, and (ii) comprises a sequence having sufficient complementarity to a target polynucleotide sequence to hybridize with the target sequence and guide sequence-specific binding of a CRISPR complex to the target sequence. As used herein, the term "capable of forming a complex with a CRISPR effector protein" means that the gRNA has a structure that allows the CRISPR effector protein to specifically bind to the gRNA so as to form a complex that can bind to the target RNA in a sequence-specific manner and can function on the target RNA. The structural components of the gRNA can include direct repeats and a guide sequence (or spacer). Sequence-specific binding to the target RNA is mediated by a portion of the gRNA that is complementary to the target RNA, the "guide sequence". In embodiments of the present invention, the term guide RNA, i.e., an RNA capable of directing Cas to a target locus, is used as described in the aforementioned references, e.g., WO 2014 / 093622 (PCT / US2013 / 074667). As used herein, the term "wherein the guide sequence is capable of hybridizing" refers to a sub-portion of the gRNA that has sufficient complementarity with the target sequence to hybridize to the target sequence and mediate binding of the CRISPR complex to the target RNA. In general, a guide sequence is any polynucleotide sequence that has sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and guide sequence-specific binding of the CRISPR complex to the target sequence. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence is about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99% or greater when optimally aligned using a suitable alignment algorithm.Optimal alignment can be determined with the aid of any suitable algorithm for aligning sequences, non-limiting examples of which include the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows-Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq.sourceforge.net).
[0225] In certain embodiments, a CRISPR system as provided herein can utilize crRNA or similar polynucleotides comprising a guide sequence, wherein the polynucleotide is RNA, DNA, or a mixture of RNA and DNA, and / or wherein the polynucleotide comprises one or more nucleotide analogs. The sequence can comprise any structure, including but not limited to the structure of native crRNA, such as a convex loop, a hairpin, or a stem-loop structure. In certain embodiments, the polynucleotide comprising the guide sequence forms a duplex with a second polynucleotide sequence, which can be an RNA or DNA sequence.
[0226] In certain embodiments, a chemically modified guide RNA is utilized. Examples of guide RNA chemical modifications include, but are not limited to, incorporating 2'-O-methyl (M), 2'-O-methyl 3' phosphorothioate (MS), or 2'-O-methyl 3' thio PACE (MSP) at one or more terminal nucleotides. Such chemically modified guide RNAs can include increased stability and increased activity compared to unmodified guide RNAs, but the on-target to off-target specificity is unpredictable. (See Hendel, 2015, Nat Biotechnol. 33 (9): 985-9, doi: 10.1038 / nbt.3290, published online on June 29, 2015). Chemically modified guide RNAs also include, but are not limited to, RNAs with phosphorothioate bonds and locked nucleic acids (LNA) nucleotides comprising a methylene bridge between the 2' and 4' carbons of the ribose ring.
[0227] In some embodiments, the length of the guide sequence is about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75 or more nucleotides. In some embodiments, the length of the guide sequence is less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or fewer nucleotides. Preferably, the guide sequence is 10 to 30 nucleotides in length. The ability of a guide sequence to direct sequence-specific binding of a CRISPR complex to a target sequence can be assessed by any suitable assay. For example, components of a CRISPR system sufficient to form a CRISPR complex, including the guide sequence to be tested, can be provided to a host cell having the corresponding target sequence, for example by transfection with a vector encoding the components of the CRISPR sequence, followed by assessment of preferential cleavage within the target sequence, for example by a Surveyor assay. Similarly, cleavage of a target RNA can be assessed in a test tube by providing a target sequence, components of a CRISPR complex (including the guide sequence to be tested), and a control guide sequence that is different from the test guide sequence, and comparing the binding or cleavage rate to the target sequence between the test and control guide sequence reactions. Other assays may exist and will occur to those skilled in the art.
[0228] The guide sequence and therefore the nucleic acid-targeting guide RNA can be selected to target any target nucleic acid sequence. In the case of forming a CRISPR complex, a "target sequence" refers to a sequence to which the guide sequence is designed to have complementarity, wherein hybridization between the target sequence and the guide sequence promotes the formation of the CRISPR complex. The target sequence may comprise an RNA polynucleotide. The term "target RNA" refers to an RNA polynucleotide that serves as a target sequence or comprises a target sequence. In other words, the target RNA may be part of a gRNA, i.e., an RNA polynucleotide or a portion of an RNA polynucleotide to which the guide sequence is designed to have complementarity and to which the effector function mediated by the complex comprising the CRISPR effector protein and the gRNA is directed. In some embodiments, the target sequence is located in the nucleus or cytoplasm of the cell. The target sequence may be DNA. The target sequence may be any RNA sequence. In some embodiments, the target sequence can be a sequence within an RNA molecule selected from the group consisting of messenger RNA (mRNA), pre-mRNA, ribosomal RNA (rRNA), transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nuclear RNA (snRNA), small nuclear RNA (snoRNA), double-stranded RNA (dsRNA), non-coding RNA (ncRNA), long non-coding RNA (lncRNA), and small cytoplasmic RNA (scRNA). In some preferred embodiments, the target sequence can be a sequence within an RNA molecule selected from the group consisting of mRNA, pre-mRNA, and rRNA. In some preferred embodiments, the target sequence can be a sequence within an RNA molecule selected from the group consisting of ncRNA and lncRNA. In some more preferred embodiments, the target sequence can be a sequence within an mRNA molecule or a pre-mRNA molecule.
[0229] In some embodiments, nucleic acid targeting guide RNA is selected to reduce the degree of secondary structure in the RNA targeting guide RNA. In some embodiments, when optimally folded, about or less than about 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1% or less nucleotides of the nucleic acid targeting guide RNA participate in self-complementary base pairing. Optimal folding can be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimum Gibbs free energy (Gibbs free energy). An example of such an algorithm is mFold as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another exemplary folding algorithm is RNAfold, an online web server developed by the Institute for Theoretical Chemistry at the University of Vienna that uses a centroid structure prediction algorithm (see, e.g., AR Gruber et al., 2008, Cell 106(1):23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12):1151-62).
[0230] In certain embodiments, the guide RNA or crRNA may comprise a forward repeat (DR) sequence and a guide sequence or a spacer sequence, consist essentially of it, or consist of it. In certain embodiments, the guide RNA or crRNA may comprise a forward repeat sequence fused or connected to a guide sequence or a spacer sequence, consist essentially of it, or consist of it. In certain embodiments, the forward repeat sequence may be located upstream (i.e., 5') of the guide sequence or the spacer sequence. In other embodiments, the forward repeat sequence may be located downstream (i.e., 3') of the guide sequence or the spacer sequence.
[0231] In certain embodiments, crRNA comprises a stem loop, preferably a single stem loop. In certain embodiments, the direct repeat sequence forms a stem loop, preferably a single stem loop.
[0232] In certain embodiments, the spacer length of the guide RNA is 15 to 35 nt. In certain embodiments, the spacer length of the guide RNA is at least 15 nucleotides, preferably at least 18 nt, such as at least 19, 20, 21, 22 nt, or more. In certain embodiments, the spacer length is 15 to 17 nt, such as 15, 16, or 17 nt; 17 to 20 nt, such as 17, 18, 19, or 20 nt; 20 to 24 nt, such as 20, 21, 22, 23, or 24 nt; 23 to 25 nt, such as 23, 24, or 25 nt; 24 to 27 nt, such as 24, 25, 26, or 27 nt; 27-30 nt, such as 27, 28, 29, or 30 nt; 30-35 nt, such as 30, 31, 32, 33, 34, or 35 nt; or 35 nt or longer.
[0233] In certain embodiments, the spacer length of a guide RNA is less than 28 nucleotides. In certain embodiments, the spacer length of a guide RNA is at least 18 nucleotides and less than 28 nucleotides. In certain embodiments, the spacer length of a guide RNA is between 19 and 28 nucleotides. In certain embodiments, the spacer length of a guide RNA is between 19 and 25 nucleotides. In certain embodiments, the spacer length of a guide RNA is 20 nucleotides. In certain embodiments, the spacer length of a guide RNA is 23 nucleotides. In certain embodiments, the spacer length of a guide RNA is 25 nucleotides.
[0234] In a typical CRISPR-Cas system, the degree of complementarity between a guide sequence and its corresponding target sequence can be about or greater than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or 100%; the length of the guide or RNA or sgRNA can be about or greater than about 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75 or more nucleotides; or, the length of the guide or RNA or sgRNA can be less than about 75, 50, 45, 40, 35, 30, 25, 20, 15, 12 or fewer nucleotides. However, one aspect of the present invention is to reduce off-target interactions, for example, to reduce the interaction of the guide with a target sequence with low complementarity. Indeed, it is shown in the examples that the present invention relates to mutations that enable the CRISPR-Cas system to distinguish between a target sequence and an off-target sequence having greater than 80% to about 95% complementarity, such as 83%-84% or 88-89% or 94-95% complementarity (e.g., distinguishing between a target having 18 nucleotides and an off-target having 18 nucleotides with 1, 2 or 3 mismatches). Thus, in the context of the present invention, the degree of complementarity between a guide sequence and its corresponding target sequence is greater than 94.5% or 95% or 95.5% or 96% or 96.5% or 97% or 97.5% or 98% or 98.5% or 99% or 99.5% or 99.9%, or 100%. The off-target is less than 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% or 94% or 93% or 92% or 91% or 90% or 89% or 88% or 87% or 86% or 85% or 84% or 83% or 82% or 81% or 80% of the complementarity between the sequence and the guide, and advantageously the off-target is 100% or 99.9% or 99.5% or 99% or 99% or 98.5% or 98% or 97.5% or 97% or 96.5% or 96% or 95.5% or 95% or 94.5% of the complementarity between the sequence and the guide.
[0235] In certain embodiments, modulation of cleavage efficiency can be explored by introducing mismatches, such as one or more mismatches, such as one or two mismatches, between the spacer sequence and the target sequence, including mismatch positions along the spacer / target. For example, the more central the double mismatch is (i.e., not 3' or 5'), the more affected the cleavage efficiency is. Therefore, by selecting the mismatch positions along the spacer, the cleavage efficiency can be modulated. By way of example, if less than 100% target cleavage is desired (e.g., in a cell population), one or more, such as preferably two, mismatches between the spacer and the target sequence can be introduced into the spacer sequence. The more central the mismatch position is along the spacer, the lower the cleavage percentage.
[0236] In certain exemplary embodiments, the cleavage efficiency can be explored to design a single guide that can distinguish between two or more targets that vary due to a single nucleotide, such as a single nucleotide polymorphism (SNP), a variation, or a (point) mutation. The CRISPR effector may have a reduced sensitivity to SNPs (or other single nucleotide variations) and continue to cleave the SNP target at a certain efficiency level. Therefore, for two targets or a group of targets, the guide RNA can be designed to have a nucleotide sequence that is complementary to one of the targets, i.e., the on-target SNP. The guide RNA is further designed to have a synthetic mismatch. As used herein, a "synthetic mismatch" refers to a non-naturally occurring mismatch that is introduced upstream or downstream of a naturally occurring SNP, such as up to 5 nucleotides upstream or downstream, such as 4, 3, 2, or 1 nucleotides upstream or downstream, preferably up to 3 nucleotides upstream or downstream, more preferably up to 2 nucleotides upstream or downstream, most preferably 1 nucleotide upstream or downstream (i.e., adjacent to the SNP). When the CRISPR effector binds to the on-target SNP, only a single mismatch will be formed along with the synthetic mismatch, and will continue to activate the CRISPR effector and produce a detectable signal. When the guide RNA hybridizes to an off-target SNP, two mismatches will be formed, the mismatch from the SNP and the synthetic mismatch, and no detectable signal will be produced. Therefore, the system disclosed herein can be designed to distinguish SNPs within a population. For example, the system can be used to distinguish pathogenic strains that differ due to a single SNP or to detect certain disease-specific SNPs, such as, but not limited to, disease-associated SNPs, such as, but not limited to, cancer-associated SNPs.
[0237] In certain embodiments, the guide RNA is designed such that the SNP is located at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the spacer sequence (taking the 5' end as the starting point). In certain embodiments, the guide RNA is designed such that the SNP is located at position 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the spacer sequence (taking the 5' end as the starting point). In certain embodiments, the guide RNA is designed such that the SNP is located at position 2, 3, 4, 5, 6, or 7 of the spacer sequence (taking the 5' end as the starting point). In certain embodiments, the guide RNA is designed such that the SNP is located at position 3, 4, 5, or 6 of the spacer sequence (taking the 5' end as the starting point). In certain embodiments, the guide RNA is designed such that the SNP is located at position 3 (starting from the 5' end) of the spacer sequence.
[0238] In certain embodiments, the guide RNA is designed such that the mismatch (e.g., a synthetic mismatch, i.e., an additional mutation other than a SNP) is located at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the spacer sequence (based on the 5' end). In certain embodiments, the guide RNA is designed such that the mismatch is located at position 1, 2, 3, 4, 5, 6, 7, 8, or 9 of the spacer sequence (based on the 5' end). In certain embodiments, the guide RNA is designed such that the mismatch is located at position 4, 5, 6, or 7 of the spacer sequence (based on the 5' end). In certain embodiments, the guide RNA is designed such that the mismatch is located at position 5 of the spacer sequence (based on the 5' end).
[0239] In certain embodiments, the guide RNA is designed such that the mismatch is located 2 nucleotides upstream of the SNP (ie, one intervening nucleotide).
[0240] In certain embodiments, the guide RNA is designed such that the mismatch is located 2 nucleotides downstream of the SNP (ie, one intervening nucleotide).
[0241] In certain embodiments, the guide RNA is designed such that the mismatch is at position 5 (from the 5' end) of the spacer sequence and the SNP is at position 3 (from the 5' end) of the spacer sequence.
[0242] Embodiments described herein encompass inducing one or more nucleotide modifications in eukaryotic cells as discussed herein (in vitro, i.e., in isolated eukaryotic cells), including delivering a vector as discussed herein to the cell. One or more mutations can include the introduction, deletion, or replacement of one or more nucleotides at each target sequence of the cell via one or more guide RNAs. Mutation can include the introduction, deletion, or replacement of 1-75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. Mutation can include the introduction, deletion, or replacement of 1, 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. The mutations may comprise the introduction, deletion or substitution of 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides per target sequence in the one or more cells via one or more guide RNAs. The mutations comprise the introduction, deletion or substitution of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides per target sequence in the one or more cells via one or more guide RNAs. The mutation may comprise the introduction, deletion or substitution of 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50 or 75 nucleotides at each target sequence of the one or more cells via one or more guide RNAs. The mutation may comprise the introduction, deletion or substitution of 40, 45, 50, 75, 100, 200, 300, 400 or 500 nucleotides at each target sequence of the one or more cells via one or more guide RNAs.
[0243] Typically, in the context of an endogenous CRISPR system, formation of a CRISPR complex (comprising a guide sequence hybridized to a target sequence and complexed with one or more Cas proteins) results in cleavage in or near (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 50 or more base pairs from) the target sequence, but can depend, for example, on secondary structure, particularly in the case of RNA targets.
[0244] RNA-based masking constructs
[0245] As used herein, a "masking construct" refers to a molecule that can be cleaved or otherwise inactivated by the activated CRISPR system effector protein described herein. The term "masking construct" may also be referred to alternatively as a "detection construct". In certain exemplary embodiments, the masking construct is an RNA-based masking construct. The masking construct prevents the generation or detection of a positive detectable signal. A positive detectable signal can be any signal that can be detected using optical, fluorescent, chemiluminescent, electrochemical or other detection methods known in the art. The masking construct can prevent the generation of a detectable positive signal or mask the presence of a detectable positive signal until the masking construct is removed or otherwise silenced. The term "positive detectable signal" is used to distinguish it from other detectable signals that can be detected in the presence of a masking construct. For example, in certain embodiments, a first signal (i.e., a negative detectable signal) can be detected when a masking agent is present, which is then converted to a second signal (e.g., a positive detectable signal) after the target molecule is detected and the masking agent is cleaved or inactivated by the activated CRISPR effector protein.
[0246] In certain exemplary embodiments, the masking construct can inhibit the generation of a gene product. The gene product can be encoded by a reporter construct added to the sample. The masking construct can be an interfering RNA involved in the RNA interference pathway, such as shRHN or siRNA. The masking construct can also include microRNA (miRNA). When present, the masking construct inhibits the expression of the gene product. The gene product can be a fluorescent protein or other RNA transcript or protein that would otherwise be detectable by a labeled probe or antibody if the masking construct were not present. After activation of the effector protein, the masking construct is cracked or otherwise silenced, thereby allowing the gene product to be expressed and detected as a positive detectable signal.
[0247] In certain exemplary embodiments, the masking construct can chelate one or more reagents required to produce a detectable positive signal, such that release of the one or more reagents from the masking construct facilitates the production of a detectable positive signal. The one or more reagents can be combined to produce a colorimetric signal, a chemiluminescent signal, a fluorescent signal, or any other detectable signal, and can include any reagent known to be suitable for such a purpose. In certain exemplary embodiments, the one or more reagents are chelated by an RNA aptamer that binds the one or more reagents. The one or more reagents are released upon activation of the effector protein following detection of the target molecule. In certain exemplary embodiments, the one or more reagents are proteins, such as enzymes, that can contribute to the production of a detectable signal, such as a colorimetric, chemiluminescent, or fluorescent signal, and are inhibited or chelated so that the protein cannot produce a detectable signal by binding to the protein via the one or more RNA aptamers. Following activation of the effector protein disclosed herein, the RNA aptamer is cleaved or degraded to the extent that it no longer inhibits the protein's ability to produce a detectable signal. In certain exemplary embodiments, the aptamer is a thrombin inhibitor aptamer. In certain exemplary embodiments, the thrombin inhibitor aptamer has the sequence GGGAACAAAGCUGAAGUACUUACCC (SEQ ID NO: 414). When this aptamer is cleaved, thrombin will become active and will cause peptide colorimetry or fluorescent substrate cleavage. In certain exemplary embodiments, the colorimetric substrate is a p-nitroanilide (pNA) covalently attached to the peptide substrate of thrombin. After being cleaved by thrombin, pNA is released and the color becomes yellow and easily visible to the eyes. In certain exemplary embodiments, the fluorescent substrate is a 7-amino-4-methylcoumarin blue fluorophore that can be detected using a fluorescence detector. Within the general principles listed above, inhibitory aptamers can also be used for horseradish peroxidase (HRP), beta-galactosidase or calf alkaline phosphatase (CAP).
[0248] In certain embodiments, the cleavage of the enzyme inhibition aptamer is detected by colorimetry. A potential mode for converting RNase activity into a colorimetric signal is to combine the cleavage of the RNA aptamer with the reactivation of the enzyme that can produce a colorimetric output. In the absence of RNA cleavage, the complete aptamer will be bound to the enzyme target and inhibit its activity. The advantage of this readout system is that the enzyme provides an additional amplification step: once released from the aptamer via incidental activity (such as Cas13a incidental activity), the colorimetric enzyme will continue to produce a colorimetric product, causing signal multiplication.
[0249] In certain embodiments, existing aptamers of inhibitory enzymes with colorimetric readout are used. Several aptamers / enzyme pairs with colorimetric readout exist, such as thrombin, protein C, neutrophil elastase, and subtilisin. These proteases have colorimetric substrates based on pNA and are commercially available. In certain embodiments, novel aptamers targeting commonly used colorimetric enzymes are used. Commonly used and stable enzymes, such as beta-galactosidase, horseradish peroxidase, or calf intestinal alkaline phosphatase, can be targeted by engineered aptamers designed by selection strategies such as SELEX. Such strategies allow rapid selection of aptamers with nanomolar binding efficiency and can be used to develop additional enzyme / aptamer pairs for colorimetric readout.
[0250] In certain embodiments, RNA enzyme activity is detected colorimetrically via the cleavage of an inhibitor limited by RNA. Many commonly used colorimetric enzymes have competitive, reversible inhibitors: for example, β-galactosidase can be inhibited by galactose. Many of these inhibitors are weak, but their effect can be increased by an increase in local concentration. By associating the local concentration of the inhibitor with the RNA enzyme activity, the colorimetric enzyme and inhibitor pair can be engineered into an RNA enzyme sensor. A colorimetric RNA enzyme sensor based on small molecule inhibitors involves three components: a colorimetric enzyme, an inhibitor, and a bridging RNA that is covalently linked to the inhibitor and the enzyme, thereby limiting the inhibitor to the enzyme. In the uncleaved structure, the enzyme is inhibited by an increase in the local concentration of the small molecule; when the RNA is cleaved (e.g., by incidental cleavage of Cas13a), the inhibitor will be released and the colorimetric enzyme will be activated.
[0251] In certain embodiments, RNase activity is detected colorimetrically via G-quadruplex formation and / or activation. G-quadruplexes in DNA can complex with heme (iron(III)-protoporphyrin IX) to form a DNAzyme with peroxidase activity. When provided with a peroxidase substrate (e.g., ABTS (2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid] diammonium salt)), the G-quadruplex-heme complex oxidizes the substrate in the presence of hydrogen peroxide, subsequently forming a green color in solution. An exemplary G-quadruplex-forming DNA sequence is: GGGTAGGGCGGGTTGGGA (SEQ. ID. No. 415). By hybridizing an RNA sequence to this DNA aptamer, the formation of G-quadruplex structures is restricted. Upon incidental activation of the RNase (e.g., incidental activation of the C2c2 complex), the RNA staple is cleaved, allowing G-quadruplex formation and heme binding. This strategy is particularly attractive because the color formation is enzymatic, meaning that there is additional amplification beyond RNase activation.
[0252] In certain exemplary embodiments, the masking construct can be immobilized in individual discrete volumes (defined further below) on a solid substrate and chelate a single agent. For example, the agent can be beads containing a dye. When chelated by the immobilized agent, the individual beads are too dispersed to produce a detectable signal, but can produce a detectable signal after being released from the masking construct, for example, by aggregation or a simple increase in solution concentration. In certain exemplary embodiments, the immobilized masking agent is an RNA-based aptamer, which can be cleaved by an activated effector protein after detection of the target molecule.
[0253] In certain other exemplary embodiments, the masking construct is bound to a fixed reagent in the solution, thereby blocking the ability of the reagent to bind to a free, individually labeled binding partner in the solution. Therefore, after the washing step is applied to the sample, the labeled binding partner can be washed away from the sample in the absence of the target molecule. However, if the effector protein is activated, the masking construct is cleaved to a degree sufficient to interfere with the ability of the masking construct to bind to the reagent, thereby allowing the labeled binding partner to bind to the fixed reagent. Therefore, the labeled binding partner is retained after the washing step, indicating the presence of the target molecule in the sample. In some aspects, the masking construct bound to the fixed reagent is an RNA aptamer. The fixed reagent can be a protein, and the labeled binding partner can be a labeled antibody. Alternatively, the fixed reagent can be avidin streptavidin, and the labeled binding partner can be labeled biotin. The label on the binding partner used in the above-mentioned embodiment can be any detectable label known in the art. In addition, other known binding partners can be used according to the overall design described herein.
[0254] In certain exemplary embodiments, the masking construct may comprise a ribozyme. A ribozyme is an RNA molecule with catalytic properties. Both natural and engineered ribozymes comprise or consist of RNA that can be targeted by the effector proteins disclosed herein. The ribozyme can be selected or engineered to catalyze a reaction that produces a negative detectable signal or prevents the production of a positive control signal. After the ribozyme is inactivated by the activated effector protein molecule, the reaction that produces the negative control signal or prevents the production of the positive detectable signal is removed, thereby allowing the detection of the positive detectable signal. In an exemplary embodiment, the ribozyme can catalyze a colorimetric reaction, causing the solution to exhibit a first color. When the ribozyme is inactivated, the solution then turns a second color, which is a detectable positive signal. An example of how ribozymes can be used to catalyze colorimetric reactions is described in Zhao et al. "Signal amplification of glucosamine-6-phosphate based on ribozyme glmS", Biosens Bioelectron. 2014; 16: 337-42, and provides an example of how such a system can be modified to function in the context of the embodiments disclosed herein. Alternatively, a ribozyme, when present, can produce, for example, a cleavage product of an RNA transcript. Thus, detection of a positive detectable signal can include detection of a non-cleaved RNA transcript produced only in the absence of the ribozyme.
[0255] In one exemplary embodiment, the masking construct comprises a detection agent that changes color depending on whether the detection agent is aggregated or dispersed in solution. For example, certain nanoparticles, such as colloidal gold, undergo a visible purple to red color shift when they move from aggregates to dispersed particles. Therefore, in certain exemplary embodiments, such detection agents can be held in aggregate by one or more bridging molecules. See, e.g., Figure 43 At least a portion of the bridging molecule comprises RNA. Upon activation of the effector protein disclosed herein, the RNA portion of the bridging molecule is cleaved, thereby allowing the detection agent to disperse and causing a corresponding change in color. See, e.g. Figure 45. In certain exemplary embodiments, the bridging molecule is an RNA molecule. In certain exemplary embodiments, the detection agent is a colloidal metal. The colloidal metal material may include water-insoluble metal particles or metal compounds dispersed in a liquid, a hydrosol or a metal sol. The colloidal metal may be selected from metals of Groups IA, IB, IIB and IIIB of the periodic table, as well as transition metals, particularly those of Group VIII. Preferred metals include gold, silver, aluminum, ruthenium, zinc, iron, nickel and calcium. Other suitable metals also include all of the following in their various oxidation states: lithium, sodium, magnesium, potassium, scandium, titanium, vanadium, chromium, manganese, cobalt, copper, gallium, strontium, niobium, molybdenum, palladium, indium, tin, tungsten, rhenium, platinum and gadolinium. The metal is preferably provided in the form of ions derived from an appropriate metal compound, such as Al3+, Ru3+, Zn2+, Fe3+, Ni2+ and Ca2+ ions.
[0256] When the RNA bridge is cleaved by the activated CRISPR effector, the aforementioned color shift is observed. In certain exemplary embodiments, the particles are colloidal metals. In certain other exemplary embodiments, the colloidal metal is colloidal gold. In certain exemplary embodiments, the colloidal nanoparticles are 15 nm gold nanoparticles (AuNPs). Due to the unique surface properties of colloidal gold nanoparticles, when fully dispersed in solution, a maximum absorbance is observed at 520 nm and the color appears red to the naked eye. After AuNP aggregation, they exhibit a red shift in maximum absorbance and a darker color, ultimately precipitating from the solution as dark purple aggregates. In certain exemplary embodiments, the nanoparticles are modified to include DNA linkers extending from the surface of the nanoparticles. Individual particles are linked together by single-stranded RNA (ssRNA) bridges that hybridize to at least a portion of the DNA linker at each end of the RNA. Thus, the nanoparticles will form a network of connected particles and aggregates, appearing as a dark precipitate. Upon activation of the CRISPR effectors disclosed herein, the ssRNA bridges will be cleaved, releasing the AuNPs from the connected mesh and producing a visible red color. Exemplary DNA linker and RNA bridge sequences are listed below. A thiol linker at the end of the DNA linker can be used for surface conjugation to AuNPs. Other forms of conjugation can be used. In certain exemplary embodiments, two populations of AuNPs can be produced, one for each DNA linker. This will help promote proper binding of ssRNA bridges with appropriate orientation. In certain exemplary embodiments, the first DNA linker is conjugated from the 3' end, while the second DNA linker is conjugated from the 5' end.
[0257] Table 6
[0258]
[0259]
[0260] In some embodiments, one or more elements of the nucleic acid targeting system are derived from a specific organism that contains an endogenous CRISPR RNA targeting system. In certain embodiments, the CRISPR RNA targeting system is found in Eubacterium and Ruminococcus. In certain embodiments, the effector protein comprises targeting and incidental ssRNA cleavage activity. In certain embodiments, the effector protein comprises a dual HEPN domain. In certain embodiments, the effector protein lacks a counterpart to the helix-1 domain of Cas13a. In certain embodiments, the effector protein is smaller than the previously characterized Class 2 CRISPR effectors with a median size of 928 aa. This median size is 190 aa (17%), which is smaller than the median size of Cas13c; greater than 200 aa (18%), which is smaller than the median size of Cas13b; and greater than 300 aa (26%), which is smaller than the median size of Cas13a. In certain embodiments, the effector protein has no requirements for flanking sequences (e.g., PFS, PAM).
[0261] In certain embodiments, the effector protein locus architecture includes an accessory protein containing a WYL domain (thus indicated after the three amino acids conserved in the original identified group of these domains; see, e.g., WYL domain IPR026881). In certain embodiments, the WYL domain accessory protein comprises at least one helix-turn-helix (HTH) or ribbon-helix-helix (RHH) DNA binding domain. In certain embodiments, the WYL domain-containing accessory protein increases the targeting and incidental ssRNA cleavage activity of the RNA-targeting effector protein. In certain embodiments, the WYL domain-containing accessory protein comprises an N-terminal RHH domain and a pattern of predominantly hydrophobic conserved residues, including an invariant tyrosine-leucine doublet corresponding to the original WYL motif. In certain embodiments, the WYL domain-containing accessory protein is WYL1. WYL1 is a single WYL domain protein primarily associated with Ruminococcus.
[0262] In other exemplary embodiments, the type VI RNA targeting Cas enzyme is Cas 13d. In certain embodiments, Cas13d is Eubacterium siraeum DSM 15702 (EsCas13d) or Ruminococcus N15.MGS-57 (RspCas13d) (see, for example, Yan et al., Cas13d Is a Compact RNA-Targeting Type VICRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein, Molecular Cell (2018), doi.org / 10.1016 / j.molcel.2018.02.028). RspCas13d and EsCas13d do not have side sequence requirements (e.g., PFS, PAM).
[0263] In certain other exemplary embodiments, the masking construct may comprise an RNA oligonucleotide to which a detectable label and a masking agent for that detectable label are attached. An example of such a detectable label / masking agent pair is a fluorophore and a fluorophore quencher. Quenching of a fluorophore can occur as a result of the formation of a non-fluorescent complex between the fluorophore and another fluorophore or a non-fluorescent molecule. This mechanism is known as ground state complex formation, static quenching, or contact quenching. Thus, the RNA oligonucleotide can be designed so that the fluorophore and quencher are in close enough proximity for contact quenching to occur. Fluorophores and their associated quenchers are known in the art and can be selected by one of ordinary skill in the art for this purpose. The specific fluorophore / quencher pair is not critical in the context of the present invention, as long as the choice of the fluorophore / quencher pair ensures masking of the fluorophore. Upon activation of the effector protein disclosed herein, the RNA oligonucleotide is cleaved, thereby severing the proximity between the fluorophore and the quencher required to maintain the contact quenching effect. Thus, detection of the fluorophore can be used to determine the presence of a target molecule in a sample.
[0264] In certain other exemplary embodiments, the masking construct may comprise one or more metal nanoparticles, such as one or more RNA oligonucleotides attached to gold nanoparticles. In some embodiments, the masking construct comprises a plurality of metal nanoparticles cross-linked by a plurality of RNA oligonucleotides to form a closed ring. In one embodiment, the masking construct comprises three gold nanoparticles cross-linked by three RNA oligonucleotides to form a closed ring. In some embodiments, cleavage of the RNA oligonucleotide by the CRISPR effector protein results in the generation of a detectable signal by the metal nanoparticles.
[0265] In certain other exemplary embodiments, the masking construct may comprise one or more RNA oligonucleotides to which one or more quantum dots are attached. In some embodiments, cleavage of the RNA oligonucleotide by the CRISPR effector protein results in the generation of a detectable signal by the quantum dots.
[0266] In one exemplary embodiment, the masking construct may comprise a quantum dot. The quantum dot may have multiple linker molecules attached to the surface. At least a portion of the linker molecule comprises RNA. The linker molecule is attached to the quantum dot at one end and is attached to one or more quenchers along the length of the linker or at the end so that the quenchers remain in sufficient proximity for quenching of the quantum dot to occur. The linker may be branched. As described above, the quantum dot / quencher pair is not critical, as long as the selection of the quantum dot / quencher pair ensures masking of the fluorophore. Quantum dots and their associated quenchers are known in the art and can be selected by one of ordinary skill in the art for this purpose. Upon activation of the effector protein disclosed herein, the RNA portion of the linker molecule is cleaved, thereby eliminating the proximity between the quantum dot and the one or more quenchers required to maintain the quenching effect. In certain exemplary embodiments, the quantum dot is conjugated to streptavidin. RNA is attached via a biotin linker and recruits a quenching molecule having the sequence / 5Biosg / UCUCGUACGUUC / 3IAbRQSp / (SEQ ID NO: 416) or / 5Biosg / UCUCGUACGUUCUCUCGUACGUUC / 3IAbRQSp / (SEQ ID NO: 417), where / 5Biosg / is a biotin tag and / 3lAbRQSp / is an Iowa black quencher. Upon cleavage by an activated effector disclosed herein, the quantum dots will visibly fluoresce.
[0267] In a similar manner, fluorescence energy transfer (FRET) can be used to generate a detectable positive signal. FRET is a radiation-free process by which a photon from an energy-excited fluorophore (i.e., a "donor fluorophore") elevates the energy state of an electron in another molecule (i.e., an "acceptor") to a higher vibrational energy level of an excited singlet state. The donor fluorophore returns to the ground state without emitting the characteristic fluorescence of that fluorophore. The acceptor can be another fluorophore or a non-fluorescent molecule. If the acceptor is a fluorophore, the transferred energy is emitted as the characteristic fluorescence of that fluorophore. If the acceptor is a non-fluorescent molecule, the absorbed energy is lost as heat. Therefore, in the context of the embodiments disclosed herein, the fluorophore / quencher pair is replaced with a donor fluorophore / acceptor pair attached to an oligonucleotide molecule. When intact, the masking construct generates a first signal (negative detectable signal) as detected by fluorescence or heat emitted from the acceptor. Upon activation of the effector protein disclosed herein, the RNA oligonucleotide is cleaved and FRET is disrupted so that fluorescence of the donor fluorophore is now detected (positive detectable signal).
[0268] In certain exemplary embodiments, the masking construct comprises the use of an intercalating dye that changes absorbance in response to cleavage of long RNA into short nucleotides. Several such dyes exist. For example, pyronine-Y will complex with RNA and form a complex that absorbs at 572 nm. Cleavage of the RNA results in a loss of absorbance and a color change. Methylene blue can be used in a similar manner, with a change in absorbance at 688 nm following RNA cleavage. Thus, in certain exemplary embodiments, the masking construct comprises RNA and an intercalating dye complex whose absorbance changes following cleavage of the RNA by an effector protein disclosed herein.
[0269] Amplification
[0270] In certain exemplary embodiments, the target RNA and / or DNA can be amplified before activating the CRISPR effector protein. Any suitable RNA or DNA amplification technique can be used. In certain exemplary embodiments, RNA or DNA amplification is isothermal amplification. In certain exemplary embodiments, isothermal amplification can be nucleic acid sequence-based amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), strand displacement amplification (SDA), helicase-dependent amplification (HDA) or nickase amplification reaction (NEAR). In certain exemplary embodiments, non-isothermal amplification methods can be used, including but not limited to PCR, multiple displacement amplification (MDA), rolling circle amplification (RCA), ligase chain reaction (LCR) or branched amplification method (RAM).
[0271] In certain exemplary embodiments, RNA or DNA amplification is a nucleic acid sequence-based amplification NASBA, which initiates reverse transcription of the target RNA by a sequence-specific reverse primer to establish an RNA / DNA duplex. RNase H is then used to degrade the RNA template, allowing a forward primer containing a promoter, such as a T7 promoter, to bind to the complementary strand and initiate extension of the complementary strand, producing a double-stranded DNA product. RNA polymerase promoter-mediated transcription of the DNA template then creates a copy of the target RNA sequence. Importantly, each of the new target RNAs can be detected by a guide RNA, thereby further enhancing the sensitivity of the assay. The target RNA is bound by the guide RNA and then activates the CRISPR effector protein and the method proceeds as outlined above. The NASBA reaction has the additional advantage of being able to proceed under moderate isothermal conditions, for example, at about 41°C, making it suitable for systems and devices deployed for early and direct detection in the field and away from clinical laboratories.
[0272] In certain other exemplary embodiments, a recombinase polymerase amplification (RPA) reaction can be used to amplify a target nucleic acid. The RPA reaction uses a recombinase that can pair sequence-specific primers with homologous sequences in duplex DNA. If target DNA is present, the initial DNA amplification is performed and no other sample manipulation, such as thermal cycling or chemical melting, is required. The entire RPA amplification system is stable in a dry formulation and can be safely transported without freezing. The RPA reaction can also be performed at an isothermal temperature, with the optimal reaction temperature being 37-42°C. Sequence-specific primers are designed to amplify sequences containing target nucleic acid sequences to be detected. In certain exemplary embodiments, an RNA polymerase promoter, such as a T7 promoter, is added to one of the primers. This results in a double-stranded DNA product containing the target sequence and the RNA polymerase promoter. After or during the RPA reaction, RNA polymerase is added, which will produce RNA from the double-stranded DNA template. The amplified target RNA can then be detected by the CRISPR effector system. In this way, the target DNA can be detected using the embodiments disclosed herein. The RPA reaction can also be used to amplify target RNA. The target RNA is first converted to cDNA using reverse transcriptase, followed by second-strand DNA synthesis, at which point the RPA reaction proceeds as outlined above.
[0273] Therefore, in certain exemplary embodiments, the system disclosed herein may include an amplification reagent. This paper describes different components or reagents suitable for nucleic acid amplification. For example, an amplification reagent as described herein may include a buffer, such as a Tris buffer. The Tris buffer can be used at any concentration suitable for the desired application or use, for example, including but not limited to concentrations such as 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 25mM, 50mM, 75mM, 1M. Those skilled in the art will be able to determine the appropriate concentration for a buffer (e.g., Tris) of the present invention.
[0274] Amplification reaction, for example, can include salt, such as magnesium chloride (MgCl ), potassium chloride (KCl) or sodium chloride (NaCl) in PCR to improve the amplification of nucleic acid fragments. Although salt concentration will depend on specific reaction and application, in some embodiments, nucleic acid fragments of a specific size may produce optimal results at a specific salt concentration. Larger products may need to have a changed salt concentration, typically a lower salt, to produce the desired result, while the amplification of smaller products may produce better results at a higher salt concentration. It will be appreciated by those skilled in the art that the presence and / or concentration of salt and the change in salt concentration can change the stringency of a biological or chemical reaction, and therefore any salt that provides appropriate conditions for the present invention and for reactions as described herein can be used.
[0275] Other components of the biological or chemical reaction may include a cell lysis component to break open or dissolve the cells for analysis of the substances therein. The cell lysis component may include, but is not limited to, detergents; salts such as NaCl, KCl, ammonium sulfate [(NH4)2SO4] as described above; or others. Detergents that may be suitable for the present invention may include Triton X-100, sodium dodecyl sulfate (SDS), CHAPS (3-[(3-cholamidopropyl)dimethylammonium]-1-propanesulfonate), ethyltrimethylammonium bromide, nonylphenoxypolyethoxyethanol (NP-40). The concentration of the detergent may depend on the specific application and, in some cases, may be specific to the reaction. The amplification reaction may include dNTPs and nucleic acid primers used at any concentration suitable for the present invention, including, but not limited to, 100 nM, 150 nM, 200 nM, 250 nM, 300 nM, 350 nM, 400 nM, 450 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, 10 ... In some embodiments, the polymerase used in the present invention can be 950nM, 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 20mM, 30mM, 40mM, 50mM, 60mM, 70mM, 80mM, 90mM, 100mM, 150mM, 200mM, 250mM, 300mM, 350mM, 400mM, 450mM, 500mM, etc. Similarly, the polymerase suitable for use in the present invention can be any specific or general polymerase known in the art and suitable for use in the present invention, including Taq polymerase, Q5 polymerase, etc.
[0276] In some embodiments, amplification reagents as described herein may be suitable for use in hot start amplification. Hot start amplification can, in some embodiments, be beneficial in reducing or eliminating dimerization of adapter molecules or oligonucleotides, or otherwise preventing undesirable amplification products or artifacts and obtaining optimal amplification of the desired product. Many of the components described herein for amplification can also be used in hot start amplification. In some embodiments, reagents or components suitable for hot start amplification can be used in place of one or more of the constituent components, as appropriate. For example, a polymerase or other reagent that exhibits the desired activity under specific temperatures or other reaction conditions can be used. In some embodiments, reagents designed or optimized for use in hot start amplification can be used, for example, to activate the polymerase after transposition or after reaching a specific temperature. Such polymerases can be antibody-based or aptamer-based. Polymerases as described herein are known in the art. Examples of such reagents may include, but are not limited to, hot start polymerases, hot start dNTPs, and light-caged dNTPs. Such reagents are known and available in the art. One skilled in the art will be able to determine the optimal temperature for individual reagents.
[0277] Nucleic acid amplification can be carried out using a specific thermal cycle machine or apparatus, and can be carried out in a single reaction or in batches, so that any desired number of reactions can be carried out simultaneously. In some embodiments, amplification can be carried out using a microfluidic or robotic device, or can be carried out using manual changes in temperature to achieve desired amplification. In some embodiments, optimization can be performed to obtain optimal reaction conditions for a particular application or material. Those skilled in the art will appreciate and be able to optimize reaction conditions to obtain enough amplification.
[0278] In certain embodiments, detection of DNA using a method or system of the invention requires transcription of the (amplified) DNA into RNA prior to detection.
[0279] Target RNA / DNA enrichment
[0280] In certain exemplary embodiments, the target RNA or DNA can be first enriched prior to detection or amplification of the target RNA or DNA. In certain exemplary embodiments, this enrichment is achieved by binding of the target nucleic acid by a CRISPR effector system.
[0281] Current target-specific enrichment schemes require single-stranded nucleic acids prior to hybridization with the probe. As one of the various advantages, embodiments of the present invention can skip this step and are able to directly target double-stranded DNA (partially or completely double-stranded). In addition, the embodiments disclosed herein are enzyme-driven targeting methods that provide faster kinetics and simpler motion flow, thereby allowing isothermal enrichment. In certain exemplary embodiments, enrichment can occur between 20-37°C. In certain exemplary embodiments, a set of guide RNAs for different target nucleic acids are used in a single assay, thereby allowing detection of multiple targets and / or multiple variants of a single target.
[0282] In certain exemplary embodiments, dead CRISPR effector proteins can bind to target nucleic acids in solution and subsequently be isolated from the solution. For example, dead CRISPR effector proteins bound to target nucleic acids can be isolated from solution using antibodies or other molecules, such as aptamers, that specifically bind to dead CRISPR effector proteins.
[0283] In other exemplary embodiments, the dead CRISPR effector protein can be bound to a solid substrate. The fixed substrate can refer to any material that is suitable for attaching polypeptides or polynucleotides or that can be modified to be suitable for attaching polypeptides or polynucleotides. Possible substrates include, but are not limited to, glass and modified functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other materials, polypropylene, polyethylene, polybutylene, polyurethane, Teflon TMetc.), polysaccharides, nylon or nitrocellulose, ceramics, resins, silica or silica-based materials (including silicon and modified silicon), carbon, metals, inorganic glass, plastics, fiber optic bundles and a variety of other polymers. In some embodiments, the solid support comprises a patterned surface suitable for molecules to be fixed in an ordered pattern. In certain embodiments, the patterned surface refers to the arrangement of different regions in or on the exposed layer of the solid support. In some embodiments, the solid support comprises an array of holes or recesses in the surface. The composition and geometry of the solid support can vary with its use. In some embodiments, the solid support is a planar structure, such as a slide, chip, microchip and / or array. Thus, the surface of the substrate can be in the form of a planar layer. In some embodiments, the solid support comprises one or more surfaces of a flow cell. The term "flow cell" as used herein refers to a chamber comprising a solid surface across which one or more fluid reagents can flow. Exemplary flow cells and related fluid systems and detection platforms that can be readily used in the methods of the present disclosure are described, for example, in Bentley et al. Nature 456:53-59 (2008); WO 04 / 0918497; US 7,057,026; WO 91 / 06678; WO 07 / 123744; US 7,329,492; US 7,211,414; US 7,315,019; US 7,405,281; and US 2008 / 0108082. In some embodiments, the solid support or its surface is non-planar, such as the inner or outer surface of a tube or container. In some embodiments, the solid support comprises microspheres or beads. "Microspheres," "beads," "particles" are intended to refer to average small discrete particles made of various materials including, but not limited to, plastics, ceramics, glass, and polystyrene within the context of a solid substrate. In certain embodiments, the microspheres are magnetic microspheres or beads. Alternatively or additionally, the beads may be porous.The bead size ranges from nanometers (eg 100 nm) to millimeters (eg 1 mm).
[0284] The sample containing or suspected of containing the target nucleic acid can then be exposed to a substrate to allow the target nucleic acid to bind to the bound dead CRISPR effector protein. Non-target molecules can then be washed away. In certain exemplary embodiments, the target nucleic acid can then be released from the CRISPR effector protein / guide RNA complex for further detection using the methods disclosed herein. In certain exemplary embodiments, the target nucleic acid can first be amplified as described herein.
[0285] In certain exemplary embodiments, the CRISPR effector can be labeled with a binding tag. In certain exemplary embodiments, the CRISPR effector can be chemically tagged. For example, the CRISPR effector can be chemically biotinylated. In another exemplary embodiment, a fusion can be created by adding an additional sequence encoding the fusion to the CRISPR effector. An example of such a fusion is AviTag TM , which uses highly targeted enzymatic conjugation of a single biotin on a unique 15 amino acid peptide tag. In certain embodiments, the CRISPR effector can be labeled with a capture tag, such as but not limited to GST, Myc, hemagglutinin (HA), green fluorescent protein (GFP), flag, His tag, TAP tag, and Fc tag. The binding tag, whether a fusion, chemical tag, or capture tag, can be used to pull down the CRISPR effector system once it has bound to the target nucleic acid or used to immobilize the CRISPR effector system on a solid substrate.
[0286] In certain exemplary embodiments, the guide RNA can be labeled with a binding tag. In certain exemplary embodiments, the entire guide RNA can be labeled with in vitro transcription (IVT) that incorporates one or more biotinylated nucleotides, such as biotinylated uracil. In some embodiments, biotin can be added to the guide RNA chemically or enzymatically, for example, by adding one or more biotin groups to the 3' end of the guide RNA. After binding has occurred, for example, by exposing the guide RNA / target nucleic acid to a streptavidin-coated solid substrate, the binding tag can be used to pull down the guide RNA / target nucleic acid complex.
[0287] Therefore, in certain exemplary embodiments, engineered or non-naturally produced CRISPR effectors can be used for enrichment purposes. In embodiments, modifications may include mutations of one or more amino acid residues of the effector protein. One or more mutations may be in one or more catalytically active domains of the effector protein. The effector protein may have reduced or eliminated nuclease activity compared to an effector protein lacking the one or more mutations. The effector protein may not guide the cleavage of the RNA chain at the target locus of interest. In a preferred embodiment, one or more mutations may include two mutations. In a preferred embodiment, one or more amino acid residues are modified in a C2c2 effector protein, such as an engineered or non-naturally produced effector protein or C2c2. In a specific embodiment, the one or more modified mutated amino acid residues are one or more of those residues corresponding to R597, H602, R1278, and H1283 (involving Lsh C2c2 amino acids) in C2c2, such as mutations R597A, H602A, R1278A, and H1283A, or the corresponding amino acid residues in Lsh C2c2 orthologs.
[0288] In certain embodiments, the one or more modified mutant amino acid residues are one or more of those residues in C2c2 corresponding to: K2, K39, V40, E479, L514, V518, N524, G534, K535, E580, L597, V602, D630, F676, L709, I713, R717 (HEPN), N718, H722 (HEPN), E773, P823, V828, I879, Y880, F884, according to the C2c2 consensus numbering. , Y997, L1001, F1009, L1013, Y1093, L1099, L1111, Y1114, L1203, D1222, Y1244, L1250, L1253, K1261, 1134, L1355, L1359, R1362, Y1366, E1371, R1372, D1373, R1509 (HEPN), H1514 (HEPN), Y1543, D1544, K1546, K1548, V1551, 11558. In certain embodiments, the one or more modified mutant amino acid residues are one or more of those residues corresponding to R717 and R1509 in C2c2. In certain embodiments, the one or more modified mutated amino acid residues are one or more of those residues corresponding to K2, K39, K535, K1261, R1362, R1372, K1546, and K1548 in C2c2. In certain embodiments, the mutations cause the protein to have an altered or modified activity. In certain embodiments, the mutations cause the protein to have a reduced activity, such as reduced specificity. In certain embodiments, the mutations cause the protein to have no catalytic activity (i.e., a "dead" C2c2). In embodiments, the amino acid residues correspond to Lsh C2c2 amino acid residues, or corresponding amino acid residues from different species of C2c2 proteins. Devices that can facilitate these steps.
[0289] The above-described enrichment system can also be used to deplete samples of certain nucleic acids. For example, guide RNAs can be designed to bind to non-target RNAs to remove non-target RNAs from a sample. In an exemplary embodiment, guide RNAs can be designed to bind to nucleic acids that do carry a specific nucleic acid variant. For example, in a given sample, a higher copy number of non-variant nucleic acids can be expected. Therefore, the embodiments disclosed herein can be used to remove non-variant nucleic acids from a sample to increase the efficiency with which a CRISPR effector system can detect target variant sequences in a given sample.
[0290] Protein detection
[0291] The systems, devices, and methods disclosed herein can be adapted to the detection of polypeptides (or other molecules) other than nucleic acid detection by incorporating specifically constructed polypeptide detection aptamers. Polypeptide detection aptamers are different from the masking construct aptamers discussed above. First, aptamers are designed to specifically bind to one or more target molecules. In one exemplary embodiment, the target molecule is a target polypeptide. In another exemplary embodiment, the target molecule is a target compound, such as a target therapeutic molecule. Methods for designing and selecting aptamers specific for a given target, such as SELEX, are known in the art. In addition to specificity for a given target, aptamers are further designed to incorporate RNA polymerase promoter binding sites. In certain exemplary embodiments, the RNA polymerase promoter is a T7 promoter. Before binding to the target, the RNA polymerase site is inaccessible or otherwise unrecognizable to the RNA polymerase. However, the aptamer is configured so that after binding to the target, the structure of the aptamer undergoes a conformational change to expose the RNA polymerase promoter. The aptamer sequence downstream of the RNA polymerase promoter serves as a template for generating trigger RNA oligonucleotides by the RNA polymerase. Thus, the template portion of the aptamer can also incorporate a barcode or other identification sequence that identifies a given aptamer and its target. Guide RNAs as described above can then be designed to recognize these specific trigger oligonucleotide sequences. Binding of the guide RNA to the trigger oligonucleotide activates the CRISPR effector protein, which in turn inactivates the masking construct and produces a positive detectable signal as previously described.
[0292] Thus, in certain exemplary embodiments, the methods disclosed herein include the following additional steps: partitioning the sample or sample group into a set of individual discrete volumes, each individual discrete volume comprising a peptide detection aptamer, a CRISPR effector protein, one or more guide RNAs, and a masking construct; and incubating the sample or sample group under conditions sufficient to allow the peptide detection aptamer to bind to one or more target molecules, wherein the aptamer binds to the corresponding target exposed RNA polymerase promoter binding site, thereby synthesizing the trigger RNA via the binding of the RNA polymerase to the RNA polymerase promoter binding site.
[0293] In another exemplary embodiment, after the aptamer binds to the target polypeptide, the binding of the aptamer can expose a primer binding site. For example, the aptamer can expose an RPA primer binding site. Thus, the addition or inclusion of a primer would then feed into an amplification reaction, such as the RPA reaction outlined above.
[0294] In certain exemplary embodiments, the aptamer can be a conformational switching aptamer, which upon binding to a target of interest can change secondary structure and expose new regions of single-stranded DNA. In certain exemplary embodiments, these new regions of single-stranded DNA can serve as substrates for attachment, thereby extending the aptamer and creating longer ssDNA molecules that can be specifically detected using the embodiments disclosed herein. The aptamer design can be further combined with a ternary complex for detection of low epitope targets, such as glucose (Yang et al. 2015: http: / / pubs.acs.org / doi / abs / 10.1021 / acs.analchem.5b01634 ). Exemplary conformational transition aptamers and corresponding guide RNAs (crRNAs) are shown in Table 7 below.
[0295] Table 7
[0296] Thrombin aptamer (SEQ.IDNo.186) Thrombin-conjugated probe (SEQ.IDNo.187) Thrombin RPA forward 1 primer (SEQ.IDNo.188) Thrombin RPA forward 2 primer (SEQ.IDNo.189) Thrombin RPA reverse 1 primer (SEQ.IDNo.190) Thrombin crRNA 1 (SEQ.IDNo.191) Thrombin crRNA 2 (SEQ.IDNo.192) Thrombin crRNA 3 (SEQ.IDNo.193) PTK7 full-length amplicon control (SEQ.IDNo.194) PTK7 aptamer (SEQ.IDNo.195) PTK7 ligation probe (SEQ.IDNo.196) PTK7 RPA forward 1 primer (SEQ.IDNo.197) PTK7 RPA reverse 1 primer (SEQ.IDNo.198) PTK7 crRNA 1 (SEQ.IDNo.199) PTK7 crRNA 2 (SEQ.IDNo.200) PTK7 crRNA 3 (SEQ.IDNo.201)
[0297] Device
[0298] System described herein can be embodied on diagnostic device.Many substrates and the structure of the device that can define multiple individual discrete volumes in device can be used.As used herein, " individual discrete volume " refers to discrete space, such as container, receptacle, or other arbitrarily defined volume or space defined by the characteristic that prevents and / or suppresses target molecule migration, such as, the volume or space defined by physical property, such as wall, such as the surface of the wall of hole, tube or droplet, it can be non-permeability or semi-permeability, or as by other means, such as chemistry, diffusion rate restriction, electromagnetic or light illumination are defined, or can contain target molecule and its any combination of indexable nucleic acid identifier (such as nucleic acid bar code). " diffusion rate restriction " (such as diffusion defined volume) means only to some molecules or reaction accessible space, this is because diffusion constraint effectively defines space or volume, will be so for the situation of two parallel laminar flows, wherein diffusion will limit target molecule from one stream migration to another stream. A "chemically" defined volume or space means a space in which only certain target molecules can exist due to their chemical or molecular properties (e.g., size), wherein, for example, gel beads can exclude certain substances from entering the beads without excluding others, for example, by the surface charge, matrix size, or other physical properties of the beads that can allow selection of substances that can enter the interior of the beads. An "electromagnetic" defined volume or space means an electromagnetic property of a target molecule or its support, such as charge or magnetic properties that can be used to define certain areas in a space, such as a space in a magnetic field or directly on a magnet to capture magnetic particles. An "optically" defined volume means any area of a space that can be illuminated with light of visible, ultraviolet, infrared, or other wavelengths so that only target molecules can be labeled within the defined space or volume. An advantage of using a non-walled or semi-permeable discrete volume is that some reagents, such as buffers, chemical activators, or other agents, can pass through the discrete volume, while other materials, such as target molecules, can remain in the discrete volume or space. Typically, the discrete volume will include a fluid medium (e.g., an aqueous solution, oil, buffer, and / or culture medium capable of supporting cell growth) suitable for labeling a target molecule with an indexable nucleic acid identifier under conditions that allow labeling. Exemplary discrete volumes or spaces suitable for use in the disclosed methods include, among others, droplets (e.g., microfluidic droplets and / or emulsion droplets), hydrogel beads or other polymer structures (e.g., polyethylene glycol diacrylate beads or agarose beads), tissue slides (e.g., fixed formalin paraffin-embedded tissue slides having specific areas, volumes, or spaces defined by chemical, optical, or physical means), microscope slides having areas defined by depositing reagents in an ordered array or random pattern, tubes (e.g., centrifuge tubes, microcentrifuge tubes, test tubes, cuvettes, conical tubes, etc.), bottles (e.g., glass bottles, plastic bottles, ceramic bottles, Erlenmeyer flasks, scintillation vials, etc.), wells (e.g., wells in a plate), plates, pipettes, or pipette tips. In certain embodiments, the compartments are aqueous droplets in a water-in-oil emulsion.In certain embodiments, any of the applications, methods, or systems described herein requiring precise or uniform volumes may employ the use of an acoustic liquid dispenser.
[0299] In certain exemplary embodiments, the device includes a flexible material substrate on which many spots can be defined. Flexible substrate materials suitable for use in diagnosis and biosensing are known in the art. Flexible substrate materials can be made of plant-derived fibers, such as cellulose fibers, or can be made of flexible polymers, such as flexible polyester films and other polymer types. Within each defined spot, the reagents of the system described herein are applied to individual spots. Each spot can contain the same reagent except for different guide RNAs or guide RNA groups or different detection aptamers for screening multiple targets at one time when applicable. Therefore, the systems and devices herein can be able to screen samples from multiple sources (such as multiple clinical samples from different individuals) for the presence of the same target or a limited number of targets, or screen aliquots of a single sample (or multiple samples from the same source) for the presence of multiple different targets in the sample. In certain exemplary embodiments, the components of the system described herein are freeze-dried onto paper or cloth substrates. Exemplary flexible material-based substrates that can be used in certain exemplary devices are disclosed in Pardee et al. Cell. 2016, 165(5): 1255-66 and Pardee et al. Cell. 2014, 159(4): 950-54. Suitable flexible material-based substrates for biological fluids including blood are disclosed in Shevkoplyas et al., International Patent Application Publication No. WO / 2013 / 071301, entitled "Paper based diagnostic test," Siegel et al., U.S. Patent Application Publication No. 2011 / 0111517, entitled "Paper-based microfluidic systems," and Shafiee et al., "Paper and Flexible Substrates as Materials for Biosensing Platforms to Detect Multiple Biotargets," Scientific Reports 5: 8719 (2015). Other flexible-based materials, including those suitable for use in wearable diagnostic devices, are disclosed in Wang et al. "Flexible Substrate-Based Devices for Point-of-Care Diagnostics" Cell 34(11):909-21 (2016). Other flexible-based materials may include nitrocellulose, polycarbonate, methylethylcellulose, polyvinylidene fluoride (PVDF), polystyrene, or glass (see, for example, US20120238008). In certain embodiments, the discrete volumes are isolated by a hydrophobic surface, such as, but not limited to, wax, photoresist, or solid ink.
[0300] In some embodiments, a metering box or dosimeter can be provided that acts as a sensor or indicator to notify the wearer of exposure to certain microorganisms or other agents. For example, the system described herein can be used to detect specific pathogens. Similarly, the aptamer-based embodiments disclosed above can be used to detect polypeptides to which specific aptamers can bind, as well as other agents, such as chemical agents. Such a device can be suitable for monitoring military personnel or other military personnel, as well as clinicians, researchers, medical personnel, etc., to provide information about exposure to potentially dangerous microorganisms as quickly as possible, for example, for biological or chemical warfare agent detection. In other embodiments, such a monitoring dosimeter can be used to prevent exposure to dangerous microorganisms or pathogens in immunocompromised patients, burn patients, patients undergoing chemotherapy, children, or elderly individuals.
[0301] The sample source that can use system and device analysis described herein comprises biological sample or environmental sample of experimenter.Environmental sample can comprise surface or fluid.Biological sample can include but not limited to saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, spinal fluid, cerebrospinal fluid, swab from skin or mucous membrane, or its combination.In exemplary embodiment, environmental sample is taken from solid surface, for example the surface used in the preparation of food or other sensitive compositions and materials.
[0302] In other exemplary embodiments, the components of the system described herein can be placed on a disposable substrate, such as a swab or cloth for wiping a surface or sample fluid. For example, the system can be used to test the presence of pathogens on food by wiping the surface of a food product, such as a fruit or vegetable. Similarly, disposable substrates can be used to wipe other surfaces for detecting certain microorganisms or agents, such as for security screening. Disposable substrates can also have applications in forensics, where the CRISPR system is designed to detect, for example, DNA SNPs, which can be used to identify suspicious or confirmed tissue or cell markers to determine the type of biological substance present in the sample. Similarly, disposable substrates can be used to collect samples from patients - such as saliva samples from the mouth - or swabs of the skin. In other embodiments, samples or swabs can be taken from meat products to detect the presence or absence of contaminants on or in the meat products.
[0303] There is a need for near real-time microbial diagnostics for use in food, clinical, industrial, and other environmental settings (see, eg, Lu TK, Bowers J, and Koeris MS., Trends Biotechnol. 2013 Jun;31(6):325-7). In certain embodiments, the present invention is useful for the use of antibodies against pathogens (e.g., Campylobacter jejuni, Clostridium perfringens, Salmonella spp., Escherichia coli, Bacillus cereus, Listeria monocytogenes, Shigella spp., Staphylococcus aureus, Staphylococcal enteritis, Streptococcus spp., Vibrio cholerae, Vibrio parahaemolyticus, Vibrio vulnificus, Yersinia enterocolitica, and Yersinia pseudotuberculosis), Brucella spp., Corynebacterium ulcerans, ulcerans), Coxiella burnetii, or Plesiomonas shigelloides) for rapid detection of foodborne pathogens.
[0304] In certain embodiments, the device is a flow strip or includes a flow strip. For example, the lateral flow strip allows RNA enzyme (such as C2c2) detection to be performed by color. The modified RNA reporter is to have a first molecule (such as FITC) attached to the 5' end and a second molecule (such as biotin) attached to the 3' end (or vice versa). The lateral flow strip is designed to have two capture circuits, wherein anti-first molecule (such as anti-FITC) antibodies hybridize in the first circuit and anti-second molecule (such as anti-biotin) antibodies in the second downstream circuit. As the SHERLOCK reactant flows down from the strip, the uncleaved reporter will be bound to the anti-first molecule antibody in the first capture circuit, and the cracked reporter will release the second molecule in the second capture circuit and allow the second molecule to bind. The second molecule sandwich antibody, for example, conjugated to nanoparticles, such as gold nanoparticles, will be in conjunction with any second molecule in the first circuit or the second circuit and produce a strong readout / signal (such as color). As more reporter cracks, more signals will accumulate in the second capture circuit and less signals will appear in the first circuit. In some aspects, the present invention relates to using tracking strips as described herein for detecting nucleic acids or polypeptides. In certain aspects, the invention relates to a method for detecting a nucleic acid or a polypeptide using a flow strip as defined herein, such as a (lateral) flow test or a (lateral) flow immunochromatographic assay.
[0305] In certain exemplary embodiments, the device is a microfluidic device that produces and / or merges different droplets (i.e., individual discrete volumes). For example, a first group of droplets containing a sample to be screened can be formed and a second group of droplets containing the components of the system described herein can be formed. The first and second groups of droplets are then merged, and the merged droplet groups are then subjected to a diagnostic method as described herein. The microfluidic device disclosed herein can be a silicone-based chip and can be manufactured using a variety of techniques, including but not limited to hot stamping, elastomer molding, injection molding, LIGA, soft etching, silicon manufacturing, and related thin film processing techniques. Suitable materials for manufacturing microfluidic devices include but are not limited to cyclic olefin copolymers (COC), polycarbonate, poly(dimethylsiloxane) (PDMS), and poly(methyl acrylate) (PMMA). In one embodiment, soft etching in PDMS can be used to prepare microfluidic devices. For example, photolithography that defines the position of flow channels, valves, and filters within a substrate can be used to make a mold. The substrate material is poured into the mold and allowed to solidify to create a stamp. The stamp is then sealed to a solid support, such as, but not limited to, glass. Due to the hydrophobic nature of some polymers such as PDMS, which absorb some proteins and can inhibit certain biological processes, a passivating agent may be necessary (Schoffner et al. Nucleic Acids Research, 1996, 24: 375-379). Suitable passivating agents are known in the art and include, but are not limited to, silanes, parylene, n-dodecyl-bD-maltoside (DDM), pluronic, Tween-20, other similar surfactants, polyethylene glycol (PEG), albumin, collagen, and other similar proteins and peptides.
[0306] In certain exemplary embodiments, the system and / or device can be adapted to convert into flow cytometry readout or allow all sensitive and quantitative measurements of millions of cells in a single experiment and improve existing flow-based methods, such as PrimeFlow assays. In certain exemplary embodiments, cells can be cast in droplets containing unpolymerized gel monomers, which can then be cast into single-cell droplets suitable for analysis by flow cytometry. A detection construct comprising a fluorescent detectable marker can be cast into a droplet comprising unpolymerized gel monomers. After polymerization of the gel monomers, beads are formed in the droplets. Because gel polymerization is formed by free radicals, the fluorescent reporter becomes covalently bound to the gel. The detection construct can be further modified to include a linker, such as an amine. A quencher can be added after gel formation and will be bound to the reporter construct via a linker. Therefore, when the reporter is cleaved by the CRISPR effector protein, the quencher is not bound to the gel and is free to diffuse. Signal amplification in the droplet can be achieved by combining the detection construct with hybridization chain reaction (HCR initiator) amplification. DNA / RNA hybrid hairpin can be incorporated into a gel, and the gel can include a hairpin loop with an RNase-sensitive domain. By protecting the strand displacement fulcrum in the hairpin loop with an RNase-sensitive domain, the HCR initiator can be selectively deprotected after the hairpin loop is cleaved by the CRISPR effector protein. After the HCR initiator is deprotected via fulcrum-mediated strand displacement, the fluorescent HCR monomer can be rinsed into the gel to enable signal amplification when the initiator is deprotected.
[0307] Examples of microfluidic devices that can be used in the context of the present invention are described in Hou et al. "Direct Dectection and drug-resistance profiling of bacteremias using inertial microfluidics" LapChip. 15(10): 2297-2307 (2016).
[0308] The systems described herein may further incorporate wearable medical devices that assess biological samples, such as biological fluids, from subjects outside of clinical settings and remotely report the results of the assays to a central server accessible to healthcare professionals. The devices may include the ability to self-sample blood, such as those disclosed in U.S. Patent Application Publication No. 2015 / 0342509 to Peeters et al., entitled “Needle-free Blood Draw,” and U.S. Patent Application Publication No. 2015 / 0065821 to Andrew Conrad, entitled “Nanoparticle Phoresis.”
[0309] In certain exemplary embodiments, the device can include individual wells, such as microplate wells. The microplate wells can be of standard 6, 24, 96, 384, 1536, 3456, or 9600 well sizes. In certain exemplary embodiments, the components of the systems described herein can be freeze-dried and applied to the surface of the wells prior to distribution and use.
[0310] Device disclosed herein can also include an inlet port and an outlet port or an opening, which can then be connected to valves, pipelines, passages, chambers and syringes and / or pumps for introducing fluid into the device and extracting from the device. Device can be connected to a fluid flow actuator that allows fluid to be directed and moved in a microfluidic device. Exemplary actuators include but are not limited to syringe pumps, mechanically actuated recirculation pumps, electroosmotic pumps, bulbs, bellows, diaphragms or bubblers intended to force fluid to move. In certain exemplary embodiments, device is connected to a controller with a programmable valve, and the valves work together to move fluid through the device. In certain exemplary embodiments, device is connected to the controller discussed in further detail below. Device can be connected to a flow actuator, a controller and a sample loading device by terminating in a metal pin for the pipeline in the inlet port on the insertion device.
[0311] As shown herein, the composition of the system is stable when freeze-dried, therefore also encompasses embodiments that do not require a supporting device, that is, the system can be applied to any surface or fluid that will support the reaction disclosed herein and allow positive detectable signals to be detected from that surface or solution. Except freeze-drying, the system can also be stably stored and utilized in agglomerated form. Polymers suitable for forming applicable agglomerated forms are known in the art.
[0312] In certain embodiments, a CRISPR effector protein is bound to each discrete volume in the device. Each discrete volume can contain different guide RNAs specific for different target molecules. In certain embodiments, a sample is exposed to a solid substrate comprising more than one discrete volume, each discrete volume containing a guide RNA specific for a target molecule. Without being bound by theory, each guide RNA will capture its target molecule from the sample and the sample does not need to be divided into separate assays. Thus, valuable samples can be preserved. The effector protein can be a fusion protein comprising an affinity tag. Affinity tags are well known in the art (e.g., HA tags, Myc tags, Flag tags, His tags, biotin). The effector protein can be linked to a biotin molecule and the discrete volume can contain avidin streptavidin. In other embodiments, the CRISPR effector protein is bound by an antibody specific for the effector protein. Methods for binding CRISPR enzymes have been previously described (see, for example, US20140356867A1).
[0313] The devices disclosed herein may also include elements of point-of-care (POC) devices known in the art for analyzing samples by other methods. See, for example, St John and Price, "Existing and Emerging Technologies for Point-of-Care Testing" (Clin Biochem Rev. 2014 Aug; 35(3): 155-167).
[0314] The present invention can be used with wireless lab-on-a-chip (LOC) diagnostic sensor systems (see, e.g., U.S. Patent No. 9,470,699 "Diagnostic radio frequency identification sensors and applications thereof"). In certain embodiments, the present invention is performed in a LOC controlled by a wireless device (e.g., a cell phone, a personal digital assistant (PDA), a tablet) and the results are reported to the device.
[0315] Radio Frequency Identification (RFID) tag systems include RFID tags that transmit data for receipt by an RFID reader (also known as an interrogator). In a typical RFID system, individual objects (such as stored goods) are equipped with relatively small tags containing transponders. The transponders have a memory chip that is assigned a unique electronic product code. The RFID reader transmits a signal, thereby activating the transponder within the tag using a communication protocol. As a result, the RFID reader can read data and write to the tag. In addition, the RFID tag reader processes the data depending on the RFID tag system application. Currently, there are passive and active RFID tags. Passive RFID tags do not contain an internal power source, but are powered by the radio frequency signal received from the RFID reader. Alternatively, active RFID tags contain an internal power source, which enables the active RFID tag to have a larger transmission range and storage capacity. The use of passive tags versus active tags depends on the specific application.
[0316] Lab-on-a-chip technology is well described in the scientific literature and consists of multiple microfluidic channels, inputs, or chemical wells. Radio frequency identification (RFID) tag technology can be used to measure the reaction in the wells because the conductive wires from the RFID electronic chip can be directly connected to each of the test wells. The antenna can be printed or mounted in another layer of the electronic chip or directly on the back of the device. In addition, the wires, antenna, and electronic chip can be embedded in the LOC chip to prevent short circuits in electrodes or electronic devices. Because LOC allows complex sample preparation and analysis, this technology allows LOC testing to be completed independently of complex or expensive readers. Instead, a simple wireless device, such as a mobile phone or PDA, can be used. In one embodiment, the wireless device also controls the separation and control of the microfluidic channels for more complex LOC analysis. In one embodiment, an LED and other electronic measurement or sensing devices are included in the LOC-RFID chip. Without being bound by theory, this technology is disposable and allows complex tests that require separation and mixing outside the laboratory.
[0317] In a preferred embodiment, the LOC can be a microfluidic device. The LOC can be a passive chip, wherein the chip is powered and controlled via a wireless device. In certain embodiments, the LOC includes a microfluidic channel for accommodating a sample and a channel for introducing the sample. In certain embodiments, a signal from the wireless device delivers power to the LOC and activates the mixing of the sample with the assay reagent. Specifically, in the case of the present invention, the system can include a masking agent, a CRISPR effector protein, and a guide RNA specific for the target molecule. After activation of the LOC, the microfluidic device can mix the sample with the assay reagent. After mixing, the sensor detects the signal and transmits the result to the wireless device. In certain embodiments, the masking agent is a conductive RNA molecule. The conductive RNA molecule can be attached to a conductive material. The conductive molecule can be a conductive nanoparticle, a conductive protein, a metal particle attached to a protein or latex, or other conductive beads. In certain embodiments, if DNA or RNA is used, the conductive molecule can be directly attached to a matching DNA or RNA chain. The release of the conductive molecule can be detected across the sensor. The assay can be a one-step process.
[0318] Because the conductivity of a surface area can be precisely measured, quantitative results can be obtained using disposable wireless RFID electrical assays. Furthermore, the test area can be extremely small, allowing more tests to be completed in a given area and thus saving costs. In certain embodiments, separate sensors, each associated with a different CRISPR effector protein and guide RNA immobilized to the sensor, are used to detect multiple target molecules. Without being bound by theory, activation of different sensors can be distinguished by the wireless device.
[0319] In addition to the conductive methods described herein, other methods can be used that rely on RFID or Bluetooth as a basic low-cost communication and power platform for disposable RFID assays. For example, optical components can be used to assess the presence and level of a given target molecule. In certain embodiments, an optical sensor detects the unmasking of a fluorescent masking agent.
[0320] In certain embodiments, the devices of the invention may comprise handheld portable devices for diagnostic reading of assays (see, e.g., Vashist et al., Commercial Smartphone-Based Devices and SmartApplications for Personalized Healthcare Monitoring and Management, Diagnostics 2014, 4(3), 104-128; mReader from Mobile Assays; and Holomic Rapid Diagnostic Test Reader).
[0321] As noted herein, when embodiments are utilized in POC situations and or in resource-poor environments where access to more complex detection equipment to read out signals may be limited, certain embodiments allow detection via colorimetric changes, which has certain attendant benefits. However, the portable embodiments disclosed herein can also be combined with a handheld spectrophotometer capable of detecting signals outside the visible range. An example of a handheld spectrophotometer device that can be used in combination with the present invention is described in Das et al. "Ultra-portable, wireless smartphone spectrophotometer for rapid, non-destructive testing of fruit ripeness." Nature Scientific Reports. 2016, 6: 32504, DOI: 10.1038 / srep32504. Finally, in certain embodiments utilizing a quantum dot-based masking construct, the use of a handheld ultraviolet light or other suitable device can be successfully used to detect signals, owing to the near-complete quantum yield provided by the quantum dots.
[0322] Exemplary Methods and Assays
[0323] The low cost and adaptability of the assay platform are suitable for many applications, including (i) general RNA / DNA / protein quantification, (ii) rapid, multiplexed RNA / DNA and protein expression detection, and (iii) sensitive detection of target nucleic acids, peptides, and proteins in clinical and environmental samples. In addition, the system disclosed herein can be adapted to biological settings, such as detection of intracellular transcripts. Given the highly specific nature of the CRISPR effectors described herein, it is possible to track allele-specific expression of transcripts or disease-associated mutations in living cells.
[0324] In certain exemplary embodiments, a single guide RNA specific for a single target is placed in a separate volume. Each volume can then receive a different sample or an aliquot of the same sample. In certain exemplary embodiments, multiple guide RNAs, each directed against a separate target, can be placed in a single well so that multiple targets can be screened in different wells. To detect multiple guide RNAs in a single volume, in certain exemplary embodiments, multiple effector proteins with different specificities can be used. For example, different orthologs with different sequence specificities can be used. For example, one ortholog may preferentially cleave A, while others preferentially cleave C, U, or T. Thus, guide RNAs can be generated that are all single nucleotides or contain a substantial portion of single nucleotides, each with a different fluorophore. In this way, up to four different targets can be screened in a single, discrete volume.
[0325] As demonstrated herein, the CRISPR effector system is capable of detecting target molecules at concentrations as low as attomolar. Figure 13 、 14 , 19, 22 and the Examples described below. Due to the sensitivity of the system, many applications requiring rapid and sensitive detection can benefit from the embodiments disclosed herein and are contemplated to be within the scope of the present invention. Exemplary assays and applications are described in further detail below.
[0326] Microbial Applications
[0327] In certain exemplary embodiments, the systems, devices, and methods disclosed herein relate to detecting the presence of one or more microbial agents in a sample, such as a biological sample obtained from a subject. In certain exemplary embodiments, the microorganism can be a bacterium, fungus, yeast, protozoa, parasite, or virus. Therefore, the methods disclosed herein can be adapted for use in conjunction with (or in combination with) other methods that require rapid identification of microbial species, monitoring the presence of microbial proteins (antigens), antibodies, antibody genes, detecting certain phenotypes (e.g., bacterial resistance), monitoring disease progression and / or outbreaks, and antibiotic screening. Because of the rapid and sensitive diagnostic capabilities of the embodiments disclosed herein, the detection of microbial species types down to single nucleotide differences, and the ability to be deployed as a POC device, the embodiments disclosed herein can be used to guide treatment regimens, such as the selection of appropriate antibiotics or antiviral agents. The embodiments disclosed herein can also be used to screen environmental samples (air, water, surfaces, food, etc.) for the presence of microbial contamination.
[0328] A method for identifying microbial species, such as bacteria, viruses, fungi, yeasts, or parasite species, is disclosed. Specific embodiments disclosed herein describe methods and systems for identifying and differentiating microbial species within a single sample or across multiple samples, thereby allowing for the identification of many different microorganisms. The methods of the present invention allow for the detection of pathogens and the differentiation of two or more species of one or more organisms in a biological or environmental sample, such as bacteria, viruses, yeasts, protozoa, and fungi, or a combination thereof, by detecting the presence of a target nucleic acid sequence in the sample. A positive signal obtained from the sample indicates the presence of a microorganism. The methods and systems of the present invention can be used to simultaneously identify multiple microorganisms by employing more than one effector protein, each of which targets a specific microbial target sequence. In this way, a multi-level analysis can be performed on a particular subject, in which many microorganisms can be detected at one time. In some embodiments, simultaneous detection of multiple microorganisms can be performed using a set of probes that can identify one or more microbial species.
[0329] Multiplexed analysis of samples enables large-scale testing of samples, thereby reducing analysis time and cost. However, multiplexed analysis is often limited by the availability of biological samples. According to the present invention, however, an alternative to multiplexed analysis can be performed such that multiple effector proteins can be added to a single sample and each masking construct can be combined with a separate quencher dye. In this case, a positive signal can be obtained from each quencher dye individually for multiple tests in a single sample.
[0330] Disclosed herein are methods for distinguishing two or more species of one or more organisms in a sample. The methods are also suitable for detecting one or more species of one or more organisms in a sample.
[0331] Microbial testing
[0332] In some embodiments, a method for detecting microorganisms in a sample is provided, the method comprising distributing a sample or sample group into one or more individual discrete volumes, the individual discrete volumes comprising a CRISPR system as described herein; incubating the sample or sample group under conditions sufficient to allow one or more guide RNAs to bind to one or more microorganism-specific targets; activating a CRISPR effector protein via one or more guide RNAs binding to one or more target molecules, wherein the activated CRISPR effector protein modifies an RNA-based masking construct to produce a detectable positive signal; and detecting the detectable positive signal, wherein detection of the detectable positive signal indicates the presence of one or more target molecules in the sample. The one or more target molecules can be mRNA, gDNA (coding or non-coding), trRNA, or RNA comprising a target nucleotide sequence, which can be used to distinguish two or more microbial species / strains from each other. The guide RNA can be designed to detect the target sequence. The embodiments disclosed herein can also utilize certain steps to improve hybridization between the guide RNA and the target RNA sequence. Methods for enhancing ribonucleic acid hybridization are disclosed in WO 2015 / 085194, entitled "Enhanced Methods of Ribonucleic Acid Hybridization," which is incorporated herein by reference. Microorganism-specific targets can be RNA, DNA, or proteins. DNA methods can also include the use of DNA primers that incorporate RNA polymerase promoters as described herein. If the target is a protein, the methods will utilize aptamers and procedures specific for protein detection as described herein.
[0333] Detection of single nucleotide variants
[0334] In some embodiments, one or more identified target sequences can be detected using guide RNAs that are specific for and bind to target sequences as described herein. The systems and methods of the present invention can even distinguish single nucleotide polymorphisms present in different microbial species, and thus the use of multiple guide RNAs according to the present invention can further expand or improve the number of target sequences that can be used to distinguish species. For example, in some embodiments, one or more guide RNAs can distinguish microorganisms based on species, genus, family, order, class, phylum, kingdom, or phenotype, or a combination thereof.
[0335] rRNA sequence-based detection
[0336] In certain exemplary embodiments, the devices, systems, and methods disclosed herein can be used to distinguish multiple microbial species in a sample. In certain exemplary embodiments, identification can be based on ribosomal RNA sequences, including 16S, 23S, and 5S subunits. Methods for identifying related rRNA sequences are disclosed in U.S. Patent Application Publication No. 2017 / 0029872. In certain exemplary embodiments, a set of guide RNAs can be designed to distinguish each species by a variable region unique to each species or strain. Guide RNAs can also be designed to target RNA genes that distinguish microorganisms at the genus, family, order, class, phylum, kingdom, or a combination thereof. In certain exemplary embodiments using amplification, a set of amplification primers can be designed to flank the constant region of the ribosomal RNA sequence and the guide RNAs can be designed to distinguish each species by a variable internal region. In certain exemplary embodiments, primers and guide RNAs can be designed to target conserved and variable regions within the 16S subunit, respectively. Other genes or genomic regions that span species or subgroups of species, such as the RecA gene family RNA polymerase β subunit, which are uniquely variable, can also be used. Other suitable phylogenetic markers and methods for their identification are discussed, for example, in Wu et al. arXiv:1307.8690 [q-bio.GN].
[0337] In certain exemplary embodiments, the method or diagnosis is designed to simultaneously screen microorganisms across multiple phylogenetic and / or phenotypic levels. For example, the method or diagnosis can include the use of multiple CRISPR systems with different guide RNAs. A first set of guide RNAs can distinguish, for example, mycobacteria, gram-positive bacteria, and gram-negative bacteria. These general categories can even be further subdivided. For example, guide RNAs can be designed and used in methods or diagnoses for distinguishing enteric bacteria from non-enteric bacteria within gram-negative bacteria. A second set of guide RNAs can be designed to distinguish microorganisms at the genus or species level. Thus, a matrix can be generated that identifies all mycobacteria, gram-positive, gram-negative (further divided into enteric bacteria and non-enteric bacteria), where each genus of bacterial species identified in a given sample belongs to one of those categories. The foregoing is for exemplary purposes only. Other methods for classifying other types of microorganisms are also contemplated and will follow the general structure described above.
[0338] Drug resistance screening
[0339] In certain exemplary embodiments, the devices, systems and methods disclosed herein can be used to screen for microbial genes of interest, such as antibiotic and / or antiviral resistance genes. Guide RNAs can be designed to distinguish known genes of interest. Samples, including clinical samples, can then be screened using the embodiments disclosed herein for detecting such genes. The ability to screen for drug resistance at POC will have enormous benefits in selecting appropriate treatment options. In certain exemplary embodiments, the antibiotic resistance gene is a carbapenemase, including KPC, NDM1, CTX-M15, OXA-48. Other antibiotic resistance genes are known and can be found, for example, in the Comprehensive Antibiotic Resistance Database (Jia et al. "CARD 2017: expansion and model-centriccuration of the Comprehensive Antibiotic Resistance Database." Nucleic Acids Research, 45, D566-573).
[0340] Ribavirin is an effective antiviral agent against many RNA viruses. Several clinically important viruses have evolved resistance to ribavirin, including foot-and-mouth disease virus (doi:10.1128 / JVI.03594-13), poliovirus (Pfeifer and Kirkegaard, PNAS, 100(12):7289-7294, 2003), and hepatitis C virus (Pfeiffer and Kirkegaard, J. Virol. 79(4):2346-2355, 2005). Many other persistent RNA viruses, such as hepatitis and HIV, have evolved resistance to existing antiviral drugs: Hepatitis B virus (lamivudine, tenofovir, entecavir) doi:10 / 1002 / hep22900; Hepatitis C virus (telaprevir, BILN2061, ITMN-191, SCh6, boceprevir, AG-021541, ACH-806) doi:10.1002 / hep.22549; and HIV (many drug resistance mutations) hivb.standford.edu. The embodiments disclosed herein are particularly useful for detecting such variants.
[0341] In addition to drug resistance, there are many clinically relevant mutations that can be detected using the embodiments disclosed herein, such as persistence versus acute infection in LCMV (doi: 10.1073 / pnas.1019304108), and increased infectivity of Ebola (Diehl et al. Cell. 2016, 167(4): 1088-1098).
[0342] As described elsewhere herein, closely related microbial species (e.g., having only a single nucleotide difference in a given target sequence) can be distinguished by introducing synthetic mismatches in the gRNA.
[0343] Set Cover Approach
[0344] In certain embodiments, a set of guide RNAs is designed that can identify, for example, all microbial species within a set of specified microorganisms. Such methods are described. In certain exemplary embodiments, the method for generating guide RNAs as described herein can be compared with the method disclosed in WO 2017 / 040316, which is incorporated herein by reference. As described in WO2017040316, group coverage solutions can identify the minimum number of target sequence probes or guide RNAs required to cover an entire target sequence or a set of target sequences, such as a set of genomic sequences. Group coverage methods have previously been used to identify primers and / or microarray probes, typically in the range of 20 to 50 base pairs. See, for example, Pearson et al., cs.virginia.edu / ~robins / papers / primers_dam11_final.pdf.; Jabado et al. Nucleic Acids Res. 2006 34(22):6605-11; Jabado et al. Nucleic Acids Res. 2008, 36(1):e3doi10.1093 / nar / gkm1106; Duitama et al. Nucleic Acids Res. 2009, 37(8):2483-2492; Phillippy et al. BMC Bioinformatics. 2009, 10:293doi:10.1186 / 1471-2105-10-293. However, such methods generally involve treating each primer / probe as a k-mer and searching for exact matches or allowing searches for inexact matches using suffix arrays. In addition, the method generally adopts a binary approach to detect hybridization by selecting primers or probes so that each input sequence only needs to be bound by one primer or probe and the position of this binding along the sequence is irrelevant. Alternative methods can divide the target genome into predefined windows and effectively process each window into a separate input sequence under a binary approach - that is, it determines whether a given probe or guide RNA binds within each window and whether all windows need to be bound by a certain probe or guide RNA. Effectively, these methods process each element of the "universal" in the group coverage problem into a predefined window of the entire input sequence or input sequence, and if the starting point of the probe or guide RNA binds within the element, each element is considered to be "covered". These methods limit the mobility of allowing different probes or guide RNA designs to cover a given target sequence.
[0345] In contrast, the embodiments disclosed herein relate to detecting longer probe or guide RNA lengths, for example, in the range of 70bp to 200bp, which are suitable for hybrid selection sequencing. In addition, the method disclosed in WO 2017 / 040316 can be applied herein to adopt a pan-target sequence method that can define a probe or guide RNA group, which can identify and promote the detection sequencing of all types and / or strain sequences in a large and / or variable target sequence group. For example, the method disclosed herein can be used to identify all variants of a given virus or multiple different viruses in a single assay. In addition, the method disclosed herein processes each element that is "universal" in the group coverage problem into the nucleotides of the target sequence, and each element is considered "covered" as long as the probe or guide RNA is bound to a certain section of the target genome that includes the element. These types of group coverage methods can be used instead of the binary method of the previous method, and the method disclosed herein better models how the probe or guide RNA can hybridize to the target sequence. Rather than simply asking whether a given guide RNA sequence binds to a given window, such methods can be used to detect hybridization patterns—that is, if a given probe or guide RNA binds to one or more target sequences—and then determine from those hybridization patterns the minimum number of probes or guide RNAs required to cover the set of target sequences to a degree sufficient to enable enrichment from a sample and sequencing of any and all target sequences. These hybridization patterns can be determined by defining certain parameters that minimize the loss function, thereby enabling the identification of minimal probe or guide RNA sets in a manner that allows the parameters to vary for each species, for example, to reflect the diversity of each species, and in a computationally efficient manner that has not been achievable using simple application of group coverage solutions, such as those previously applied in the context of probe or guide RNA design.
[0346] The ability to detect the abundance of multiple transcripts can allow the generation of unique microbial signatures that indicate specific phenotypes. Various machine learning techniques can be used to derive gene signatures. Thus, the guide RNAs of the CRISPR system can be used to identify and / or quantify the relative levels of biomarkers defined by gene signatures to detect certain phenotypes. In certain exemplary embodiments, the gene signature indicates susceptibility to antibiotics, resistance to antibiotics, or a combination thereof.
[0347] In one aspect of the present invention, the method includes detecting one or more pathogens. In this way, it is possible to distinguish between individual microbial infections of a subject. In some embodiments, such distinctions can be used by clinicians to detect or diagnose specific diseases, such as different variants of a disease. Preferably, the pathogen sequence is the genome of the pathogen or a fragment thereof. The method may also include determining the evolution of the pathogen. Determining the evolution of the pathogen may include identifying pathogen mutations, such as nucleotide deletions, nucleotide insertions, and nucleotide substitutions. Among the latter, there are non-synonymous, synonymous, and non-coding substitutions. Mutations are more frequently non-synonymous during outbreaks. The method may also include determining the substitution rate between two pathogen sequences analyzed as described above. Whether a mutation is deleterious or even adaptive will require functional analysis; however, the non-synonymous mutation rate suggests that the continued progression of the epidemic may provide opportunities for pathogen adaptation, highlighting the need for rapid containment. Therefore, the method may also include assessing the risk of viral adaptation, wherein the number of non-synonymous mutations is determined. (Gire et al., Science 345, 1369, 2014).
[0348] Monitoring microbial outbreaks
[0349] In some embodiments, a CRISPR system or method of using the same as described herein can be used to determine the evolution of a pathogen outbreak. The method can include detecting one or more target sequences in multiple samples from one or more subjects, wherein the target sequence is a sequence from a microorganism causing the outbreak. Such a method can also include determining patterns of pathogen spread, or mechanisms involved in an outbreak caused by a pathogen.
[0350] The pattern of pathogen transmission can include continuous new transmission from the natural reservoir of the pathogen or transmission between subjects (e.g., person-to-person transmission) after a single transmission from a natural reservoir, or a mixture of the two. In one embodiment, pathogen transmission can be bacterial or viral transmission, in which case the target sequence is preferably a microbial genome or a fragment thereof. In one embodiment, the pattern of pathogen transmission is an early pattern of pathogen transmission, that is, at the beginning of a pathogen outbreak. Determining the pattern of pathogen transmission at the beginning of an outbreak increases the likelihood of preventing an outbreak at the earliest possible time, thereby reducing the likelihood of local and international spread.
[0351] Determining patterns of pathogen transmission can include detecting pathogen sequences according to the methods described herein. Determining patterns of pathogen transmission can also include detecting shared intra-host variation in pathogen sequences between subjects and determining whether the shared intra-host variation exhibits temporal patterns. Observed patterns in intra- and inter-host variation provide important insights into transmission and epidemiology (Gire et al., 2014).
[0352] The detection of shared host intravariation between subjects that shows a temporal pattern is an indication of a transmission link between subjects (particularly between humans) because it can be explained by infection of subjects from multiple sources (superinfection), sample contamination reproducible mutations (in the presence or absence of balancing selection to enhance mutations), or co-transmission of slightly divergent viruses arising from mutations earlier in the transmission chain (Park et al., Cell 161(7):1516-1526, 2015). The detection of shared host intravariation between subjects can include the detection of host intravariants located at common single nucleotide polymorphism (SNP) positions. Positive detection of host intravariants located at common (SNP) positions indicates superinfection and contamination as the main explanation for host intravariants. Superinfection and contamination can be separated on the basis of the SNP frequencies that appear as inter-host variants (Park et al., 2015). Other forms of superinfection and contamination can be excluded. In this latter case, the detection of shared host intravariation between subjects can also include evaluating the frequencies of synonymous and non-synonymous variants and comparing the frequencies of synonymous and non-synonymous variants with each other. Non-synonymous mutations are mutations that change the amino acids of a protein, which may cause biological changes in microorganisms that are subject to natural selection. Synonymous substitutions do not change the amino acid sequence. The equal frequency of synonymous and non-synonymous variants indicates neutrally evolving intra-host variants. If the frequencies of synonymous and non-synonymous variants diverge, then the intra-host variants may be maintained by balancing selection. If the frequency of synonymous and non-synonymous variants is very low, then this indicates a recurrent mutation. If the frequency of synonymous and non-synonymous variants is very high, then this indicates co-transmission (Park et al., 2015).
[0353] Like Ebola virus, Lassa virus (LASV) can cause hemorrhagic fever with a high case fatality rate. Andersen et al. generated a genome catalog of nearly 200 LASV sequences from clinical and rodent reservoir samples (Andersen et al., Cell Vol. 162, No. 4, pp. 738-750, August 13, 2015). Andersen et al. showed that although the EVD epidemic in 2013-2015 was driven by human-to-human transmission, LASV infection was mainly caused by infection between reservoirs and humans. Andersen et al. illustrate the spread of LASV across West Africa and show that this migration is accompanied by changes in LASV genome abundance, lethality, codon adaptation, and translation efficiency. The method can also include comparing the first pathogen sequence with the second pathogen sequence on a phylogenetic basis, and determining whether there is a phylogenetic association between the first pathogen sequence and the second pathogen sequence. The second pathogen sequence can be an earlier reference sequence. If there is a phylogenetic association, the method can also include tracing the phylogenetic roots of the first pathogen sequence for the second pathogen sequence. Therefore, it is possible to construct a pedigree of the first pathogen sequence. (Park et al., 2015).
[0354] The method can also include determining whether the mutation is deleterious or adaptive. Deleterious mutations indicate impaired transmission of the virus and terminal infection, and therefore are typically present only in individual subjects. Mutations unique to an individual subject are those that appear on the outer branches of the phylogenetic tree, while inner branch mutations are those that are present in multiple samples (i.e., in multiple subjects). A higher non-synonymous substitution rate is characteristic of the outer branches of the phylogenetic tree (Park et al., 2015).
[0355] In the inner branches of the phylogenetic tree, selection has had more opportunities to filter out deleterious mutants. By definition, inner branches have produced multiple derived lineages and are therefore less likely to include mutations with fitness costs. Therefore, a lower non-synonymous substitution rate indicates an inner branch (Park et al., 2015).
[0356] Synonymous mutations, which may have less impact on fitness, appear at more comparable frequencies on inner and outer branches (Park et al., 2015).
[0357] By analyzing sequenced target sequences, such as viral genomes, it is possible to discover the mechanisms that contributed to the severity of the epidemic, such as during the 2014 Ebola outbreak. For example, Gire et al. made a phylogenetic comparison of the genomes of the 2014 outbreak with all 20 genomes from earlier outbreaks, suggesting that the 2014 West African virus may have spread from Central Africa within the past decade. Tracing back the origin of the phylogeny using divergences from other Ebola virus genomes is problematic (6, 13). However, tracing back the roots of the earliest outbreaks of the tree revealed a strong correlation between sample date and root-to-tip distance, with a substitution rate of 8×10-4 per location per year (13). This suggests that the lineages of the three most recent outbreaks all diverged from a common ancestor at approximately the same time, i.e., around 2004, which suggests the hypothesis that each outbreak represents an independent zoonotic event from the same genetically diverse viral population in a natural reservoir. It was also found that the 2014 EBOV outbreak may have been caused by a single transmission from a natural reservoir, which then spread from person to person during the outbreak. The results also suggested that the outbreak in Sierra Leone may have originated from the introduction of two genetically distinct viruses from Guinea at approximately the same time (Gire et al., 2014).
[0358] It has also been possible to determine how Lassa virus spread from its point of origin, particularly thanks to human-to-human transmission and even trace the history of this spread back 400 years (Andersen et al., Cell 162(4):738-50, 2015).
[0359] In relation to the work required during the 2013-2015 EBOV outbreak and the difficulties encountered by medical personnel at the outbreak site, and more generally, the methods of the present invention make it possible to use a smaller selection of probes for sequencing so that sequencing can be accelerated, thereby shortening the time required from sample acquisition to result. In addition, the kits and systems can be designed to be field-ready so that patient diagnosis can be easily performed without the need to send or transport samples to another part of the country or the world.
[0360] In any of the methods described above, sequencing the target sequence or its fragments can use any of the sequencing processes described above. In addition, sequencing the target sequence or its fragments can be near real-time sequencing. Sequencing the target sequence or its fragments can be performed according to previously described methods (Experimental Procedures: Matranga et al., 2014; and Gire et al., 2014). Sequencing the target sequence or its fragments can include parallel sequencing of multiple target sequences. Sequencing the target sequence or its fragments can include Illumina sequencing.
[0361] Analyzing a target sequence or fragment thereof that hybridizes to one or more of the selected probes can be a differential assay, wherein hybridization of the selected probes to the target sequence or fragment thereof indicates the presence of the target sequence within the sample.
[0362] Currently, diagnosis is primarily based on the symptoms the patient presents. However, various diseases can share common symptoms, making diagnosis too statistically dependent. For example, malaria triggers flu-like symptoms: headache, fever, chills, joint pain, vomiting, hemolytic anemia, jaundice, hemoglobin in the urine, retinal damage, and convulsions. These symptoms are also common with sepsis, gastroenteritis, and viral illnesses. Among the latter, Ebola hemorrhagic fever has the following symptoms: fever, sore throat, muscle pain, headache, vomiting, diarrhea, rash, decreased liver and kidney function, and internal and external bleeding.
[0363] When the patient is submitted to the medical unit, for example in tropical Africa, basic diagnosis will be inferred to malaria, and this is because statistically, malaria is the most likely disease in that region of Africa.Therefore for malaria treatment patient, but the patient may not actually catch this disease and the patient does not obtain correct treatment and dies.This shortage of correct treatment may be life-threatening, especially when the disease that the patient has caught presents rapid evolution.Recognizing that giving the patient's treatment is invalid and obtains correct diagnosis and may be too late before the patient uses enough treatment at medical staff.
[0364] The method of the present invention provides a solution to this situation. Indeed, because the number of guide RNAs can be significantly reduced, it makes it possible to provide on a single chip selected probes divided into groups, each group being specific for a disease, so that multiple diseases, such as viral infections, can be diagnosed simultaneously. Thanks to the present invention, more than 3 diseases, preferably more than 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 diseases, can be diagnosed simultaneously on a single chip, preferably the diseases that occur most frequently within a population in a given geographical area. Because each group of selected probes is specific for one of the diagnosed diseases, a more accurate diagnosis can be made, thereby reducing the risk of administering the wrong treatment to a patient.
[0365] In other cases, illnesses such as viral infections may occur without any symptoms, or may cause symptoms that resolve before the patient is referred to medical personnel. In such cases, the patient does not seek any medical attention or the diagnosis is complicated by the lack of symptoms on the day of presentation.
[0366] The present invention can also be used in conjunction with other methods for diagnosing disease, identifying pathogens, and optimizing treatment based on the detection of nucleic acids, such as mRNA, in unpurified crude samples.
[0367] The method of the present invention also provides a powerful tool for addressing this situation. Indeed, because a single diagnostic contains multiple sets of selected guide RNAs, each specific for the most common disease occurring within a given region's population, medical personnel only need to contact the chip with a biological sample obtained from the patient. Reading the chip reveals which disease the patient has contracted.
[0368] In some cases, patients are referred to medical personnel for diagnosis of specific symptoms.The method of the present invention makes it possible not only to identify which disease is causing these symptoms, but also to determine at the same time whether the patient is suffering from another disease of which they are unaware.
[0369] This information could be crucial when exploring the mechanisms of an outbreak. Indeed, groups of patients with the same virus also showed temporal patterns, suggesting links of transmission from subject to subject.
[0370] In some embodiments, the CRISPR system or methods of use thereof as described herein can be used to predict disease outcomes in patients suffering from viral diseases. In certain embodiments, such viral diseases may include, but are not necessarily limited to, Lassa fever. Specific factors associated with Lassa fever disease outcomes may include, but are not necessarily limited to, age, degree of renal impairment, and / or CNS loss.
[0371] Screening for microbial genetic perturbations
[0372] In certain exemplary embodiments, the CRISPR system disclosed herein can be used to screen for microbial genetic perturbations. Such methods can be applicable, for example, to developing microbial pathways and functional networks. Microbial cells can be genetically modified and then screened under different experimental conditions. As described above, the embodiments disclosed herein can screen multiple target molecules in a single sample or a single target in a single individual discrete volume in a multiplexed manner. Genetically modified microorganisms can be modified to include nucleic acid barcode sequences that identify specific genetic modifications carried by specific microbial cells or microbial cell populations. A barcode is a short sequence of nucleotides (e.g., DNA, RNA, or a combination thereof) used as an identifier. Nucleic acid barcodes can have a length of 4-100 nucleotides and be single-stranded or double-stranded. Methods for identifying cells with barcodes are known in the art. Therefore, the guide RNA of the CRISPR effector system described herein can be used to detect barcodes. Detection of a positive detectable signal indicates the presence of a specific genetic modification in the sample. The methods disclosed herein can be combined with other methods for detecting complementary genotypes or phenotypic readouts to indicate the effect of genetic modification under the experimental conditions tested. The genetic modifications to be screened can include, but are not limited to, gene knock-in, gene knock-out, inversion, translocation, transposition, or one or more nucleotide insertions, deletions, substitutions, mutations, or additions of nucleic acids encoding epitopes with functional consequences, such as altered protein stability or detection. In a similar manner, the methods described herein can be used in synthetic biology applications to screen for the functionality of specific arrangements of gene regulatory elements and gene expression modules.
[0373] In certain exemplary embodiments, the method can be used to screen for hypoalleles. The generation of hypoalleles and their use in identifying key bacterial functional genes and the identification of new antibiotic therapeutic agents are disclosed in PCT / US2016 / 060730, entitled "Multiplex High-Resolution Detection of Micro-organism Strains, Related Kits, Diagnostic Methods and Screening Assays," filed on November 4, 2016, which is incorporated herein by reference.
[0374] Different experimental conditions can include exposure of the microbial cells to different chemicals, combinations of chemicals, different concentrations of chemicals or combinations of chemicals, different durations of exposure to chemicals or combinations of chemicals, different physical parameters, or both. In certain exemplary embodiments, the chemical agent is an antibiotic or an antiviral agent. The different physical parameters to be screened can include different temperatures, atmospheric pressures, different atmospheric and non-atmospheric gas concentrations, different pH levels, different culture medium compositions, or combinations thereof.
[0375] Screening environmental samples
[0376] The methods disclosed herein can also be used to screen environmental samples for contaminants by detecting the presence of target nucleic acids or polypeptides. For example, in some embodiments, the present invention provides a method for detecting microorganisms, the method comprising: exposing a CRISPR system as described herein to a sample; activating an RNA effector protein via one or more guide RNAs binding to one or more microorganism-specific target RNAs or one or more trigger RNAs to produce a detectable positive signal. A positive signal can be detected and indicates the presence of one or more microorganisms in the sample. In some embodiments, the CRISPR system can be on a substrate as described herein, and the substrate can be exposed to the sample. In other embodiments, the same CRISPR system and / or different CRISPR systems can be applied to multiple discrete locations on a substrate. In other embodiments, different CRISPR systems can detect different microorganisms at each location. As further described above, the substrate can be a flexible material substrate, for example, including but not limited to a paper substrate, a fabric substrate, or a flexible polymer-based substrate.
[0377] According to the present invention, the substrate can be passively exposed to the sample by briefly immersing the substrate in the fluid to be sampled, by applying the fluid to be tested to the substrate, or by contacting the surface to be tested with the substrate. Any means of introducing the sample to the substrate can be used, as appropriate.
[0378] As described herein, the sample for the present invention can be a biological or environmental sample, such as a food sample (fresh fruit or vegetables, meat), a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a fresh water sample, a wastewater sample, a salt water sample, an exposure to atmosphere or other gas samples, or a combination thereof. For example, a household / commercial / industrial surface made of any material including but not limited to metal, wood, plastic, rubber, etc. can be wiped and tested for pollutants. Soil samples can be tested for the presence of pathogenic bacteria or parasites or other microorganisms for environmental purposes and / or for human, animal or plant disease testing. Cleanliness and safety and / or drinkability of a water sample such as a fresh water sample, a wastewater sample or a salt water sample can be assessed to detect the presence of, for example, Cryptosporidium parvum, Giardia lamblia or other microbial contamination. In other embodiments, biological sample can be obtained from following source: include but not limited to tissue sample, saliva, blood, blood plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural effusion, seroma, pus, or the swab of skin or mucosal surface.In some specific embodiments, environmental sample or biological sample can be thick sample and / or one or more target molecules may not be from sample purification or amplification before application method.The differentiation of microorganism can be applicable to many applications and / or is required for many applications, and therefore can use those skilled in the art to think that suitable sample of any type from any source according to the present invention.
[0379] In some embodiments, food surfaces are inspected for bacterial contamination, such as E. coli, at restaurants or other food services; water is tested for pathogens, such as Salmonella, Campylobacter, or E. coli; and food quality is inspected for manufacturers and regulators to determine the purity of meat sources; air contamination by pathogens, such as Legionella, is identified; beer is inspected for contamination or spoilage by pathogens, such as Pediococcus and Lactobacillus; and pasteurized or unpasteurized cheese is inspected for bacterial or fungal contamination during manufacturing.
[0380] The microorganism according to the present invention can be a pathogenic microorganism or a microorganism that causes food or consumable products to spoil. Pathogenic microorganisms may be pathogenic or otherwise undesirable for humans, animals or plants. For humans or animals, microorganisms can cause disease or lead to illness. Animal or veterinary applications of the present invention can identify animals infected by microorganisms. For example, the method and system of the present invention can identify companion animals with pathogens, including but not limited to kennel cough, rabies virus and heartworm. In other embodiments, the method and system of the present invention can be used for kinship testing for breeding purposes. Plant microorganisms can cause damage or disease to plants, reduce yields, or change properties, such as color, taste, consistency, odor. For food or consumable contamination, microorganisms can adversely affect the taste, odor, color, consistency or other commercial characteristics of food or consumable products. In certain exemplary embodiments, the microorganism is a bacterial species. The bacterium can be a facultative psychrotroph, coliform bacteria, lactic acid bacteria or spore-forming bacteria. In certain exemplary embodiments, the bacterium can be any bacterial species that causes disease or illness, or otherwise results in an undesirable product or trait.The bacteria according to the present invention may be pathogenic to humans, animals or plants.
[0381] Sample type
[0382] Suitable samples for use in the methods disclosed herein include any conventional biological sample obtained from an organism or a part thereof, such as a plant, an animal, a bacterium, or the like. In a specific embodiment, the biological sample is obtained from an animal subject, such as a human subject. A biological sample is any solid or fluid sample obtained from, excreted by, or secreted by any living organism, including but not limited to single-cell organisms, such as bacteria, yeast, protozoa, and amoebae, among others; multicellular organisms (e.g., plants or animals, including samples from healthy or apparently healthy human subjects or human patients affected by a condition or disease to be diagnosed or studied, such as infection by pathogenic microorganisms, such as pathogenic bacteria or viruses). For example, a biological sample can be a biological fluid obtained from, for example, blood, plasma, serum, urine, feces, sputum, mucus, lymph, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous humor, or vitreous humor, or any body secretion, exudate, or discharge (e.g., fluid obtained from an abscess or any other site of infection or inflammation), or fluid obtained from a joint (e.g., a normal joint or a joint affected by a disease such as rheumatoid arthritis, osteoarthritis, gout, or septic arthritis), or a swab of the skin or mucosal surface.
[0383] Sample can also be the sample (including biopsy or autopsy specimen, such as tumor biopsy body) obtained from any organ or tissue, or can include cell (no matter it is primary cell or cultured cell) or the culture medium regulated by any cell, tissue or organ.Illustrative samples include but are not limited to cell, cell lysate, blood smear, cell centrifugation preparation, cytology smear, body fluid (such as blood, plasma, serum, saliva, sputum, urine, bronchoalveolar lavage fluid, semen etc.), tissue biopsy body (such as tumor biopsy body), fine needle aspiration liquid, and / or tissue section (such as frozen tissue section and / or paraffin embedded tissue section).In other examples, sample includes circulating tumor cell (it can be differentiated by cell surface marker).In particular instances, sample directly uses (such as fresh or freezing), or can be before use, for example, by fixing (such as using formalin) and / or being embedded in wax (such as formalin fixed paraffin embedded (FFPE) tissue sample) and operate. It will be appreciated that any method of obtaining tissue from a subject can be utilized, and the choice of method used will depend on various factors, such as tissue type, subject age, or procedures available to the practitioner. Standard techniques for obtaining such samples are available in the art. See, for example, Schluger et al., J. Exp. Med. 176: 1327-33 (1992); Bigby et al., Am. Rev. Respir. Dis. 133: 515-18 (1986); Kovacs et al., NEJM 318: 589-93 (1988); and Ognibene et al., Am. Rev. Respir. Dis. 129: 929-32 (1984).
[0384] In other embodiments, the sample can be an environmental sample, such as water, soil, or a surface, such as an industrial or medical surface. In some embodiments, methods such as those disclosed in U.S. Patent Publication No. 2013 / 0190196 can be applied to detect nucleic acid markers, particularly at the RNA level, directly from crude cell samples with high sensitivity and specificity. Sequences specific for each pathogen of interest can be identified or selected by comparing the coding sequence from the pathogen of interest with all coding sequences in other organisms using BLAST software.
[0385] Several embodiments of the present disclosure involve the use of procedures and methods known in the art to successfully fractionate clinical blood samples. See, for example, the procedures described in: Han Wei Hou et al., Microfluidic Devices for Blood Fractionation, Micromachines 2011, 2, 319-343; Ali Asgar S. Bhagat et al., Dean Flow Fractionation (DFF) Isolation of Circulating Tumor Cells (CTCs) from Blood, 15 th International Conference on Miniaturized Systems for Chemistry and Life Sciences, October 2-6, 2011, Seattle, WA; and International Patent Publication No. WO2011109762, the disclosure of which is incorporated herein by reference in its entirety. Blood samples are often expanded in culture to increase the sample size for testing purposes. In some embodiments of the present invention, blood or other biological samples can be used in the methods described herein without expansion in culture.
[0386] In addition, several embodiments of the present disclosure relate to the use of procedures and methods known in the art to successfully isolate pathogens from whole blood using spiral microchannels, as described in Han Wei Hou et al., Pathogen Isolation from Whole Blood Using Spiral Microchannel, Case No. 15995JR, Massachusetts Institute of Technology (manuscript in preparation), the disclosure of which is incorporated herein by reference in its entirety.
[0387] Due to the increased sensitivity of the embodiments disclosed herein, in certain exemplary embodiments, the assays and methods can be run on crude samples or samples in which the target molecule to be detected has not been further fractionated or purified from the sample.
[0388] Exemplary microorganisms
[0389] The embodiments disclosed herein can be used to detect many different microorganisms.The term microorganism as used herein includes bacteria, fungi, protozoa, parasites and viruses.
[0390] bacteria
[0391] The following provides an exemplary list of types of microorganisms that may be detected using the embodiments disclosed herein.In certain exemplary embodiments, the microorganism is a bacterium. Examples of bacteria that can be detected according to the disclosed methods include, but are not limited to, any one or more of the following (or any combination thereof): Acinetobacter baumanii, Actinobacillus sp., Actinomycetes, Actinomyces sp. (e.g., Actinomyces israelii and Actinomyces naeslundii), Aeromonas sp. (e.g., Aeromonas hydrophila, Aeromonas veronii biovar sobria (Aeromonas sobria), and Aeromonas caviae), Anaplasma phagocytophilum, Anaplasma marginale, Alcaligenes xylosoxidans, xylosoxidans), Acinetobacter baumannii, Actinobacillus actinomycetemcomitans, Bacillus sp. (e.g., Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Bacillus thuringiensis, and Bacillus stearothermophilus), Bacteroides sp. (e.g., Bacteroides fragilis), Bartonella sp. (e.g., Bartonella bacilliformis and Bartonella henselae), Bifidobacterium sp., Bordetella sp.) (e.g., Bordetella pertussis, Bordetella parapertussis, and Bordetella bronchiseptica), Borrelia sp. (e.g., Borrelia recurrentis and Borrelia burgdorferi), Brucella sp. (e.g., Brucella abortus, Brucella canis, Brucella melintensis, and Brucella suis), Burkholderia sp. (e.g., Burkholderia pseudomallei and Burkholderia cepacia), Campylobacter sp. (e.g., Campylobacter jejuni, Campylobacter coli, coli), Campylobacter lari, and Campylobacter fetus), Capnocytophaga species, Cardiobacterium hominis, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, Citrobacter sp., Coxiella burnetii, Corynebacterium sp. (e.g., Corynebacterium diphtheriae, Corynebacterium jeikeum, and Corynebacterium), Clostridium sp. (e.g., Clostridium perfringens, Clostridium difficile, Clostridium botulinum, botulinum and Clostridium tetani), Eikenella corrodens, Enterobacter spp.coli), Enterococcus species (e.g., Enterococcus faecalis and Enterococcus faecium), Ehrlichia species (e.g., Ehrlichia chafeensia and Ehrlichia canis), Epidermophyton floccosum and Enterococcus spp. floccosum), Erysipelothrix rhusiopathiae, Eubacterium sp., Francisella tularensis, Fusobacterium nucleatum, Gardnerella vaginalis, Gemella morbillorum, Haemophilus sp. (e.g., Haemophilus influenzae, Haemophilus ducreyi, Haemophilus aegyptius, Haemophilus parainfluenzae, Haemophilus haemolyticus, and Haemophilus parahaemolyticus), Helicobacter sp. sp.) (e.g., Helicobacter pylori, Helicobacter cinaedi, and Helicobacter fennelliae), Kingella kingii, Klebsiella sp.) (e.g., Klebsiella pneumoniae, Klebsiella granulomatis, and Klebsiella oxytoca), Lactobacillus sp., Listeria monocytogenes, Leptospira interrogans, Legionella pneumophila, Leptospira interrogans, Peptostreptococcus sp., Mannheimia hemolytica, Microsporum canis, Moraxella catarrhalis, Morganella sp., Mobiluncus sp., Micrococcus sp., Mycobacterium sp. (e.g., Mycobacterium leprae), leprae), Mycobacterium tuberculosis, Mycobacterium paratuberculosis, Mycobacterium intracellulare, Mycobacterium avium, Mycobacterium bovis, and Mycobacterium marinum), Mycoplasma sp. (e.g., Mycoplasma pneumoniae, Mycoplasma hominis, and Mycoplasma genitalium), Nocardia sp. (e.g., Nocardia asteroides, Nocardia cyriacigeorgica, and Nocardia brasiliensis), Neisseria sp.) (e.g., Neisseria gonorrhoeae and Neisseria meningitidis), Pasteurella multocida, Pityrosporum orbiculare (Malassezia furfur), Plesiomonas shigelloides, Prevotella spp., Porphyromonas spp., Prevotella melaninogenica, Proteus sp. (e.g., Proteus vulgaris and Proteus mirabilis), Providencia sp. (e.g., Providencia alcalifaciens, Providencia rettgeri, and Providencia stuartii), Pseudomonas aeruginosa, Propionibacterium acnes, Rhodococcus equi, Rickettsia sp. (e.g., Rickettsia rickettsii, Rickettsia akari, and Rickettsia prowazekii), Orientia tsutsugamushi (formerly Rickettsia tsutsugamushi), and Rickettsia typhi), Rhodococcus sp., Serratia marcescens, Stenotrophomonas maltophilia, Salmonella sp. (e.g., Salmonella enterica enterica), Salmonella typhi, Salmonella paratyphi, Salmonella enteritidis, Salmonella cholerasuis, and Salmonella typhimurium), Serratia sp.) (e.g., Serratia marcesans and Serratia liquifaciens), Shigella sp. (e.g., Shigella dysenteriae, Shigella flexneri, Shigella boydii, and Shigella sonnei), Staphylococcus sp. (e.g., Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hemolyticus, Staphylococcus saprophyticus), Streptococcus sp.) (e.g., Streptococcus pneumoniae (e.g., chloramphenicol-resistant serotype 4 Streptococcus pneumoniae, spectinomycin-resistant serotype 6B Streptococcus pneumoniae, streptomycin-resistant serotype 9V Streptococcus pneumoniae, erythromycin-resistant serotype 14 Streptococcus pneumoniae, optochin-resistant serotype 14 Streptococcus pneumoniae, rifampicin-resistant serotype 18C Streptococcus pneumoniae, tetracycline-resistant resistant serotype 19F pneumoniae, penicillin-resistant serotype 19F pneumoniae and trimethoprim-resistant serotype 23F pneumoniae, chloramphenicol-resistant serotype 4 pneumoniae, spectinomycin-resistant serotype 6B pneumoniae, streptomycin-resistant serotype 9V pneumoniae, optoxin-resistant serotype 14 pneumoniae, rifampicin-resistant serotype 18C pneumoniae, penicillin-resistant serotype 19F pneumoniae or trimethoprim-resistant serotype 23F pneumoniae), Streptococcus agalactiae agalactiae), Streptococcus mutans, Streptococcus pyogenes, Group A streptococci, Streptococcus pyogenes, Group B streptococci, Streptococcus agalactiae, Group C streptococci, Streptococcus anginosus, Streptococcus equismilis, Group D streptococci, Streptococcus bovis, Group F streptococci, and Group G streptococci), Spirillumminus, Streptobacillus moniliformi, Treponema sp.) (e.g., Treponema carateum, Treponema petenue, Treponema pallidum, and Treponema endemicum), Trichophyton rubrum, T. mentagrophytes, Tropheryma whippelii, Ureaplasma urealyticum, Veillonella sp., Vibrio sp. (e.g., Vibrio cholerae, Vibrio parahemolyticus, Vibrio vulnificus, Vibrio parahemolyticus, Vibrio vulnificus, Vibrio alginolyticus, Vibrio mimicus, Vibrio hollisae, Vibrio fluvialis, Vibrio mechnikovi, Vibrio cholerae, Vibrio spp. metchnikovii), Vibrio damsela, and Vibrio furnisii), Yersinia sp. (e.g., Yersinia enterocolitica, Yersinia pestis, and Yersinia pseudotuberculosis), and Xanthomonas maltophilia.
[0392] fungi
[0393] In certain exemplary embodiments, the microorganism is a fungus or a fungal species. Examples of fungi that can be detected according to the disclosed methods include, but are not limited to, any one or more of the following (or any combination thereof): Aspergillus, Blastomyces, Candidiasis, Coccidiodomycosis, Cryptococcus neoformans, Cryptococcus gatti, Histoplasma sp. (e.g., Histoplasma capsulatum), Pneumocystis sp. (e.g., Pneumocystis jirovecii), Stachybotrys (e.g., Stachybotrys chartarum), Mucroymcosis, Sporothrix, eye fungal infections tinea corporis, Exserohilum, Cladosporium.
[0394] In certain exemplary embodiments, the fungus is a yeast. Examples of yeasts that can be detected according to the disclosed method include, but are not limited to, one or more of the following (or any combination thereof): Aspergillus (e.g., Aspergillus fumigatus, Aspergillus flavus, and Aspergillus clavatus), Cryptococcus sp. (e.g., Cryptococcus neoformans, Cryptococcus gattii, Cryptococcus laurentii, and Cryptococcus albidus), Geotrichum, Saccharomyces, Hansenula, Candida (e.g., Candida albicans), Kluyveromyces, Debaryomyces, Pichia, or a combination thereof. In certain exemplary embodiments, the fungus is a mold. Exemplary molds include, but are not limited to, Penicillium, Cladosporium, Byssochlamys, or a combination thereof.
[0395] protozoa
[0396] In certain exemplary embodiments, the microorganism is a protozoa. Examples of protozoa that can be detected according to the disclosed methods and apparatus include, but are not limited to, any one or more of the following (or any combination thereof): Euglenozoa, Heterolobosea, Diplomonadida, Amoebozoa, Blastocystic, and Apicomplexa. Exemplary Euglena include, but are not limited to, Trypanosoma cruzi (Chagas disease), T. brucei gambiense, T. brucei rhodesiense, Leishmania braziliensis, L. infantum, L. mexicana, L. major, L. tropica, and L. donovani. Exemplary Heteropoda include, but are not limited to, Naegleria fowleri. Exemplary Diplomonas include, but are not limited to, Giardia intestinalis (G. lamblia, G. duodenalis). Exemplary Amoeba include, but are not limited to, Acanthamoeba castellanii, Balamuthia madrillaris, Entamoeba histolytica. Exemplary Blastocystis include, but are not limited to, Blastocystic hominis. Exemplary Apicomplexa include, but are not limited to, Babesia microti, Cryptosporidium parvum, Cyclospora cayetanensis, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and Toxoplasma gondii, Babesia microti, Cryptosporidium parvum, Cyclospora cayetanensis, Plasmodium falciparum, P. vivax, P. ovale, P. malariae, and Toxoplasma gondii.
[0397] parasites
[0398] In certain exemplary embodiments, the microorganism is a parasite. Examples of parasites that can be detected according to the disclosed methods include, but are not limited to, one or more of the following (or any combination thereof): Onchocerca spp. and Plasmodium spp.
[0399] Virus
[0400] In certain exemplary embodiments, the systems, devices, and methods disclosed herein relate to detecting viruses in samples. The embodiments disclosed herein can be used to detect viral infections (e.g., viral infections of subjects or plants), or to determine viral strains, including viral strains that differ due to single nucleotide polymorphisms. The virus can be a DNA virus, an RNA virus, or a retrovirus. Non-limiting examples of viruses suitable for use in the present invention include, but are not limited to, Ebola, measles, SARS, chikungunya, hepatitis, Marburg, yellow fever, MERS, dengue, Lassa, influenza, rhabdovirus, or HIV. Hepatitis viruses can include hepatitis A, hepatitis B, or hepatitis C. Influenza viruses can include, for example, influenza A or influenza B. HIV can include HIV 1 or HIV 2. In certain exemplary embodiments, the viral sequence can be human respiratory syncytial virus, Sudan ebola virus, Bundibugyo virus, Tai Forest ebola virus, Reston ebola virus, Achimota, Aedes flavivirus, Aguacate virus, Akabane virus, Alethinophid reptarenavirus, Allpahuayomammarenavirus, Amapari mmarenavirus, Andesvirus, Apoi virus, Aravan virus, Aroavirus, Arumwot virus, Atlantic salmon paramyoxivirus, Australian bat lyssavirus, lyssavirus), Avian bornavirus, Avian metapneumovirus, Avian paramyxovirus, penguin or Falkland Islands virus, BK polyomavirus, Bagaza virus, Banna virus, Bathepevirus, Bat sapovirus, Bear Jianong mammalian arenavirusCanonmammarenavirus), Beilong virus, Betacoronoavirus, Betapapillomavirus 1-6, Bhanja virus, Bokeloh bat lyssavirus, Borna disease virus, Bourbon virus, Bovine hepacivirus, Bovine parainfluenza virus 3, Bovine respiratory syncytial virus, Brazoranvirus, Bunyamwere virus, Caliciviridae, California encephalitis virus, Candiru virus, Canine distemper virus, Canaine pneumovirus, Cedar virus, Cell fusing agent virus, Cetacean morbillivirus, Chandipura virus virus), Chaoyang virus, Chaparemammarenavirus, Chikungunya virus, Colobus monkey papillomavirus, Colorado tick fever virus, vaccinia virus, Crimean-Congo hemorrhagic fever virus, Culex mosquito flavivirus, Cupixi mammarenavirus, dengue virus, Dobrava-Belgrade virus, Donggang virus, Dugbevirus, Duvenhage virus, Eastern equine encephalitis virus, Entebbe bat virus, enterovirus AD, European bat lyssavirus 1-2, Eyach virus, Feline morbillivirus, Fer-de-Lance virus paramyxovirus), Fitzroy River virusvirus), Flaviviridae, Flexal mammarenavirus, GB virus C, Gairovirus, Gemycircularvirus, Goose paramyxovirus SF02, Great Islandvirus, Guanarito mammarenavirus, Hantaanvirus, Hantaanvirus Z10, Heartland virus, Hendra virus, Hepatitis A / B / C / E, Hepatitis D virus, Human bocavirus, Human coronavirus, Human endogenous retrovirus K, Human enteric coronavirus, Human genital-associated circular DNA virus-1, Human herpesviruses 1-8, Human immunodeficiency virus 1 / 2, Huan mastadenovirus AG, Human papillomavirus, Human parainfluenza viruses 1-4, Human parechovirus paraechovirus), human picobirnavirus, human smacovirus, Ikomalyssavirus, Ilheus virus, influenza A-C, Ippymammarenavirus, Irkut virus, J-virus, JC polyomavirus, Japanese encephalitis virus, Junin mammalian arenavirus, KI polyomavirus, Kadipiro virus, Kamiti River virus, Kedougou virus, Khujandvirus, Kokobera virus, Kyasanur forestdisease virus, Lagos bat virus, Langat virus, Lassa mammalian arenavirus mammarenavirus), Latinomammarenavirus, Leopards Hill virus, Liaoning virus, Ljungan virusvirus), Lloviu virus, Louping illvirus, Lujo mammarenavirus, Lunamammarenavirus, Lunk virus, Lymphocytic choriomeningitis mammarenavirus, Lyssavirus Ozernoe, MSSI2\.225 virus, Machupo mammarenavirus, Mamastrovirus 1, Manzanilla virus, Mapuera virus, Marburg virus, Mayaro virus, Measles virus, Menangle virus, Mercadeo virus, Merkel cell polyomavirus cell polyomavirus), Middle East respiratory syndrome coronavirus, Mobalamammarenavirus, Modoc virus, Moijang virus, Mokolo virus, monkeypox virus, Montana myotisleukoenchalitis virus, Mopeia lassa virus reassortant 29, Mopeia mammarenavirus, Morogoro virus, Mossman virus, mumps virus, murine pneumovirus, Murray Valley encephalitis virus, Nariva virus, Newcastle disease virus, Nipah virus, Norwalk virus, Norway rat hepacivirus, Ntaya virus virus), O'nyong-nyong virus, Oliveros mammalian arenavirus, Omsk hemorrhagic fever virusvirus), Oropouche virus, parainfluenza virus 5, Parana mammarenavirus, Parramatta River virus, Peste-des-petits-ruminants virus, Pichande mammarenavirus, Picornaviridae virus, Pirital mammarenavirus, Piscihepevirus A, porcine parainfluenza virus 1, porcine mumps virus, Powassan virus, primate T-lymphotropic viruses 1-2, primate erythroparvovirus 1, Punta Toro virus, Puumala virus, Quang Binh virus virus), rabies virus, Razdanvirus, Reptile bornavirus 1, Rhinovirus AB, Rift Valley fever virus, Rinderpest virus, Rio Bravo virus, Rodent Torque Teno virus, Rodent hepacivirus, Ross River virus, Rotavirus AI, Royal Farm virus, Rubella virus, Sabia mammarenavirus, Salem virus, Sandfly fever Naples virus, Sandfly fever Sicilian virus, Sapporo virus, Sathuperi virus, Seal anellovirus, Semliki Forest virus, Sendai virus virus), Seoul virus, Sepik virusvirus), severe acute respiratory syndrome-related coronavirus, severe fever with thrombocytopenia syndrome virus, Shamonda virus, Shimoni bat virus, Shuni virus, Simbu virus, Simiantorque teno virus, Simian virus 40-41, Sin Nombre virus, Sindbis virus, Small anellovirus, Sosuga virus, Spanish goat encephalitis virus, Spondweni virus, St. Louis encephalitis virus, Sunshine virus, TTV-like mini virus, Tacaribe mammarenavirus, Taila virus, Tamana bat virus virus), Tamiami mammarenavirus, Tembusu virus, Thogoto virus, Thotapalayam virus, Tick-borne encephalitis virus, Tioman virus, Togaviridae virus, Torque teno canisvirus, Torque teno douroucouli virus, Torque tenofelis virus, Torque teno midi virus, Torque teno susvirus, Torque teno tamarin virus, Torque teno virus, Torque teno zalophus virus, Tuhoko virus virus), Tulavirus, Tree Shrew Paramyxovirus, Usutu virus, Uukuniemi virusvirus, vaccinia virus, variola virus, Venezuelan equine encephalitis virus, Vesicular stomatitis Indiana virus, WU polyomavirus, Wesselsbron virus, West Caucasian bat virus, West Nile virus, Western equine encephalitis virus, Whitewater Arroyo mammarenavirus, yellow fever virus, Yokose virus, Yug Bogdanovac virus, Zaireebolavirus, Zika virus, or Zygosaccharomyces bailiivirus Z viral sequence. Examples of RNA viruses that can be detected include one or more of the following (or any combination thereof): Coronaviridae, Picornaviridae, Caliciviridae, Flaviviridae, Togaviridae, Bornaviridae, Filoviridae, Paramyxoviridae, Alveoviridae, Rhabdoviridae, Arenaviridae, Bunyaviridae, Orthomyxoviridae, or Deltavirus. In certain exemplary embodiments, the virus is a coronavirus, SARS, poliovirus, rhinovirus, hepatitis A, Norwalk virus, yellow fever virus, West Nile virus, hepatitis C virus, dengue virus, Zika virus, rubella virus, Ross River virus, Sindbis virus, Chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, measles virus, mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, human respiratory syncytial virus, rabies virus, Lassa virus, Hantavirus, Crimean-Congo hemorrhagic fever virus, influenza, or hepatitis D virus.
[0401] In certain exemplary embodiments, the virus can be a plant virus selected from the group consisting of tobacco mosaic virus (TMV), tomato spotted wilt virus (TSWV), cucumber mosaic virus (CMV), potato virus Y (PVY), RT virus cauliflower mosaic virus (CaMV), plum pox virus (PPV), brome mosaic virus (BMV), potato virus X (PVX), citrus tristeza virus (CTV), barley yellow dwarf virus (BYDV), potato leafroll virus (PLRV), tomato bushy stunt virus (TBSV), rice tungro spherical virus (RTSV), rice yellow mottle virus (RYMV), rice white leaf virus (RHBV), maize rayado fino virus (MRFV), maize dwarf mosaic virus (MDMV), sugarcane mosaic virus (SCMV), sweet potato feathery mottle virus (SPFMV), sweet potato sunken vein yellow filamentous virus (SPVV), and rice tungro spherical virus (RTSV). In a preferred embodiment, the target RNA molecule is part of the pathogen or is transcribed from a DNA molecule of the pathogen. For example, the target sequence may be contained in the genome of an RNA virus. It is further preferred that the CRISPR effector protein hydrolyzes the target RNA molecule of the pathogen in the plant if the pathogen infects or has infected the plant. It is therefore preferred that the CRISPR system is capable of cleaving the target RNA molecule from the plant pathogen when the CRISPR system (or the part thereof required for its completion) is applied therapeutically, i.e. after infection has occurred, or prophylactically, i.e. before infection has occurred.
[0402] In certain exemplary embodiments, the virus can be a retrovirus. Exemplary retroviruses that can be detected using the embodiments disclosed herein include one or more or any combination of the following viruses: alpharetrovirus, betaretrovirus, gammaretrovirus, deltaretrovirus, epsilonretrovirus, lentivirus, spumavirus, or Metaviridae, Pseudoviridae, and Retroviridae (including HIV), Hepadnaviridae (including hepatitis B virus), and Caulimoviridae (including cauliflower mosaic virus).
[0403] In certain exemplary embodiments, the virus is a DNA virus. Exemplary DNA viruses that can be detected using the embodiments disclosed herein include, among others, one or more of the following families (or any combination thereof): Myoviridae, Podoviridae, Siphoviridae, Alloherpesviridae, Herpesviridae (including human herpesvirus and varicella-zoster virus), Malocoherpesviridae, Lipothrixviridae, Parvoviridae, and Rudiviridae, Adenoviridae, Ampullaviridae, Ascoviridae, Asfarviridae (including African swine fever virus), Baculoviridae, Cicaudaviridae, Clavaviridae, Corticoviridae, Fuselloviridae, Globuloviridae ridae), Guttaviridae, Hytrosaviridae, Iridoviridae, Maseilleviridae, Mimiviridae, Nudiviridae, Nimaviridae, Pandoraviridae, Papillomaviridae, Phycodnaviridae, Protoplasmviridae asmaviridae), Polydnavirus, Polyomaviridae (including simian virus 40, JC virus, BK virus), Poxviridae (including cowpox and smallpox), Sphaerolipoviridae, Tectiviridae, Turriviridae, Dinodnavirus, Salterprovirus, Rhizidovirus.In some embodiments, a method of diagnosing a species-specific bacterial infection in a subject suspected of having a bacterial infection is described as obtaining a sample comprising bacterial ribosomal ribonucleic acid from the subject; contacting the sample with one or more of the described probes; and detecting hybridization between bacterial ribosomal ribonucleic acid sequences present in the sample and the probes, wherein detection of hybridization indicates that the subject is infected with the following bacteria: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Acinetobacter baumannii, Candida albicans, Enterobacter cloacae, Enterococcus faecalis, Enterococcus faecium, Proteus mirabilis, Staphylococcus agalactiae, or Staphylococcus maltophilia, or a combination thereof.
[0404] In certain exemplary embodiments, the virus is a virus listed in Table 8 below, or a virus of the indicated genus / family.
[0405] Table 8
[0406]
[0407]
[0408]
[0409]
[0410]
[0411]
[0412]
[0413]
[0414]
[0415]
[0416] In certain embodiments, the virus is a virus listed in the table below.
[0417]
[0418]
[0419] In certain embodiments, the virus is a virus listed in Table 9 below.
[0420] Table 9
[0421]
[0422]
[0423] In certain embodiments, the virus is a drug-resistant virus. By way of example and not limitation, the virus can be a ribavirin-resistant virus. Ribavirin is a very effective antiviral agent against many RNA viruses. The following are several important viruses that have evolved resistance to ribavirin. Foot-and-mouth disease virus: doi:10.1128 / JVI.03594-13. Poliovirus: www.pnas.org / content / 100 / 12 / 7289.full.pdf. Hepatitis C virus: jvi.asm.org / content / 79 / 4 / 2346.full. Many other persistent RNA viruses, such as hepatitis and HIV, have evolved resistance to existing antiviral drugs. Hepatitis B virus (lamivudine, tenofovir, entecavir): doi:10.1002 / hep.22900. Hepatitis C virus (telaprevir, BILN2061, ITMN-191, SCH6, boceprevir, AG-021541, ACH-806): doi:10.1002 / hep.22549. HIV has many drug resistance mutations, for more information see hivdb.stan ford.edu / . In addition to drug resistance, there are many clinically relevant mutations that can be targeted with the CRISPR system according to the present invention as described herein. For example, persistence in LCMV versus acute infection: doi:10.1073 / pnas.1019304108; or increased Ebola infectivity: http: / / doi.org / 10.1016 / j.cell.2016.10.014 and http: / / doi.org / 10.1016 / j.cell.2016.10.013.
[0424] Malaria detection and surveillance
[0425] Malaria is a mosquito-borne disease caused by Plasmodium parasites. The parasite is transmitted to humans via the bite of infected female Anopheles mosquitoes. Five Plasmodium species cause malaria in humans: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi. Among these, according to the World Health Organization (WHO), Plasmodium falciparum and Plasmodium vivax pose the greatest threat. Plasmodium falciparum (P.falciparum) is the most prevalent malaria parasite in Africa and causes most malaria-related deaths worldwide. Plasmodium vivax is the main malaria parasite in most countries outside sub-Saharan Africa.
[0426] In 2015, 91 countries and territories had ongoing malaria transmission. According to the most recent WHO estimates, there were 212 million cases of malaria and 429,000 deaths in 2015. In areas with high malaria transmission, children under the age of five are particularly vulnerable to infection, illness, and death; more than two-thirds (70%) of all malaria deaths occur in this age group. Between 2010 and 2015, the global under-five malaria mortality rate decreased by 29%. However, malaria remains the leading killer of children under five, claiming the life of one child every two minutes.
[0427] As described by the WHO, malaria is an acute febrile illness. In non-immune individuals, symptoms appear 7 or more days after the bite of an infective mosquito. The first symptoms—fever, headache, chills, and vomiting—may be mild and difficult to recognize as malaria. However, if not treated within 24 hours, Plasmodium falciparum malaria can progress to severe illness, often leading to death.
[0428] Children with severe malaria frequently develop one or more of the following symptoms: severe anemia, respiratory distress associated with metabolic acidosis, or cerebral malaria. In adults, multiorgan involvement is also frequent. In malaria-endemic areas, people may develop partial immunity, allowing asymptomatic infection to occur.
[0429] The development of rapid and effective diagnostic tests is highly relevant to public health. Indeed, early diagnosis and treatment of malaria not only alleviates illness and prevents death, but also helps reduce the spread of malaria. According to the WHO recommendation, all cases of suspected malaria should be confirmed using parasite-based diagnostic tests (particularly rapid diagnostic tests) before treatment is administered (see "WHO Guidelines for the treatment of malaria", third edition, published in April 2015).
[0430] Resistance to antimalarial therapy presents a critical health problem, which greatly reduces treatment strategies. Indeed, as reported on the WHO website, resistance of Plasmodium falciparum to previous generation drugs, such as chloroquine and sulfadoxine / pyrimethamine (SP), became widespread in the 1950s and 1960s, weakening efforts to control malaria and reversing the increase in child survival rates. Therefore, the WHO recommends routine monitoring of antimalarial drug resistance. Indeed, accurate diagnosis can avoid inappropriate treatment and limit the spread of resistance to antimalarial drugs.
[0431] In this context, the WHO Global Technical Strategy for Malaria 2016-2030—formally adopted by the World Health Assembly in May 2015—provides a technical framework for all malaria-endemic countries. It is intended to guide and support regional and national programs working towards malaria control and elimination. The strategy sets ambitious but achievable global goals, including:
[0432] ● Reduce the incidence of malaria cases by at least 90% by 2030.
[0433] ● Reduce malaria mortality by at least 90% by 2030.
[0434] ● Eliminate malaria in at least 35 countries by 2030.
[0435] ●Prevent the resurgence of malaria in all malaria-free countries.
[0436] This strategy is the result of an extensive consultation process spanning two years and involving the participation of more than 400 technical experts from 70 Member States. It is based on three key axes:
[0437] ● Ensure universal access to malaria prevention, diagnosis and treatment;
[0438] ● Accelerate efforts towards elimination and achieving malaria-free status; and
[0439] ●Transform malaria surveillance into a core intervention.
[0440] Treatments for Plasmodium include aryl-amino alcohols, such as quinine or quinine derivatives, such as chloroquine, amodiaquine, mefloquine, piperaquine, lumefantrine, primaquine; lipophilic hydroxynaphthoquinone analogs, such as atovaquone; antifolates, such as the sulfonamides sulfadoxine, dapsone, and pyrimethamine; proguanil; atovaquone / proguanil combinations; artemisinins; and combinations thereof.
[0441] Target sequences diagnostic for the presence of mosquito-borne pathogens include sequences diagnostic for the presence of Plasmodia, particularly Plasmodia species that affect humans, such as Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, and Plasmodium knowlesi, including sequences from their genomes.
[0442] As a diagnostic target sequence for monitoring resistance to treatment of Plasmodium species, particularly Plasmodium species affecting humans, such as Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae and Plasmodium knowlesi.
[0443] Other target sequences include sequences that include target molecules / nucleic acid molecules encoding proteins involved in essential biological processes of the Plasmodium parasite and in particular transport proteins, such as proteins from the drug / metabolite transporter family; ATP-binding cassette (ABC) proteins involved in substrate translocation, such as ABC transporter subfamily C or Na+ / H+ exchangers, membrane glutathione S-transferases; proteins involved in the folate pathway, such as dihydropteroate synthase, dihydrofolate reductase activity or dihydrofolate reductase-thymidylate synthase; and proteins involved in proton translocation across the inner mitochondrial membrane, and in particular the cytochrome b complex. Additional targets may also include one or more genes encoding heme polymerase.
[0444] Other target sequences include target molecules / nucleic acid molecules encoding proteins involved in basic biological processes, which can be selected from Plasmodium falciparum chloroquine resistance transporter gene (pfcrt), Plasmodium falciparum multidrug resistance transporter 1 (pfmdr1), Plasmodium falciparum multidrug resistance-associated protein gene (Pfmrp), Plasmodium falciparum Na+ / H+ exchanger gene (pfnhe), gene encoding Plasmodium falciparum export protein 1, Plasmodium falciparum Ca2+ transporting ATPase 6 (pfatp6); Plasmodium falciparum dihydropteroate synthase (pfdhps), dihydrofolate reductase activity (pfdhpr) and dihydrofolate reductase-thymidylate synthase (pfdhfr) genes, cytochrome b gene, gtp cyclohydrolase and Kelch13 (K13) genes, as well as functional heterologous genes thereof in other Plasmodium species.
[0445] Many mutations, particularly single point mutations, have been identified in proteins that are targets of current therapies and are associated with specific resistance phenotypes.Thus, the present invention allows for the detection of various resistance phenotypes in mosquito-borne parasites, such as Plasmodium.
[0446] The present invention allows for the detection of one or more mutations and in particular one or more single nucleotide polymorphisms in a target nucleic acid / molecule.Thus, any one of the following mutations or a combination thereof may be used as a drug resistance marker and may be detected according to the present invention.
[0447] Single point mutations in Plasmodium falciparum K13 include those at positions 252, 441, 446, 449, 458, 493, 539, 543, 553, 561, 568, 574, 578, 580, 675, 476, 469, 481, 522, 537, 538, 579, 584, and 719, and in particular mutations E252Q, P441 L, F446I, G449A, N458Y, Y493H, R539T, I543T, P553L, R561H, V568G, P574L, A578S, C580Y, A675V, M476I, C469Y, A481V, S522C, N537I, N537D, G538V, M579I, D584V, and H719N. These mutations are generally associated with artemisinin drug resistance (Artemisinin and artemisinin-based combination therapy resistance, April 2016 WHO / HTM / GMP / 2016.5).
[0448] In Plasmodium falciparum dihydrofolate reductase (DHFR) (PfDHFR-TS, PFD0830w), important polymorphisms include mutations at positions 108, 51, 59, and 164, particularly 108D, 164L, 51I, and 59R, which mediate resistance to pyrimethamine. Other polymorphisms include 437G, 581G, 540E, 436A, and 613S, which are associated with resistance to sulfadoxine. Additional observed mutations include Ser108Asn, Asn51Ile, Cys59Arg, Ile164Leu, Cys50Arg, Ile164Leu, Asn188Lys, Ser189Arg, and Val213Ala, Ser108Thr, and Ala16Val. Mutations Ser108Asn, Asn51Ile, Cys59Arg, Ile164Leu, Cys50Arg, and Ile164Leu are significantly associated with resistance to pyrimethamine-based therapies and / or chloroguanine-dapsone combination therapy. Cycloguanil resistance appears to be associated with the double mutations Ser108Thr and Ala16Val. dhfr amplification may also be highly correlated with therapy resistance, particularly pyrimethamine resistance.
[0449] In Plasmodium falciparum dihydropteroate synthase (DHPS) (PfDHPS, PF08_0095), important polymorphisms include mutations Ser436Ala / Phe, Ala437Gly, Lys540Glu, Ala581Gly, and Ala613Thr / Ser at positions 436, 437, 581, and 613. Polymorphisms at positions 581 and / or 613 have also been associated with resistance to sulfadoxine-pyrimethamine-based therapy.
[0450] In the Plasmodium falciparum chloroquine resistance transporter (PfCRT), a polymorphism at position 76, specifically the mutation Lys76Thr, is associated with resistance to chloroquine. Other polymorphisms include Cys72Ser, Met74Ile, Asn75Glu, Ala220Ser, Gln271Glu, Asn326Ser, Ile356Thr, and Arg371Ile, which may be associated with chloroquine resistance. PfCRT is also phosphorylated at residues S33, S411, and T416, which may regulate the transport activity or specificity of the protein.
[0451] In the Plasmodium falciparum multidrug resistance transporter 1 (PfMDR1) (PFE1150w), polymorphisms at positions 86, 184, 1034, and 1042, particularly Asn86Tyr, Tyr184-Phe, Ser1034Cys, Asn1042Asp, and Asp1246Tyr, have been identified and reported to influence susceptibility to lumefantrine, artemisinin, quinine, mefloquine, halofantrine, and chloroquine. In addition, amplification of PfMDR1 is associated with reduced susceptibility to lumefantrine, artemisinin, quinine, mefloquine, and halofantrine, and deamplification of PfMDR1 leads to increased resistance to chloroquine. Amplification of pfmdr1 can also be detected. The phosphorylation state of PfMDR1 is also highly correlated.
[0452] In the Plasmodium falciparum multidrug resistance-associated protein (PfMRP) (gene reference PFA0590w), polymorphisms at positions 191 and / or 437, such as Y191H and A437S, have been identified and are associated with the chloroquine-resistant phenotype.
[0453] In the Plasmodium falciparum NA+ / H+ exchanger (PfNHE) (reference PF13_0019), an increase in the DNNND repeat in the microsatellite ms4670 can be a marker for quinine resistance.
[0454] Mutations that alter the ubiquinol binding site of the cytochrome b protein, encoded by the cytochrome b gene (cytb, mal_mito_3), are associated with atovaquone resistance. Mutations at positions 26, 268, 276, 133, and 280, and particularly Tyr26Asn, Tyr268Ser, M1331, and G280D, may be associated with atovaquone resistance.
[0455] For example, in Plasmodium vivax, mutations in PvMDR1, a homologue of Pf MDR1, have been associated with chloroquine resistance, particularly polymorphisms at position 976, such as the mutation Y976F.
[0456] The above mutations are defined based on protein sequences. However, a skilled person is able to determine corresponding mutations, including SNPs, to be identified as nucleic acid target sequences.
[0457] Other identified drug resistance markers are known in the art, for example, as described in the following references: "Susceptibility of Plasmodium falciparum to antimalarial drugs (1996-2004)"; WHO; Artemisinin and artemisinin-based combination therapy resistance (April 2016 WHO / HTM / GMP / 2016.5); "Drug-resistant malaria: molecular mechanisms and implications for public health" FEBS Lett. 2011 Jun 6; 585(11): 1551-62. doi: 10.1016 / j.febslet.2011.04.042. Epub 2011 Apr 23. Review. PubMed PMID: 21530510; the contents of which are incorporated herein by reference.
[0458] Regarding polypeptides that can be detected according to the present invention, gene products of all genes mentioned herein can be used as targets. Accordingly, it is expected that such polypeptides can be used for the identification, typing and / or detection of drug resistance.
[0459] In certain exemplary embodiments, the systems, devices, and methods disclosed herein relate to detecting the presence of one or more mosquito-borne parasites in a sample, such as a biological sample obtained from a subject. In certain exemplary embodiments, the parasite may be selected from the following species: Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, Plasmodium malariae, or Plasmodium knowlesi. Therefore, the methods disclosed herein can be adapted for use in conjunction with (or in combination with) other methods in other methods that require rapid identification of parasite species, monitoring the presence of parasites and parasite forms (e.g., corresponding to various stages of infection and parasite life cycles, such as the extraerythrocytic stage, the intraerythrocytic stage, the sporogenous stage; parasite forms include merozoites, sporozoites, schizonts, gametocytes); detection of certain phenotypes (e.g., pathogen resistance), monitoring of disease ...
Claims
1. A nucleic acid detection system, comprising: A CRISPR system, the CRISPR system comprising A CRISPR type VI RNA targeting effector protein, which is a C2c2 effector protein or a Cas13b effector protein, wherein the C2c2 effector protein is from the following organisms: Leptotrichia sabdariffa or Leptotrichia wadeii; one or more guide RNAs designed to hybridize to a ribonucleotide sequence of an RNA target molecule or a complementary ribonucleotide sequence of a DNA target molecule; and an RNA-based masking construct comprising an RNA oligonucleotide to which a detectable ligand and a masking component are attached, wherein the target molecule comprises one or more viral target molecules, a reagent for amplifying a target nucleic acid molecule, which is a nucleic acid sequence-based amplification (NASBA) reagent or a recombinase polymerase amplification (RPA) reagent; and Crude sample, wherein the one or more viral target molecules are not extracted and / or isolated from the crude sample, Optionally, wherein the crude sample comprises inactivated nucleases and / or inactivated viruses, Optionally wherein the crude sample comprises nuclease and / or viral inactivation reagents, In which the complex formation between the CRISPR type VI RNA targeting effector protein and the guide RNA hybridized to the ribonucleotide sequence of the RNA target molecule or the complementary ribonucleotide sequence of the DNA target molecule triggers the non-sequence-specific incidental cleavage activity of the effector protein, which cleaves the non-target ribonucleotide sequence of the RNA-based masking construct to produce or mask a detectable signal.
2. A method for detecting a virus in a sample, the method comprising: Distributing a sample or sample group into one or more individual discrete volumes, wherein the individual discrete volumes contain the CRISPR system of claim 1; incubating the sample or set of samples under conditions sufficient to allow the one or more guide RNAs to hybridize to the ribonucleotide sequence of the RNA target molecule or the complementary ribonucleotide sequence of the DNA target molecule; and detecting a detectable signal, wherein detection of the detectable signal indicates the presence of one or more viruses in the sample, The method described herein is not a method for diagnosis and treatment of a disease.
3. The method of claim 2, wherein the sample comprises two or more viruses, and wherein the method distinguishes between the two or more viruses.
4. The method of claim 2, wherein the guide RNA detects a single nucleotide variant of the one or more viruses.
5. The method of claim 4, wherein the guide RNA further comprises one or more synthetic mismatches.
6. The method of claim 2, wherein the guide RNA comprises a pan-viral guide RNA set that detects each virus and / or virus strain in a group of viruses.
7. The method of claim 6, wherein the guide RNA is obtained using a group coverage method.
8. A method for detecting a virus, the method comprising: Exposing the CRISPR system of claim 1 to a sample; activating the RNA targeting effector protein via binding of the one or more guide RNAs to one or more virus-specific target RNA molecules to produce a detectable signal; and detecting the detectable positive signal, wherein detecting the detectable positive signal indicates the presence of one or more viruses in the sample, The method described herein is not a method for diagnosis and treatment of a disease.
9. The method of claim 8, wherein the CRISPR system is on a substrate, and wherein the substrate is exposed to the sample.
10. The method of claim 9, wherein the same or different CRISPR systems are applied to multiple discrete locations on the substrate.
11. The method of claim 10, wherein the same or different CRISPR systems are applied to multiple discrete locations on the substrate.
12. The method of claim 9, wherein the substrate is a flexible material substrate.
13. The method of claim 12, wherein the flexible material substrate is a paper substrate, a fabric substrate or a flexible polymer based substrate.
14. The method of claim 11, wherein the different CRISPR systems detect different microorganisms at each location.
15. The method of claim 12, wherein the substrate is passively exposed to the sample by briefly immersing the substrate in a fluid to be sampled, by applying a fluid to be tested to the substrate, or by contacting a surface to be tested with the substrate.
16. The method of claim 15, wherein the sample is a biological or environmental sample.
17. The method of claim 16, wherein the environmental sample is obtained from a food sample, a beverage sample, a paper surface, a fabric surface, a metal surface, a wood surface, a plastic surface, a soil sample, a fresh water sample, a waste water sample, a salt water sample, a sample exposed to the atmosphere or other gases, or a combination thereof.
18. The method of claim 16, wherein the biological sample is obtained from a tissue sample, saliva, blood, plasma, serum, feces, urine, sputum, mucus, lymph, synovial fluid, cerebrospinal fluid, ascites, pleural effusion, seroma, pus, or a swab of the skin or mucosal surface.
19. The method of claim 16, wherein the environmental or biological sample is a crude sample and / or wherein the one or more target molecules are not purified or amplified from the sample prior to applying the method.
20. A method for monitoring the outbreak and / or evolution of a viral disease, the method comprising: Exposing the CRISPR system of claim 1 to a sample; activating the RNA targeting effector protein via binding of the one or more guide RNAs to one or more target sequences comprising non-synonymous viral mutations to produce a detectable signal; and detecting a detectable signal, wherein detection of the detectable signal indicates the type of viral strain present in the sample, The method described herein is not a method for diagnosis and treatment of a disease.
21. The method of claim 20, wherein exposing the CRISPR system comprises positioning one or more CRISPR systems within one or more individual discrete volumes and adding a sample or a sample aliquot to the one or more individual discrete volumes.
22. The method of any one of claims 2 to 21, wherein the virus is a DNA virus.
23. The method of claim 22, wherein the DNA virus is a member of the family Myoviridae, Brachyviridae, Longiviridae, Heteroherpesviridae, Herpesviridae, Maloherpesviridae, Lipoviridae, Parvoviridae, Adenoviridae, Bottleviridae, Vesciviridae, Afriswiridae, Baculoviridae, Sikandaviridae, Rhabdoviridae, Coverbacteriophage, Microspindleviridae, Spheroviridae, Tropoviridae, Megasiaviridae, Iridoviridae, Masaiviridae, Mimiviridae, Nudiviridae, Filoviridae, Pandoraviridae, Papillomaviridae, Phycodnaviridae, Protoplasmaviridae, Polydnavirus, Polyomaviridae, Poxviridae, Spherolipoviridae, Multilaminaviridae, Turiviridae, Denodnavirus, Haloperidovirus, Razeviridae, or a combination thereof.
24. The method of claim 22, wherein the DNA virus is human herpes virus, varicella zoster virus, African swine fever virus, simian virus 40, JC virus, BK virus, vaccinia, smallpox, or a combination thereof.
25. The method of any one of claims 2 to 21, wherein the virus is a double-stranded RNA virus, a positive-sense RNA virus, a negative-sense RNA virus, a retrovirus, or a combination thereof.
26. The method of claim 25, wherein the virus is a Coronaviridae virus, a Picornaviridae virus, a Caliciviridae virus, a Flaviviridae virus, a Togaviridae virus, a Bornaviridae virus, a Filoviridae virus, a Paramyxoviridae virus, an Alveoviridae virus, a Rhabdoviridae virus, an Arenaviridae virus, a Bunyaviridae virus, an Orthomyxoviridae virus, or a Delta virus.
27. The method of claim 25, wherein the virus is a coronavirus, poliovirus, rhinovirus, hepatitis A, Norwalk virus, yellow fever virus, West Nile virus, hepatitis C virus, dengue virus, Zika virus, rubella virus, Ross River virus, Sindbis virus, chikungunya virus, Borna disease virus, Ebola virus, Marburg virus, measles virus, mumps virus, Nipah virus, Hendra virus, Newcastle disease virus, human respiratory syncytial virus, rabies virus, Lassa virus, Hanta virus, Crimean-Congo hemorrhagic fever virus, influenza, or hepatitis D virus.
28. The method of claim 25, wherein the virus is SARS.
29. A method for detecting one or more microorganisms in a sample, the method comprising: Contacting the sample with the nucleic acid detection system as described in claim 1; as well as applying the contacted sample to a lateral flow immunochromatographic assay, The method described herein is not a method for diagnosis and treatment of a disease.
30. The method of claim 29, wherein the nucleic acid detection system comprises an RNA-based masking construct comprising a first molecule and a second molecule, and wherein the lateral flow immunochromatographic assay comprises detecting the first molecule and the second molecule.
31. The method of claim 30, wherein the first and second molecules are detected at discrete detection sites on a lateral flow strip.
32. The method of claim 30, wherein the first molecule and the second molecule are detected by binding to an antibody that recognizes the first molecule or the second molecule and detecting the bound molecule.
33. The method of claim 32, wherein the bound molecule is detected using a sandwich antibody.
34. A method as claimed in claim 31, wherein the lateral flow strip comprises an upstream first antibody against the first molecule and a downstream second antibody against the second molecule, and wherein if the target nucleic acid is not present in the sample, then the uncleaved RNA-based masking construct is bound by the first antibody, and wherein if the target nucleic acid is present in the sample, then the cleaved RNA-based masking construct is bound by the first antibody and the second antibody.
35. A method for detecting a virus, the method comprising: obtaining a sample from a subject, wherein the sample is a urine, serum, blood, or saliva sample; amplifying RNA from the sample using a nucleic acid sequence-based amplification (NASBA) reagent or a recombinase polymerase amplification (RPA) reagent; combining the sample with an effector protein, one or more guide RNAs designed to hybridize to a virus-specific target molecule, and an RNA-based masking construct, wherein the effector protein is a C2c2 effector protein or a Cas13b effector protein, the C2c2 effector protein is from the following organisms: Leptotrichia saburoi or Leptotrichia wadeii, and the RNA-based masking construct comprises an RNA oligonucleotide to which a detectable ligand and a masking component are attached, activating the effector protein via binding of the one or more guide RNAs to the one or more virus-specific target RNAs, wherein activation of the effector protein modifies the RNA-based masking construct to produce a detectable positive signal; and detecting the signal, wherein detecting the signal indicates the presence of the virus; and wherein the method does not include the step of extracting RNA from the sample, The method described herein is not a method for diagnosis and treatment of a disease.
36. The method of claim 35, wherein the duration of the amplification step is selected from the group consisting of: 2 hours, 1 hour, 30 minutes, 20 minutes, and 10 minutes.
37. The method of claim 35, wherein the duration of the detecting step is selected from the group consisting of: 3 hours, 2 hours, 1 hour, 30 minutes, 20 minutes, and 10 minutes.
38. The method of claim 35, wherein the sample volume required for detection is 100 μl to 1 μl.
39. The method of claim 35, wherein the virus is Zika virus.
40. The method of claim 35, wherein the sample comprises two or more viruses, and wherein the method distinguishes between the two or more viruses.
41. The method of claim 35, wherein the method further comprises a nuclease inactivation step and a virus inactivation step prior to amplifying the RNA of the sample.
42. The method of claim 41, wherein the nuclease inactivation step is performed at a temperature in the range of 37°C to 50°C.
43. The method of claim 41, wherein the duration of the nuclease inactivation step is selected from 5 minutes, 10 minutes, 15 minutes and 20 minutes.
44. The method of claim 41, wherein the viral inactivation step is performed at a temperature in the range of 64°C to 95°C.
45. The method of claim 41, wherein the viral inactivation step lasts for 5 minutes.
